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Prostate cancer (PCa) is the most common non-cutaneous male malignancy in the world. 
The diagnosis is challenging. Too many clinically insignificant, but not all clinically 
significant PCas are found. Active surveillance (AS) is an approach to monitor clinically 
insignificant PCas and, when needed, offer curative treatment to patients in a timely 
manner. Multiparametric magnetic resonance imaging (mpMRI) with its structured 
imaging reporting system (PI-RADS), and biomarker analysis of histopathology may aid 
diagnosing the clinically significant PCas. 
In Study I, we focused on depicting the performance of repeated mpMRIs in an AS cohort. 
During AS, patients underwent multiple prostate biopsies (Bx) to obtain histopathological 
specimens for detecting the possible development of PCa. Bx sampling may cause Bx-related 
side effects, such as discomfort and even re-hospitalization for patients. In Study II, we 
compared patient experience in two groups receiving either systematically targeted prostate 
biopsies (SBx) or mpMRI/ultrasound fusion targeted Bxs (FBx). We assessed the accuracy 
of mpMRI further in Study III by comparing mpMRI visible (true positive) and mpMRI 
invisible (false-negative) tumor lesions when we matched their locations with the 
histopathological analysis of radical prostatectomy (RP) specimens. We also assessed the 
risks for biochemical recurrence (BCR) and analyzed PTEN and ERG biomarker expressions 
and their roles in mpMRI visibility. In Study IV, we addressed the benefits of mpMRI as an 
addition to Partin tables, Memorial Sloan Kettering Cancer Center (MSKCC) nomogram and 
Cancer of the Prostate Risk Assessment Score (CAPRA) risk score, i.e. traditional risk 
stratification tools in PCa. 
Main results: I: PCa progression was seen in 69% of patients using mpMRI. High-risk PI-
RADS scores of 4-5 associated with treatment change (TC) from AS to active treatment. 
Tumor progression on repeated mpMRIs associated with TC. II: Patients in the FBx vs SBx 
groups received a median of three vs 12 Bx cores. The FBx group reported significantly less 
pain and hematuria at 30 days after Bx. Patients who were willing to undergo rebiopsy 
reported lower pain and discomfort scores and less fever than unwilling patients. III: 
Patients with mpMRI invisible lesions had higher BCR-free survival time and fewer adverse 
findings (extraprostatic extension, seminal vesicle invasion and lymph node metastasis) 
than mpMRI visible lesions. Loss of PTEN biomarker staining was more common in mpMRI 
visible lesions. IV: Models with mpMRI outperformed the models with only clinical data, 
MSKCC nomogram and Partin tables for the prediction of adverse findings in RP. Survival 
analysis for BCR revealed that mpMRI separated the curves significantly in CAPRA and 
MSKCC risk nomograms. 
Conclusions: mpMRI depicts changes in PCa during AS and seems beneficial in patient 
diagnosing and monitoring. During AS, where multiple Bxs are needed over years, FBx 
causes less harm for the patient than routine SBx. mpMRI invisible lesions appear less 
aggressive than mpMRI visible lesions as indicated by aggressive cancer growth beyond the 
prostate. PTEN loss is associated with aggressive types of PCa, and was more often seen in 
mpMRI visible than mpMRI invisible tumor lesions. Finally, adding mpMRI to traditional 
risk stratification models with clinical data is beneficial in the detection of aggressive types 
of PCa.  
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Tiivistelmä 
Eturauhassyöpä on miesten yleisin syöpä. Nykyään tunnistetaan liikaa kliinisesti 
merkityksetöntä syöpää, joka ei vaikuta elinajanodotteeseen. Toisaalta, kaikkia 
aggressiivisia, kliinisesti merkityksellisiä syöpiä (csPCa) ei pystytä tunnistamaan riittävän 
ajoissa. Kliinisesti merkityksettömiä syöpiä todetessa potilaita voidaan aktiiviseurata (AS), 
jolloin pidättäydytään välittömästä hoidosta. AS aikana voidaan edetä hoitoihin, mikäli 
csPCa:ään viittaavaa ilmenee. Eturauhasen multiparametrinen magneettikuva (mpMRI) 
raportoituna stukturoidun lausunnon (PI-RADS) mukaisesti sekä biomarkkerianalyysit 
kudosnäytteistä saattavat auttaa csPCa:n tunnistamisessa. 
Osatyössä I tutkimme mpMRI:n ominaisuuksia AS:n aikana. Potilailta otettiin useita kertoja 
koepaloja eturauhasesta, jotta mahdolliset aggressiiviset syöpäpesäkkeet tunnistettaisiin. 
Koepalojen otto voi aiheuttaa kipua, infektioita ja jopa sairaalahoitoja. Osatyössä II 
vertailimme potilaiden raportoimaa tyytyväisyyttä ja haittavaikutusten määrää 
systemaattisen koepalaoton (SBx) tai mpMRI-ultraäänikohdennetun koepalaoton (FBx) 
jälkeen. Osatyössä III verrattiin mpMRI:ssä näkyviä ja näkymättömiä syöpiä eturauhasen 
poistoleikkauksen kudosnäytteisiin. PTEN- ja ERG-biomarkkerien ilmaantuvuutta 
kudosnäytteissä ja leikkauksenjälkeistä laboratoriokokeissa havaittavaa syövän 
uudelleenaktivaatiota (BCR) vertailtiin mpMRI:n kykyyn tunnistaa syöpäpesäkkeet. 
Osatyössä IV arvioitiin mpMRI:n hyötyä tavanomaisten syövän riskilaskurien, kuten 
Partinin taulukoiden, MSKCC-nomogrammin ja CAPRA-riskipisteytyksen, apuna csPCa:n 
tunnistamisessa. 
Tulokset: I: mpMRI:ssä näkyi syövän muttuminen aggresiivisemmaksi 69%:lla potilaista. 
Korkean syöpäriskin PI-RADS-pisteet 4-5 mpMRI:ssä liittyivät potilaan siirtymiseen AS:sta 
aktiivihoitoon. Syövän muuttuminen aggressivisemmaksi toistetussa mpMRI:ssä liittyi 
AS:sta aktiivihoitoon siirtymiseen. II: FBx- ja SBx-ryhmissä potilailta otettiin kolme ja 12 
koepalaa (mediaani). FBx-ryhmässä raportoitiin vähemmän verivirtsaisuutta ja kipua 30 
vrk kohdalla toimenpiteen jälkeen. Potilaiden halukkuus uusintabiopsiaan toimenpiteen 
jälkeen liittyi vähäisempään raportoituun kipuun ja epämukavuuteen. III: mpMRI:ssä 
näkymättömät syövät liittyivät parempaan ennusteeseen BCR:n ja syövän aggressiivisten 
muotojen (syövän kasvu eturauhasen kapselin ulkopuolelle, seminaalivesikkeleihin ja 
imusolmukkeisiin) suhteen verrattuna mpMRI:ssä näkyviin pesäkkeisiin. PTEN-
biomarkkerin puutos oli tyypillisempää mpMRI:ssä näkyvissä kuin näkymättömissä 
syövissä. IV: MSKCC-nomogrammi ja Partinin taulukot yhdessä mpMRI:n kanssa olivat 
parempia tunnistamaan syövän aggressiivisia muotoja kuin pelkkä tilanteen arviointi 
kliinisesti tai riskilaskurit yksinään. mpMRI oli hyödyllinen BCR:n tunnistamisessa 
verrattuna pelkkään CAPRA-riskilaskurin tai MSKCC-nomogrammin käyttöön. 
Johtopäätökset: mpMRI tunnistaa syövän muutoksia AS aikana ja näyttää olevan 
hyödyllinen eturauhassyövän diagnosoinnissa ja seurannassa. AS aikana otetaan useita 
kertoja koepaloja eturauhasesta ja FBx-koepalat aiheuttavat vähemmän haittavaikutuksia 
kuin SBx-koepalat. mpMRI:ssä näkymättömät syöpäpesäkkeet ovat vähemmän 
aggressiivisia kuin näkyvät pesäkkeet. PTEN-biomarkkeripuutos kudosanalyysissä liittyi 
syövän aggressiivisiin muotoihin ja sitä tavattiin useammin mpMRI:ssä näkyvissä kuin 





Prostate cancer (PCa) is the most common non-cutaneous malignancy in men in the western 
world. It is a disease characterized by a high prevalence and a low mortality, and PCa 
represents up to 28% of new cancer diagnoses and 13% of cancerous causes of death in 
Finland [1]. Typically, the PCa patient is a Caucasian aged 50 to 70 years and lives in western 
countries [2]. 
The diagnosis of PCa is typically based on the prostate-specific antigen (PSA) test, digital 
rectal examination (DRE) and prostate histopathological samples (biopsies, Bx). Usually 12 
systematically targeted Bx cores (SBx) are taken and they cover the entire prostate. However, 
due to the random nature of these Bxs, i.e. the Bxs are not visually targeted for a tumor 
lesion, diagnostic accuracy is a compromise. SBx may miss the most aggressive form of PCa 
present in the prostate (i.e. underdiagnosis). Bxs may also detect clinically insignificant PCa 
(i.e. overdiagnosis), and cause complications such as pain, discomfort and infections [3]. 
Furthermore, PSA is not a cancer-specific laboratory test and DRE may miss anterior 
cancers that extend beyond the prostate capsule. Therefore, new diagnostic tools are needed 
to detect better the clinically significant, i.e. large, aggressive and potentially lethal, PCa 
(csPCa), while also avoiding a diagnosis of clinically insignificant “indolent” cancers. The 
variable nature and heterogeneous phenotype of the disease is likewise problematic 
regarding diagnosis. PCa is often multifocal and may develop over time. The least aggressive 
forms of PCa are localized, small and unifocal cancers, and don’t affect patient’s life 
expectancy (i.e. clinically insignificant PCa). The clinically insignificant PCas can therefore 
be monitored by active surveillance (AS). AS is an established and accepted form of 
treatment and is typically based on repeated DRE, PSA, and Bxs during follow-up. The main 
goal of AS is to defer radical treatment when not immediately needed. If suspicion of more 
aggressive forms of PCa arise, patients are referred to active treatment. 
Multiparametric magnetic resonance imaging (mpMRI) may aid in diagnosing csPCa more 
accurately. Contemporary mpMRI combines anatomical imaging with functional 
assessment and a structured reporting system such as Prostate Imaging Reporting and Data 
system (PI-RADS) [4]. When compared with SBxs, mpMRI has been shown to detect more 
csPCa, and less clinically insignificant PCa [5-8]. mpMRI can also be used for targeting PCa 
lesions in the prostate. A combination of MRI and ultrasound (US), known as fusion Bx 
(FBx), combines an accurate MR image with a live US image. This allows clinicians to 
potentially target PCa lesions that are visible on mpMRI, but not visible in US. By targeting 
PCa lesions in this way fewer samples are taken, thus causing fewer complications that arise 
from sampling. However, FBx is limited when a PCa lesion is invisible under mpMRI, and 
the lesion cannot be targeted. Hence, FBx may not fully replace SBx until the clinical 
characteristics of mpMRI invisible lesions are known. 
Biomarkers, such as Phosphatase and Tensin Homolog (PTEN) and v-ets avian 
erythroblastosis virus E26 oncogene homolog gene (ERG), are another approach to improve 
diagnostics. Loss of a tumor suppressor gene PTEN is shown to be associated with adverse 
findings in RP specimen [9-11]. By detecting these biomarkers in Bxs, the potentially 
aggressive forms of PCas can probably be detected and radical treatment can be given in a 
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timely manner. Thus far, PTEN and ERG have not yet gained wider clinical acceptance. 
Instead, risk stratification of PCa patients is accomplished using conventional tools, such as 
risk calculators and nomograms. 
The aim of this PhD project was to contribute to the efforts of improving PCa diagnostics by 
diagnosing only csPCa but not the insignificant PCa. Studies I and II focus on an AS 
population and investigate the role of repeated mpMRI and the experience and complication 
rates of patients undergoing FBx. Studies III and IV focus on RP patients, they elucidate the 
role of the biomarkers PTEN and ERG. They also investigate mpMRI invisible PCa lesions, 





















2. Literature review 
 
2.1 The prostate 
The word prostate originates from mid-17th century and comes from the Greek words “pro” 
and “statos”, translated as “one that stands before” [12]. The prostate is a key member of the 
male reproductive system. It is a gland that surrounds the urethra and it is located in the 
pelvis between the bladder, rectum and pubic symphysis. Formation and development of the 
prostate occurs between gestational weeks 8-36. Prostate growth is induced by androgens 
and the post-pubertal weight of the prostate is approximately 20 grams [13]. 
 
Figure 1. The genitourinary tract of a man. Reprinted from Gray’s Anatomy for 
Students 4th edition, Copyright 2020, with permission from Elsevier, accessed Mar. 10, 
2020. 
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Sperm are produced in the testicles, then they are stored and matured in the epididymis and 
subsequently secreted into the urethra by the ejaculatory ducts. The ejaculatory ducts of the 
prostate open into the urethra. Prostatic fluid and the fluid secreted by the seminal vesicles 
are added to sperm. This mixture is called the ejaculate (semen). The prostatic secretion is 
accountable for 30% of the volume of semen. PSA is a glycoprotein secreted by the epithelial 
cells of the prostate gland. It is a constituent of semen. Its only known function is the 
liquefication of semen to allow sperm move towards to the ovum. This enzymatic action of 
PSA and other kallikrein proteins is crucial to male fertility [14]. 
 
 
Figure 2. Prostatic urethra and ejaculatory ducts. Reprinted from Gray’s Anatomy 
for Students 4th edition, Copyright 2020, with permission from Elsevier, accessed Mar. 10, 
2020. 
 
The prostate can be divided into three or four zones as depicted in Figure 3 [15]. The 
peripheral zone contributes 70% of the whole gland volume. Between 70 to 80% of all PCa 
originate in this area. The central zone includes the openings of the ejaculatory ducts and 
constitutes of 25% of glandular prostate volume. Only approximately 2.5% of PCas originate 
in the central zone [16]. The transition zone surrounds the prostatic urethra and is the 
location of obstructive urinary disorders caused by PCa or benign prostate hyperplasia 
(BPH). About 20-30% of PCa arise in the transition zone. The fourth, anterior zone, consists 
of more fibromuscular and less glandular structures [15].  
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Figure 3. Zones of the prostate. Modified from Franz et al. Zinc transporters in prostate 
cancer. Mol Aspects Med, Copyright 2013, with permission from Elsevier, accessed Mar. 26, 
2020. 
 
2.2 Prostate cancer 
 
2.2.1 Definition 
PCa is the most common male malignancy and it accounts for 15% of all cancers diagnosed 
worldwide [2]. Up to 95% of PCa are adenocarcinomas. The remaining 5% comprise for 
example lymphomas and sarcomas. This academic dissertation focuses solely on prostate 
adenocarcinoma. PCa is usually encountered in the peripheral zone of the prostate. When 
diagnosed, the vast majority of PCas are multifocal, i.e. they consist of multiple cancer 
lesions inside the prostate gland. The most typical sites of metastases are the lymph nodes 
(LN), bones, and lungs. 
 
2.2.2 Risk factors 
The well-known risk factors for PCa are age, family history of PCa and individuals with 
African ethnicity. The risk of harboring a high-risk (Gleason score [GS] ≥8 and/or T3-4 
and/or PSA ≥20ng/ml and/or N1 and/or M1) PCa on a population level is 1.4%. However, 
the risk increases several fold, up to 11.4% in men at the age of 65 whose father and two 
brothers had PCa [17]. The lifetime risk of having any PCa is dependent on age, and at the 
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age of 65 the risk is 4.5% of any form of PCa [17]. Genetic predisposing factors for PCa have 
also been investigated, and BRCA2 gene mutation carriers seem to have increased risk of 
early-onset aggressive PCa [18]. 
PSA testing has become a widely adopted part of “the men’s health check-up” and this 
increases the lifetime risk of being diagnosed with any PCa (clinically significant or 
insignificant PCa). This phenomenon is sometimes referred to as “opportunistic screening”, 
i.e. non-systematic and non-organized cancer screening with no proven net benefit for the 
man. According to a recent long-term follow-up of a PCa prevention trial cohort (PCPT-
trial), only every sixth man of the study population harbored any PCa [19]. 
Metabolic syndrome (diabetes, obesity, high blood cholesterol levels, high blood pressure) 
has been shown weakly and non-significantly to associate with PCa. According to a recent 
meta-analysis, among the single components of metabolic syndrome only waist 
circumference of >102cm and hypertension were significantly associated with PCa [20]. 
However, the results vary geographically. Another meta-analysis revealed that elevated total 
cholesterol, high-density lipoprotein, and low-density lipoprotein levels were not associated 
with a higher risk of PCa [21]. 
The association of medication and the risk of PCa has been and still is being widely studied 
and many medications, including metformin, statins, NSAID and thiazide diuretics, are 
known to alter PSA levels [22]. A population-based study with more than 134 000 patients 
suggested that metformin use is associated with a reduced risk of PCa (Odds Ratio [OR] 
0.84; 95% confidence interval [CI] 0.74-0.96) when compared with non-users [23]. The 
same effect was not however evident with other oral antihyperglycemic medicine. Metformin 
is assumed to inhibit cancer development and progression directly. Statins are used to lower 
blood cholesterol levels, and are associated with lower PSA levels among users when 
compared with non-users [24]. Statins were also shown to inhibit pathways important to 
cancer cells [25]. It is unclear whether low PSA levels achieved by statins prevent PCa or 
delay the diagnosis of advanced PCa [24,26,27]. All in all, a recent large meta-analysis with 
over 6700 men concluded that statins could not be associated with any or high-risk PCa 
among men with a negative baseline Bx [28].  
5-alpha-reductase inhibitors (5-ARIs) have been suggested to play a role in preventing PCa. 
Finasteride and dutasteride are used mainly for urinary symptoms caused by BPH. It seems 
that the use of 5-ARIs reduces PSA levels by up to 50% and also reduces the risk of clinically 
insignificant PCa (GS 6) while also increasing the detection rate of csPCa [29,30]. A study of 
over 18 000 men showed that 5-ARIs lower PSA, which might delay the diagnosis of PCa, 
and thereby increase the risk of advanced (GS 7 to 10) PCa [31]. However, after 18 years of 
follow-up, there were no differences between the finasteride group and placebo group in 
rates of overall survival (OS) or survival after diagnosis of PCa [31]. Thus, it is likely that the 
increased detection rate of csPCa in men who take 5-ARIs relates to improved diagnostics 
(smaller prostate, i.e. biopsies are more likely to hit the csPCa lesion). So far, 5-ARIs have 
no indication for PCa prevention. 5-ARIs cause other well-known side effects, such as sexual 
dysfunction, and, therefore, their use and potential benefit and harm must be discussed with 
the patient [32]. Testosterone therapy has also been suggested to cause PCa, because the 
treatment of PCa is crucially linked to androgen deprivation therapy (ADT). So far, long-
term evidence on this is absent, but a study with a median follow-up of five years among 
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1000 hypogonadal men receiving long-term testosterone therapy showed no signs of 
increased risk of PCa [33]. 
A western diet seems to increase the risk of PCa [34]. Obesity is shown to be associated with 
a lower risk for low-grade PCa (OR 0.79; 95% CI 0.65-0.94; p=0.01) but a higher risk for 
high-grade PCa (OR 1.28; 95% CI 1.01-1.63; p=0.042) [35]. A western type diet therefore 
seems to increase the risk for PCa and a number of studies on different substances have been 
conducted to find out if dietary interventions can affect the natural course of PCa. Red meat 
or processed red meat did not have an association with PCa in a large meta-analysis [36]. 
Long-chain omega-3 polyunsaturated fatty acids were also not associated with PCa [37], 
whereas fried food was shown to increase the risk of PCa by 35% in a recent meta-analysis 
[38]. A cohort of over 35 000 relatively healthy men was studied to ascertain whether the 
consumption of selenium and Vitamin E could prevent PCa. Selenium and Vitamin E alone 
or any combination of these substances did not have a preventive effect on PCa [39]. 
Phytoestrogen intake, however, has been shown to lower the risk for PCa in a large 
epidemiological study [40]. So far, the European Association of Urology (EAU) guidelines 
suggests no certain diet for the prevention of PCa [41]. 
 
2.2.3 Incidence and prevalence 
Men with newly diagnosed PCa are typically between 50 and 70 years and the natural 
development of the disease occurs slowly. Autopsy studies show that the risk of harboring 
PCa grows with ageing: each subsequent decade increases the likelihood of harboring PCa 
(OR 1.7; 95% CI 1.6-1.8) [42,43]. Men from different geographical regions and countries 
carry a different risk of being diagnosed with PCa. The risk of having PCa is the greatest in 
well-developed regions such as North America (97.2, age-standardized rate per 100 000 
men), Western and Northern Europe (94.9 and 85.0, respectively) and in Australia/New 
Zealand (111.6). In contrast, Eastern Asia (10.5) and South-Central Asia (4.5) show very low 
incidences of PCa [44].  
In Finland, 5016 new PCa diagnoses and 914 deaths due to PCa were reported in 2018, which 
represents 28% of all new cancer diagnoses and 13% of all deaths due to cancer in men [1]. 
The incidence was 76.6 per 100 000 men in 2018 [1,2]. At the same time, PCa prevalence in 
Finland was over 55 000 representing 44% of all prevalent cancers in Finland [1,45]. 
 
2.2.4 Histology of prostate cancer 
Up to 95% of PCa consist of adenocarcinomas. The remaining 5% of PCa comprise e.g. 
lymphomas and sarcomas. Primary urothelial carcinoma without bladder extension 
accounts for 1-4% of PCas [46]. Sarcomas of the prostate, leiomyosarcoma being the most 
common variant, are rare and account for only around 0.1% of all prostate malignancies 
[47]. Lymphomas are also a rare but very lethal form of PCa and they may occur as a 
secondary infiltration to the prostate among patients whose primary lymphoma is in 
remission [48]. Neuroendocrine PCas are rare, and they are associated with a poor prognosis 
[49,50]. After castration or ADT, neuroendocrine cells in prostatic tissue may activate and 
gain a survival benefit over other cell types, thus initial adenocarcinoma may transform to 
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neuroendocrine type cancer [51]. This is especially true for men with metastatic PCa that is 
treated with novel hormonal treatments (CYP17-inhibitors and anti-androgens), for which 
eventually up to 50% of metastatic lesions may show neuroendocrine differentiation in Bxs 
[52]. Very rare types of PCa are mucinous carcinomas [53], in which extracellular mucin 
accounts for up to 25% of tumor volume, and small cell carcinoma [54], which may be 
present as a solitary foci in an otherwise typical adenocarcinoma. Many small cell 
carcinomas express neuroendocrine markers, such as chromogranin A and neuron specific 
enolase, and also have a very poor prognosis [54]. High-Grade Prostatic Intraepithelial 
Neoplasia (High-grade PIN) seems to precede PCa in most of the cases, and if encountered 
in a Bx, this should lead to a suspicion of PCa [55]. 
 
2.2.5 Mortality and prognosis 
In Finland, 914 men died of PCa in 2018, which represents 13% of all male cancer deaths. 
PCa is the second most common cause of cancer death in Finland is preceded by only lung 
cancer [1]. Worldwide, PCa caused 358 989 deaths in 2018 and this represents 6.7% of all 
cancer deaths preceded by lung, liver, stomach and colorectal cancers. African populations 
and their descendants carry a higher risk of having a clinically significant and even lethal 
PCa variant with high mortality rates (Caribbean 29 deaths per 100 000 men; Sub-Saharan 
Africa between 14 to 19; compared with South and Central Asia of only 2.9) [56]. 
PCa is a heterogeneous disease and so is its prognosis. Low-risk PCa may not affect life 
expectancy at all. However, according to a large study with over 900 patients, median OS 
with newly diagnosed M1 disease is around 42 months [44]. 
 
2.3 Diagnosis of prostate cancer 
 
2.3.1 Digital rectal examination and transrectal ultrasound 
DRE is a method that involves the palpation of the prostate enabling the identification of 
abnormal extensions that may be PCa. The majority of PCas are located in the peripheral 
zone of the prostate and, therefore, they can be detected by DRE. Up to 18% of PCa cases 
have been reported to be detected by DRE alone [57]. The EAU guidelines for PCa advice to 
perform DRE in addition with PSA for both asymptomatic and symptomatic men to 
determine whether Bxs are needed [41]. 
Transrectal ultrasound (TRUS) is an imaging tool that is widely used in urological outpatient 
clinics. It is primarily used to visualize the prostate, seminal vesicles and periprostatic areas, 
measure the gland’s dimensions and look for tissue homogeneity or abnormal protrusions 
around the prostate. TRUS can also be used to target Bxs. However, TRUS alone is an 
insufficient tool to detect focal PCa reliably [58]. TRUS-guided Bxs are the current standard 
in obtaining histological specimens of the prostate for PCa diagnosis. The transperineal 
approach to prostate Bxs is also available and in no way inferior to transrectal approach in 
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terms of PCa detection and complication rate [59]. TRUS-guided Bxs are taken under local 
periprostatic anesthesia, which usually provides sufficient pain control for the procedure. 
 
2.3.2 PSA 
PSA is also known as human kallikrein 3 and it is part of the human kallikrein protein family. 
PSA secretion mainly occurs from the prostate but some minor amounts of PSA can be found 
in breast tissue, in adrenal and in renal carcinoma [60]. PSA was discovered in the 1970s 
and later the PSA test was introduced to clinical practice in the USA in the 1980s. The use of 
PSA spread rapidly and by the 1990s the PSA test was already in wide use by the Nordic 
countries [61]. PSA is used as a tumor marker. Tumor markers can be developed for blood 
tests that are used by physicians to help detect malignancies. Ideally, tumor marker values 
increase only when a malignancy is present and not for other non-malignant reasons. 
However, it was soon noticed that PSA is an organ-specific but not a cancer-specific marker, 
and its levels also rise for reasons other than the presence of PCa, which include prostatitis, 
prostatic manipulation, and BPH. Moreover, it was soon realized that the concentration of 
PSA also increases with age due to increasing prostate size, and the rate of rise of PSA is 
approximately 3.2% per year [62]. In addition to this patients with a very low PSA levels can 
also harbor a csPCa. This makes the use of PSA in PCa screening problematic.  
The rate at which PSA rises is, however, useful when considering whether a patient might 
require further diagnostic procedures [63]. PSA velocity is the increase in PSA over time 
usually one year (ng/ml/year). However, a short prostate-specific antigen doubling time 
(PSA-DT) has not been linked to adverse findings [64]. Today, the EAU guidelines advise 
that PSA-DT and PSA velocity do not offer useful information in PCa diagnostics when 
compared to PSA alone [41].  
The introduction of PSA to clinical use and its effect on PCa incidence and mortality in 
Finland can be seen in Figure 4 [1]. There was a surge in number of diagnosed PCa after the 
discovery of PSA in the 1990s, but the found PCas had very little, if any, effect in PCa 
mortality. Hence, the majority of newly diagnosed PCas were low-risk cancers that did not 





Figure 4. Incidence and mortality due to prostate cancer between 1953 and 
2018 in Finland. Modified from Cancer Registry Finland (https://cancerregistry.fi) 
 
2.3.3 Prostate biopsy 
 
2.3.3.1 Systematic biopsy 
Upon deciding who would benefit from Bxs, traditionally PSA, DRE, and additional risk 
stratification tools have been used to decide whether Bx is needed [41]. Prior to the 
procedure, the patient should be informed of the advantages, such as early diagnosis and 
adequate treatment in a timely manner, and also of the disadvantages, such as diagnosis of 
clinically insignificant PCa and anxiety that it generates. In addition the risks to the patient 
associated with the Bx procedure are another consideration. The standard procedure is 
TRUS-guided Bx. Antibiotic prophylaxis is given prior to procedure to prevent infections. 
Antibiotic guidelines vary due to differences in bacterial resistance rates locally. Quinolones 
were usually the drug of choice for their proper tissue concentrations [3], until the European 
Comission banned fluoroquinolones in March 2019 due to their adverse side effects and 
rising concerns of bacterial resistance [65]. At the time of writing, the EAU guidelines have 
not yet adapted this regulation. SBxs are taken in a sextant pattern, equally from left and 
right lobes, medially and laterally, usually resulting in 12 biopsy cores, which seems to be a 
compromise between diagnostic accuracy and Bx-related side effects [66]. Typical 
complications include lower urinary tract symptoms, hematuria, hematospermia, rectal 
bleeding and infections. Septic infection is the most feared complication and it is 
encountered in 1-3% of cases at significantly varying rates [3,41]. Data suggest that SBx with 
12 cores suboptimally predicts RP findings in up to 40% of patients [67]. Moreover, AS 
cohort studies with RP or confirmatory Bx show GS upgrading in 20 to 30% of the cases 
[68,69]. Hence, either PCa is multifocal and SBx does not always find the most adverse 




2.3.3.2 Targeted biopsy 
Targeting PCa lesions in the prostate can be performed either cognitively (trying to aim at 
lesions detected by US or MRI) or using fusion techniques (in-bore, MRI/TRUS). MRI-
targeting of Bx with fusion techniques (FBx) has been available now for some years. Patients 
go through a prostate MRI prior to Bx procedure and using technical applications the MRI 
image is fused with a TRUS image as the patient typically lies in lateral recumbency or in the 
supine position. This fusion allows the region of interest (ROI) seen on the MRI, but not in 
TRUS, to be targeted using FBx more accurately (Figure 5). Fusion techniques include not 
only MRI/TRUS-fusion, but also direct in-bore Bxs, where patient is in the MRI suite and 
targeted Bxs are taken using real-time MRI guidance [70]. No superiority between cognitive, 
in-bore or mpMRI/TRUS-fusion techniques has been reported, so far [41,71]. The inter-
operator reproducibility of mpMRI-targeted Bxs has not yet been evaluated, so even if 
mpMRI detects csPCa the Bx procedure itself may not be useful for all operators. 
 
 
Figure 5. MRI-ultrasound fusion prostate biopsy. A) Identification of a prostate 
cancer lesion in multiparametric MRI; B) Drawing an outline of the prostate; 
C) Highlighting and marking the tumor; D) MRI-ultrasound fusion image 
visualizes the lesion in transrectal ultrasound; E) The tumor is otherwise not 
clearly visible in transrectal ultrasound; F) Targeted biopsies can be taken from 
the tumor. Reprinted by permission from Copyright Clearance Center: Springer. 
Abdominal Imaging. TRUS-MRI image registration: a paradigm shift in the diagnosis of 




2.3.4 Classification of prostate cancer  
 
2.3.4.1 TNM 
Patients with similar histological PCa types and clinical outcome are pooled using the WHO 
Tumor, Node, Metastasis (TNM) classification system [72]. The TNM system is divided into 
two different branches the first being clinical TNM (cTNM), which comprises DRE, TRUS, 
mpMRI, computer tomography (CT) and bone scan. The second branch is pathological TMN 
(pTNM), which refers to histopathological tissue analysis of the prostate and seminal 
vesicles after RP (Table 1). 
 
 
Table 1. Clinical Tumor Node Metastasis (TNM) classification of prostate 
cancer. ¹ Metastasis size up to 0.2cm can be designated as lymph node metastasis. ² If  >1 
metastasis sites are present, the most advanced category site is used. Modified from Brierley 
et al. TNM Classification of Malignant tumors, 8th Edition, Copyright 2017, John Wiley and 
Sons. Reused with permission under a Creative Commons Attributions License, accessed 




2.3.4.2 Gleason score and ISUP Grade Grouping 
The most commonly used method to grade PCa is GS. It was first published by a pathologist 
Dr. Gleason in 1966 [73]. The difference between commonly used WHO grading and Gleason 
grading is that instead of the cell nucleus, emphasis in GS is given to the glandular structure. 
The patterns of prostate glands were pooled by their histopathological appearance and a 
numerical value was given. The glandular architecture ranges from 1 to 5, i.e. from uniform 
and concordant to unorganized and infiltrative. The GS is the sum of the most common and 
the second most common pattern values in histological analysis with a sum value that ranges 
from 2 to 10. When only one pattern is present, this value is doubled. When three different 
patterns are present in Bxs, the GS consists of the most common and the most aggressive 
pattern, irrespective of its extent. 
 
 
Figure 6. Gleason scoring system illustrating the differences in cell patterns 
between Gleason scores 1 to 5 and the changes in the scoring system after the 
two consensus meetings. Modified from Brimo et al. Contemporary Grading for Prostate 
Cancer: Implications for Patient Care. Eur Urol, Copyright 2013, with permission from 
Elsevier, accessed Mar. 20, 2020. 
 
Two major consensus meetings have since modified the GS grading system. The ISUP 2005 
consensus meeting suggested many changes to the system inter alia Gleason grade 1 was no 
longer diagnosed as cancer, and the criteria of Gleason grade 3 to 5 were altered (Figure 6) 
[74]. Later in 2014, another consensus meeting further modified these rules [75]. A new 
system for grading histological specimen of the prostate was also introduced. The system is 
based on a large study of over 20 000 men with PCa, and their probability for biochemical 
recurrence (BCR) during ten years of follow-up after radical treatment [76]. The study 
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results distinguish five groups that are linked to the patients’ GS [76] (see Table 2). This 
grading system is called the International Society of Urological Pathology Grade Grouping 
(GG), and it makes a better distinction between the significant, more aggressive and the non-
significant forms of PCa (Table 3). The GG comprises values that range from 1 to 5, which 
makes it easier to understand for patients. A GS 6 out of 10 may sound like an intermediate 




Table 2. The equivalent of ISUP Grade Grouping to Gleason score.  
Modified from Mottet et al. 2016. www.uroweb.org 
 
 
Table 3. Risk stratification of prostate cancer.  
Modified from Mottet et al. 2016. www.uroweb.org 
 
2.3.5 Prostate MRI 
MRI has been used in medical imaging since the 1980s. Initially MRI was used in PCa 
imaging to assess the location and regional staging of patients with a prior positive Bx. With 
time, technical advancements resulted in a better understanding of the capabilities of MRI. 
Today, MRI is used in the differentiation of malignant and benign tissues in the prostate and 
surrounding areas. MRI supports the following objectives: tumor detection, risk 
stratification, assessment of suspected recurrence and image guidance for Bxs, focal and 
radiation therepies, and even surgery. 
Prostate MRI uses 1.5T or 3T magnetic field. T2-weighted imaging (T2WI) depicts the zonal 
anatomy of the prostate [77].  Normal peripheral zone tissue is water-rich and has a bright 
or high-intensity appearance in T2WI. Cancer tissue has higher cellularity and lower water 
content, and therefore PCa located in the peripheral zone are poorly defined and have low-
signal intensity thus creating a contrast with the normal tissue [77]. Conditions such as 
prostatitis, atrophy, and Bx-related hemorrhages may depict similar round images in T2WI 
to those of PCa and therefore low-signal intensity focus does not always indicate PCa 
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exclusively [77]. The transition zone has less water and therefore PCa tumors appear darker 
in T2WI. PCa in the transition zone manifests with indistinct margins and has low-signal 
intensity. BPH in transition zone may also mimic PCa appearance. Nonetheless, T2WI is the 
best at predicting the peripheral zone of the prostate [77]. Another imaging modality used is 
diffusion-weighted imaging (DWI), which is a functional technique that measures Brownian 
motion of water molecules in the tissue [77]. Changes in the strength and duration of the 
magnetic field (indicated by a b value) leads to differences in water diffusion between tissues, 
which can be depicted in images. DWI b values can be used to create an apparent diffusion 
coefficient (ADC) map, where cancer appears as low-intensity dark spots [77]. As a further 
investigation of tumor angiogenesis, T1WI are acquired prior, during and after the 
administration of an intravenous contrast medium, typically gadolinium. This is called 
dynamic contrast enhancement (DCE) imaging. These images are interpreted in terms of 
focal enhancements suspicious of cancer. Additional values including time-to-peak-
concentration, and wash-in or wash-out times, can be calculated to recognize patterns 
typical of PCa [77].  
Magnetic spectroscopy imaging can be used for analyzing cellular metabolite concentrations 
in prostatic tissue. Healthy prostatic tissue has high levels of citrate, whereas cancer tissue 
has decreased values of citrate and elevated values of choline. Elevated choline-to-citrate 
ratios form the basis of distinguishing PCa tissue from healthy tissue [77]. 
 
2.3.5.1 Biparametric MRI 
Biparametric MRI (bpMRI) is one way to perform prostate imaging. It is defined as T2WI 
and DWI sequences without the use of DCE. Compared to mpMRI, bpMRI is faster, cheaper 
to perform and carries fewer risks as no contrast medium is administered. The images are 
also faster to interpret: an mpMRI requires 45 minutes for imaging and 21 minutes for image 
interpretation on average, whereas the corresponding times for bpMRI are only 15 minutes 
and 16 minutes [78]. bpMRI seems to be equally accurate as mpMRI in diagnosing PCa in 
treatment-naïve patients, albeit the heterogeneity of the studies warrants caution in the 
interpretation of data [79-81]. A study compared the detection rates of csPCa between 
mpMRI and bpMRI, using either Bx or prostatectomy specimen as a reference, against the 
performance of the radiologists who had 1, 3 and 7 years of expertise [80]. They found no 
statistically significant differences either in the performance of the radiologists interpreting 
the images of the 85 patients or between the imaging modalities [80]. The BIDOC study was 
a prospective, single-center study that evaluated csPCa (GS≥4+3, or GS≥3+4 and >50% 
cancerous core length) detection rates for 1020 Bx-naïve patients [81]. That study compared 
the Bx-naïve patients’ bpMRI results with the standard Bx route (SBx) and also a combined 
Bx route (SBx plus FBx). Patients were assigned to the combined Bx route when their bpMRI 
showed a suspicion of csPCa. There were no statistically significant differences in csPCa 
detection rates between the standard Bx and combined Bx groups. FBx was performed for 
715/1020 men (70%), and the remaining 305 men (30%) received only SBx. Of these 305 
men with negative MRI, who received only SBx, 8/305 men (3%) were diagnosed with 
csPCa. The negative predictive value (NPV) of bpMRI for ruling out csPCa was 97%. Thus, 
almost 30% of the study population could have been spared Bx when bpMRI results were 
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available. However, their reference standard was prostate Bx, not whole-gland prostate 
specimen after RP [81].  
Even though bpMRI has many advantages in comparison to mpMRI, the lack of DCE affects 
the quality of the images and therefore the use of bpMRI should be restricted to patients 
with no prior PCa treatments [82]. mpMRI is suggested to be performed instead of bpMRI 
for men under the following circumstances: high suspicion of csPCa, ongoing or prior 
surgical or medical intervention of the prostate (including 5-ARIs or testosterone), prior 
operation of hip implants, after a prior negative bpMRI and persistent suspicion of csPCa, 
after a prior negative Bx or during AS [82]. Even though the need for DCE in prostate 
imaging is currently debated, bpMRI seems to be more cost-effective than mpMRI and may 
thus gain popularity in the future [78]. To date, the EAU guidelines do not recommend the 
use of bpMRI [41]. Further studies are needed to determine if imaging can be performed on 
treatment-naïve patients in a biparametric setting without DCE [82]. 
 
2.3.5.2 Multiparametric MRI 
MpMRI is currently the most up-to-date method to visualize the prostate. It combines 
anatomical imaging with physiologic and functional assessment including DCE, DWI and 
ADC [4]. The European Society of Urogenital Radiology has created imaging criteria in order 
to gain the best images of the prostate [83]. mpMRI is fairly accurate at PCa detection. When 
preoperative mpMRI images are matched with RP whole-mount specimens, it has been 
shown that mpMRI will detect large and high-grade tumors. Small (<0.5cm) and less 
aggressive (GG 1) tumors are not easily detected, which makes mpMRI an ideal tool for 
detecting more csPCa (GG ≥2) and fewer clinically insignificant PCa [5-7]. 
To date, there are four high-quality prospective multicenter studies that have assessed the 
performance of mpMRI in PCa diagnostics. These are the PROMIS [5], the PRECISION [84], 
the 4M [85], and the MRI-FIRST [86] studies. 
First, the paired-cohort PROMIS trial (n=576) was published in 2017 [5]. The authors 
compared the detection rates of csPCa (GS≥7) in mpMRI and SBx with template Bx as a 
reference standard. The patients were biopsy-naïve and the Likert scoring system was used 
for mpMRI interpretation. mpMRI was more sensitive (93%; 95% CI 88-96% vs 48%; 95% 
CI 42-55%; p<0.001) and less specific (41%; 95% CI 36-46% vs 96%; 95% CI 94-98%; 
p<0.001) than SBx. The reported NPV for mpMRI for GS≥4+3 PCa was 89%, but lowered 
to 76% when the cut-off was set to GS≥3+4. No targeted biopsies were performed in this 
study, and SBx was taken after template prostate biopsies, hence the hemorrhage and 
swelling of the prostate may have affected SBx results, as no targeting using TRUS was 
feasible. 
Second, the PRECISION trial, published in 2018, compared 500 biopsy-naïve men, who 
were suspected for csPCa due to elevated PSA levels [84]. Patients were randomized into 
SBx and FBx groups. All men underwent mpMRI, and if no suspicion of cancer was evident, 
no Bx was offered. If a PI-RADS 3-5 lesion(s) were seen, men in the FBx group were offered 
a targeted Bx only, and men in the SBx group were offered a SBx only. For the FBx group 
71/252 men (28%) had no suspicion of cancer, hence they did not undergo any Bx. In the 
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FBx vs SBx groups comparison, csPCa (GS≥3+4) was detected in 95/252 (38%) vs 64/248 
(26%) men, respectively (p=0.005). Insignificant PCa was less prevalent in the FBx (9%) vs 
SBx (22%) group (p<0.001) comparison. The follow-up time was, however, absent from this 
study. It is likely that in the future, the authors will publish long-term follow-up results of 
this study cohort. The participating centers also had experienced radiologists who read a 
median of over 300 prostate MRIs yearly. 
Third, the 4M study published in 2019, investigated 626 biopsy-naïve men with a PSA ≥3 
ng/ml and a suspicion of PCa [85]. This study compared the detection rates of csPCa (GS 
≥3+4 or GG≥2) between the SBx pathway (mpMRI and SBx) and the FBx pathway (mpMRI, 
SBx, and in-bore FBx). The men were assigned to the FBx pathway if they had PI-RADS 3-5 
lesion(s) in their MRIs. The study authors reported no statistically significant differences in 
the csPCa detection rates between the FBx pathway (159/626 men, 25%) or the SBx pathway 
(146/626 men, 23%). Detection rates for insignificant PCa was significantly lower in the FBx 
pathway vs the SBx pathway (14% vs 25%, p<0.001). The follow-up time was one year. The 
FBx pathway showed negative mpMRI in 309 men, and among these, SBx detected csPCa at 
a prevalence of only 10/309 (3%). After one year of surveillance the prevalence had risen to 
13/309 (4%). No reference RP data were available for this study. 
Fourth, the MRI-FIRST trial involving a population of 251 men was published in 2019 [86]. 
All patients were biopsy-naïve and underwent an mpMRI prior to Bxs. All men underwent 
SBx, and those with suspicion of csPCa (Likert score 3-5 in mpMRI) also underwent FBx. 
There were no significant differences in the detection rates of csPCa (GS ≥3+4) in the FBx 
pathway (mMRI, SBx + FBx) (29%) or the SBx pathway (mpMRI and SBx) (32%; p=0.4). 
csPCa would have been missed in 5.2% of the study population had SBx not been done, and 
in 7.6% had FBx not been done. The detection rates for csPCa were highest when the two Bx 
methods were combined. FBx in the MRI-FIRST detected fewer low-grade, and low volume 
tumors than SBx. The swelling and hemorrhage after SBx may have affected FBx targeting 
and the results. As in the case of the PRECISION trial, no follow-up time was presented in 
this study. 
The results of these four prospective, multicenter trials are similar: i.e. FBx detects more 
csPCa than SBx, and mpMRI has high NPV. This implies that if an mpMRI shows no 
suspicion of PCa, csPCa is also unlikely in the histopathological samples. 
A recent large meta-analysis of over 14 000 patients reported a higher overall detection rate 
of csPCa (1.16; 95% CI 1.09-1.24; p<0.001) and lower detection rate for clinically 
insignificant PCa (0.66; 95% CI 0.57-0.76; p<0.001) when using the FBx than when using 
the SBx pathway [87]. The authors reported no significant differences between biopsy-naïve  
and previous biopsy-negative cohorts. Another review of 13 845 patients compared the 
detection rate of any, clinically significant, high-grade, and clinically insignificant PCa [88]. 
Compared to SBx, FBx was associated with 15% higher risk of any PCa (95% CI 10-20; 
p<0.001), 11% higher risk of csPCa (95% CI 0-20; p=0.05), and 2% higher risk for high-
grade PCa (95% CI 1-4; p=0.005). There was no difference in clinically insignificant PCa 
between FBx and SBx pathways. Similar results to other meta-analyses were seen in a large 
Cochrane review of over 6800 men that compared FBx to SBx, with different groups 
assigned for Bx-naïve and for those with a prior negative Bx [8]. The review reported that 
overall sensitivity for FBx detecting csPCa was 0.70 and a specificity of 0.96, which 
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outperformed the TRUS SBx detection rates (0.63 sensitivity and 1.00 specificity). The same 
Cochrane review recommends performing mpMRI prior to Bx among Bx-naïve men 
suspicious of harboring csPCa. Furthermore, the EAU guidelines recommend mpMRI to be 
performed for those patients with a suspicion of PCa who are either Bx-naïve or have prior 
negative Bx [41]. 
mpMRI also has its limitations. Using FBx and omitting SBx is beneficial due to the decrease 
of Bx-related complications but a proportion of PCas are missed. The increased proportion 
of missed PCas consists largely of low-risk PCas however, and is estimated to be between 4-
30% of the study cohort undergoing only FBx [85,88-92]. Whether SBx can be omitted is 
currently debated [93]. The increasing use of mpMRI also requires resources and the effect 
on healthcare costs must be further evaluated. Thus, to gain the best results for csPCa 
detection, SBx and FBx should both be performed, but this elevates the risk for Bx-related 
complications and also increases the burden on healthcare systems. 
mpMRI is also used during AS. A consensus statement by Briganti et al. encourages the use 
of mpMRI to either rule out the presence of csPCa at the initial diagnosis of low-risk PCa, or 
before having a confirmatory Bx at 12 months in AS [94]. Targeted Bxs along with SBx are 
recommended when PI-RADS lesions ≥3 are seen. The role of mpMRI during AS and its 
ability to replace repeat Bxs is debated. So far, the evidence in favor of serial mpMRI instead 
of serial Bxs comes only from single-center studies with allegedly established routines and 
expertise for imaging [94-96]. To date, mpMRI and FBxs solely, cannot be recommended to 
replace repeat Bxs [41,97] and PSA and mpMRI only are insufficient for AS [98]. 
 
2.3.5.3 Prostate Imaging Reporting and Data System (PI-RADS) 
The increasing use of mpMRI has led to a need of a structured image reporting system. PI-
RADS was created to diminish variation, unify image interpretation and help reproducibility 
between clinics. PI-RADS is an accurate way to report PCa lesions and visually mark them 
in a sector map (Figure 7). PI-RADS version 1 was launched in 2012 [83]. It is a 5-stage 
classification system to classify lesions suspicious for cancer in MRI. The stages are as 
follows 
• PI-RADS score 1: Clinically significant cancer is highly unlikely 
• PI-RADS score 2: Clinically significant cancer is unlikely to be present 
• PI-RADS score 3: The presence of clinically significant cancer is equivocal 
• PI-RADS score 4: Clinically significant cancer is likely to be present 
• PI-RADS score 5: Clinically significant cancer is highly likely to be present 
• PI-RADS score X: Component of examination inadequate or not performed 
Experiences with PI-RADS version 1 revealed some limitations including the lack of uniform 
structure in reporting findings and no clear threshold for csPCa [99]. Only four years later 
PI-RADS version 2 was published [4]. The changes with the updated version include inter 
alia adjustments in mpMRI technical parameters. Such parameters are ADC map windowing 
and DCE-MRI interpretation recommendations, and also instructions on how reporting and 
prostate sectoring mappings should be performed. It is still too soon to interpret the long-
term results of PI-RADS v 2 but recent validation studies show promising results, which 
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indicate low inter-reader variability within different levels of expertise [99,100]. A few 
studies have compared PI-RADS version 1 and version 2 and show inconsistent results [101-
103]. Their sample sizes are unfortunately small and they use either Bx or RP as a reference 
standard, which introduces more variability. A recent systematic review and meta-analysis 
that evaluated PI-RADS version 2 for PCa detection assessed over 3800 patients’ mpMRI 
results and reported a sensitivity of 0.89 (95% CI 0.86-0.92), and a specificity of 0.73 (95% 
CI 0.60-0.83) [104]. They also compared PI-RADS version 1 with version 2 and reported 
higher pooled sensitivity for version 2 (0.88 vs 0.95, p=0.04) but no difference in specificity 
(0.75 vs 0.73, p=0.90, respectively). Their reference standard was either whole-mount RP 
specimen or Bx. Other studies show similar results [105]. PI-RADS scoring system for PCa 
seems to be a constantly evolving process as PI-RADS version 2.1 has already been published 
[82]. It supports clinicians further on the technical specifications such as clarification of the 
DWI b-values of diffusion, and T2WI planes. The updated version also revises the sector 






Figure 7. PI-RADS sector map for prostate cancer localization in 
multiparametric MRI. PZ=peripheral zone, CZ=central zone, TZ=transition zone, 
US=urethral sphincter, AS/AFS=anterior fibromuscular stroma, a=anterior, p=posterior, 
pl=posterolateral, pm=posteromedial. Reprinted from Weinreb et al. PI-RADS Prostate 
Imaging – Reporting and Data System: 2015, version 2, Eur Urol. Copyright 2015, with 
permission from Elsevier. Accessed Mar. 10, 2020. 
 
2.3.5.4 Likert 
The 5-stage Likert scoring system differs from PI-RADS because it also includes clinical 
data, and is designed to be used in detection, AS, recurrence and post focal treatment 
monitoring. The Likert scoring system rates a score between one and five and is based on 
the overall impression of mpMRI findings [106,107]. The analysis can be performed as 
lesion-based or patient-based. In contrast, PI-RADS was designed to be used only in the 
detection of cancer lesions. PI-RADS also focuses solely on imaging and not clinical data. 
Likert has been shown to be the equivalent or even perform superior to PI-RADS in detecting 
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any PCa [108]. Recommendations on how to report mpMRI during AS has been presented 
by the Prostate Cancer Radiological Estimation of Change in Sequential Evaluation 
(PRECISE) panel, which consists of urologists, radiologists and radiation oncologists [107]. 
Their consensus statement recommends that for follow-up mpMRI reports include a 
likelihood score between one and five for significant change in tumor characteristics, change 
in extension to seminal vesicles, LN or bone lesion, and the appearance of new lesions. The 
expert panel recommendations are necessary for congruent mpMRI reporting during AS. 
 
2.4 Treatment of prostate cancer 
 
2.4.1 Active surveillance and watchful waiting 
Many PCas are small, localized and clinically insignificant and may not affect patients’ life 
expectancies. These PCas are suitable for AS, which is a strategy for deferred PCa treatment. 
Patients who do not require immediate treatment are monitored regularly, and if no signs 
of cancer activation are seen, no radical treatment will be given. Prostate cancer Research 
International: Active Surveillance (PRIAS) protocol is the most used AS protocol in Finland 
[109]. Patients with a life expectancy of at least ten years are eligible for AS when they harbor 
a localized (≤pT2) PCa, have PSA values between 4 and 10 ng/ml, PSA density ≤0.2ng/ml², 
GG score of 1, and a maximum of two cancer cores in Bxs [69,110]. 
At one year after the diagnostic Bx a confirmatory Bx is taken. A recent meta-analysis stated 
that mpMRI should be performed before the confirmatory Bx, and combining TRUS Bx and 
FBx gives the most accurate results in finding csPCa [111]. The opposite results were seen in 
another randomized multicenter trial as the group was unable to prove significant 
differences in GG upgrading in confirmatory Bx between TRUS Bx and the FBx group [97]. 
However, the FBx group received only a median of two samples per target, which may have 
reduced the detection rates of csPCa. Thus, incorporating mpMRI with a confirmatory Bx 
protocol gives different results depending on the experience and volume of the center. 
Monitoring AS patients includes PSA, DRE, TRUS and Bx, which all vary over three to 24 
month intervals. Studies show that OS and cancer-specific survival (CSS) of AS patients at 
ten years after diagnosis are very good and reach values up to 93% and 99%, respectively 
[110,112]. Repeating Bxs during monitoring exposes patients not only to discomfort and 
minor side effects, such as rectal bleeding, but also to major complications such as sepsis 
and even death [113]. During the past decade mpMRI has become an attractive alternative 
to reduce the number of repeated follow-up Bxs mainly due to the high NPV of mpMRI. The 
hypothesis is that patients with a negative mpMRI in addition to stagnant PSA value and a 
normal DRE could be spared from repeat Bx. The studies show mixed results, and the 
limitation is that mpMRI has been shown to miss up to 30% of csPCa [91]. To date, large 
validation prospective studies, such as the ongoing Scandinavian Prostate Cancer Group 
(SPCG)-17 [114], are needed to be able to decide upon whether mpMRI can replace repeated 
Bxs during the follow-up in an AS protocol. 
34 
To conclude, EAU guidelines recommend mpMRI to be carried out on Bx-naïve patients 
with suspicion for PCa and, if possible, combining FBx with SBx in confirmatory Bx [41]. 
However, the volume and experience of the clinic may affect the results of mpMRI [41]. 
The decision of when to change from AS to active treatment is made in cooperation with the 
patient. Usually the criteria include Gleason score upgrading (GU) in repeated Bxs, or stage 
progression, but the patient’s willingness to proceed to active treatment is also taken into 
consideration. PSA kinetics is only weakly associated with grade progression and, therefore, 
should not solely be the reason for change [115,116]. Differences in biomarker expression in 
cancer tissue in Bx have been shown to associate with increased risk of the disease 
progression [10,117]. However, the published results are heterogeneous and clear 
recommendations about the use of biomarkers in AS cannot yet be given [41]. 
No randomized controlled trials exist that compare contemporary AS with standard 
treatments. Interestingly, a recent large trial randomized over 1600 men to receive surgery, 
radiotherapy or active monitoring for local PCa, and the results showed no significant 
difference in cancer-specific mortality irrespective of the treatment assigned. However, the 
monitoring group encountered more metastasis and disease progression than groups with 
active treatments. The monitoring group, though, was monitored almost exclusively by 
measuring PSA. Moreover, a preplanned AS protocol with triggers for treatment was not 
followed thus it does not represent a contemporary AS cohort, such as PRIAS [118]. 
Given the heterogeneity in AS inclusion criteria, the use of mpMRI, incoherence in repeat 
Bx frequency and the timing of clinical follow-up, there is an unmet need for unified rules 
for AS. This project has been initiated and the future will show how the criteria will be 
formed [119]. Cancer extent and other pathology parameters in Bxs have a role [120] and 
accurate detection of cancer locations are important [121,122]. 
Watchful waiting (WW) is a reasonable choice for treatment for men with localized, ≤cT2 
tumor and a life expectancy of less than ten years. It may also be an option for elderly 
patients with metastatic (±castration resistant) PCa and a burden of comorbidities. WW 
aims to refrain from active treatment in order to avoid treatment-related side effects, such 
as urinary incontinence, and compromises in quality of life. WW also aims to avoid 
treatments that do not prolong the patient’s life expectancy, i.e. treatments that would do 
more harm than good. A study of over 19 000 men with PCa aged 66 and older who were not 
given curative treatment were monitored for ten years. Tumor aggressiveness did not have 
a role in OS, which suggests that patients died of other causes [123]. The results of other 
published studies report CSS rates of 82-87% for all, and 80-95% for ≤cT2 tumors with WW 
at 10 years [41,124]. 
 
2.4.2 Radiotherapy 
External beam radiotherapy (EBRT) is a treatment option for PCa. The gold standard for 
EBRT is intensity-modulated radiotherapy (IMRT) with or without image-guided 
radiotherapy (IGRT). A dosage of 74-80 Gy is recommended for the best results to avoid 
BCR and least harm for the normal tissue at five years follow-up [125]. The best OS results 
with IGRT are seen with intermediate or high-risk, but not with low-risk, PCa patients. 
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IMRT is given in a fractionated manner. Hypofractioned IMRT with doses of 2.5-4 Gy is a 
way to reduce the injury of adjacent normal tissue, as pauses in treatment allow for DNA 
repair mechanisms to function [41]. 
EBRT can be used as a part of multimodality treatment for PCa. EBRT is often combined 
with ADT, which is used along with RT for four to six months with intermediate risk and 24-
36 months for high-risk PCa. In a study comparing multimodality vs unimodality 
treatments, the OS rate of combination therapy RT with ADT (58.1%; 95% CI 49.2-66.0) was 
reported superior at ten years when compared to IMRT alone (39.8%; 95% CI 31.9-47.5) 
[126]. 
Other methods of radiating the prostate are also available. High-dose rate brachytherapy 
(HDR-BT) uses temporary implantation of a radiating substance placed near to the patient’s 
prostate and a radiation dose is delivered in minutes. HDR-BT can be combined with IMRT 
for better adjustment of dosage and is a treatment alternative for intermediate-risk PCa. 
However, prospective randomized controlled trials comparing HDR-BT plus IMRT and 
HDR-BT alone are still lacking [41]. 
A detected BCR after RP will induce (salvage) EBRT. It has been shown to improve 
biochemical-free survival time compared with a wait-and-see policy and even offer a cure 
after BCR [41,127]. Salvage RT should be given before PSA rises >0.5ng/ml [41,128]. Salvage 
BT is an option after radical EBRT, when BCR is encountered [129]. 
 
2.4.3 Radical prostatectomy 
The principal treatment for patients with localized csPCa and a life expectancy of over ten 
years is RP. The question who benefits from RP has been studied over the years. A study was 
conducted in randomized patients with localized PCa to RP and WW groups in the pre-PSA 
era [130]. After a follow-up of 13 years the study results showed a significant difference in 
OS, CSS and progression-free survival and significantly fewer bone metastases in favor of 
the RP group. Nearly ten years later in the early PSA era, another randomized controlled 
trial (RCT) of 731 men and follow-up time of 12 years compared RP and WW and found no 
significant differences in PCa-specific mortality [131]. However, patients with PSA 
>10ng/ml or high-risk PCa benefited significantly from RP regarding OS when compared 
with WW. The same study cohort was studied at 22 years, and a small benefit in all-cause 
mortality and increases in years of life gained from RP compared to WW was reported [132]. 
In the RP procedure, prostate, seminal vesicles and possibly iliac LN are removed either in 
an open, laparoscopic or robot-assisted laparoscopic (RALP) prostatectomy. The differences 
between the three techniques have been studied and in 2017 a large Cochrane review 
compiled the results of 446 randomized patients of two studies together [133]. Primary 
outcomes in these studies were CSS, urinary function and sexual quality of life. Secondary 
outcomes were BCR-free survival, OS, overall surgical complications, serious postoperative 
surgical complications, postoperative pain, hospital stay and blood transfusions. There were 
no significant differences in primary outcomes between the techniques. Patients who 
underwent laparoscopic or RALP, however, were discharged from the hospital earlier and 
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received fewer blood transfusions. On a guideline level, no clear recommendation of 
preferred surgical method can be given [134]. 
The role of removing pelvic LN in RP remains a debated topic. The risk of disease spreading 
to the pelvic LNs is assessed using preoperative risk assessment tools and nomograms, and 
a >5% risk of nodal metastases is an indication for LN dissection [134,135]. So far, the 
published reports have high risk of being biased, but implicate that removing LNs gives no 
improvement in oncological outcomes, but extended pelvic LN dissection provides 
information in staging and prognosis of PCa [136]. Furthermore, the optimal number of LNs 
removed is not known. The more extensive the LN dissection is, the more operation time 
and possible complications, such as blood loss, and lymphedema in the lower extremities. 
Therefore, the role of pelvic LN dissection in RP still requires statistically robust RCTs to 
address the issue comprehensively. 
Whether to administer neoadjuvant ADT prior to RP has been evaluated in a number of 
studies and a comprehensive systematic Cochrane review compiled the results together 
[137]. The use of ADT prior to RP shows a significant reduction in positive surgical margin 
rate and significant improvement in LN involvement, pathological staging and organ 
confined (OC) rates. However, the study also reported that PSA relapse-free survival and 
CSS were not shown to improve and therefore the EAU Guidelines do not recommend the 
use of neoadjuvant ADT in clinical practice [134]. 
RP is initially considered a feasible treatment option for localized PCa, and patients with 
high PSA levels (≥20ng/ml), high-grade PCa on Bx, and advanced cancer status have poorer 
survival outcomes when compared with their OC counterparts [138]. However, patients with 
high-risk PCas undergoing RP also have reasonably good results in retrospective studies, 
even though approximately 30% of GG 3-5 PCas are OC at diagnosis [139,140]. The SPCG-
15 is currently recruiting patients into a randomized, multi-center, prospective trial that 
aims to investigate how patients with locally advanced PCa benefit from RP, EBRT and 
possibly ADT vs EBRT and ADT only [141]. This RCT setting will hopefully validate the use 
of RP in advanced disease. 
 
2.4.4 Hormonal therapy 
ADT is defined as either surgical or chemical castration resulting in testosterone levels as 
low as <1.7 nmol/l [142]. Chemical substances include luteinizing hormone-releasing 
hormone (LHRH) -agonists, LHRH-antagonists, oral oestrogens and oral anti-androgens. 
Lack of testosterone in the body arrests the growth and development of hormone-sensitive 
PCas. Side effects include reduced bone mineral density, increased risk for diabetes mellitus 
or cardiovascular disease, diminished muscle mass, depression, loss of libido and hot flashes 
[143]. ADT should be the first-line treatment in metastatic PCa and it should be 
administered at diagnosis [134]. There is at the moment no highest level evidence on which 
ADT method to choose, but some data seem to support the risk of increased side effects in 
chemical castration over surgical castration [144]. 
Bilateral orchiectomy or subcapsular orchiectomy has been performed for decades and is a 
simple, effective and well-tolerated procedure after which castration levels of testosterone 
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are achieved within 12 hours. However, it is irreversible and, therefore, not suitable for 
intermittent treatment [145]. 
Similar castration levels of testosterone are achieved with long-acting LHRH-agonists, 
which are injected at one-, three-, six- or 12-month intervals. LHRH-agonists induce a rise 
in luteinizing hormone (LH) and follicle-stimulating hormone (FSH) and result in a 
testosterone surge. This causes the “flare” phenomenon that begins two to three days after 
the first injection and lasts about one week. When administered to a patient with metastases, 
flare may result in bone pain, acute bladder obstruction, spinal cord compression or 
hypercoagulation [146]. Flare can be countered with additional anti-androgen therapy 
(complete androgen blockade, CAB) that will suppress these symptoms. Chronic secretion 
of LHRH-agonist will cause LH and FSH levels to plummet and therefore testosterone levels 
will lower to castration levels within two to four weeks. There are no differences between the 
LHRH-agonists (leuprolide, buserelin, goserelin) or orchiectomy in terms of effect [147]. 
LHRH-antagonists lead to a rapid fall in FSH and LH levels, which cause testosterone to 
lower to castration levels within three days after administration. This mechanism causes no 
flare. There are only 1-monthly injections of one substance, degarelix, available. Degarelix 
has been shown to perform equally effective as the LHRH-agonists [148], and even cause 
less cardiovascular side effects at one year after the onset of treatment [149]. The long-term 
side effect profile of degarelix vs LHRH-agonist (leuprolin) are under investigation and the 
results are expected in the near future [150]. 
Anti-androgens are either steroidal (cyproterone acetate) or non-steroidal (bicalutamide) 
and they block androgen receptors (AR) and thereby they result in a compensatory rise in 
testosterone levels. Their side effect profile is usually better tolerated and they provide better 
bone-density than LHRH-antagonists because they do not cause testosterone to drop to 
castration levels [151]. Bicalutamide is widely used as an anti-androgen in Finland and it can 
be used as monotherapy or as part of CAB. Non-steroidal anti-androgen monotherapy for 
advanced PCa has been shown to be inferior in performance when compared with LHRH-
agonists or surgical castration in terms of OS, clinical progression and treatment failure, 
therefore monotherapy with bicalutamide is not recommended [152]. 
Administering oestrogen results in testosterone suppression and is equally effective in 
treating PCa as LHRH-agonists. However, oestrogens have a different risk profile and their 
use is associated with increased risk for cardiovascular mortality and thromboembolic 
complications. Their use is not recommended as a first-line treatment [153]. 
Intermittent androgen deprivation therapy (IADT) is a treatment option for some well-
informed patients harboring M1a-b PCa. Allegedly quality of life is better when 
administering IADT but trials have so far not been able to find whether IADT is inferior to 
continuous ADT. Treatment cycles are given at 3-6-month intervals and IADT can be given 
when there is no clinical progression of PCa, when the patient understands the risks of 
possible incomplete castration, and during monitoring PSA responds to treatment [134]. 
In addition to ADT, new compounds have been developed to target the AR axis. Abiraterone 
acetate is a second-generation anti-androgen that inhibits CYP17-enzyme, which mediates 
steroid synthesis. Thereby, abiraterone acetate eventually blocks the synthesis of 
testosterone. Abiraterone acetate with prednisone (5 mg) and with ADT has been shown to 
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prolong OS in metastatic castration-sensitive and castration-resistant PCa in comparison to 
ADT only [154,155]. Another compound, enzalutamide, is a second-generation anti-
androgen that has a high affinity for AR and that also blocks the translocation of AR to the 
cell nucleus. Enzalutamide has been shown to prolong OS among patients with 
nonmetastatic and metastatic castration-resistant PCa when compared to placebo [156,157]. 
Other novel compounds, apalutamide [158-160] and darolutamide [161-164], function 
identically with enzalutamide, but darolutamide does not cross the blood-brain barrier and 
thereby eventually causes less fatigue than other second-generation anti-androgens. 
 
2.4.5 Other treatments 
High-intensity focused ultrasound (HIFU) frequencies are emitted from a probe that is 
inserted near the prostate and this mechanically and thermally coagulates malignant 
prostatic tissue. It can be used to destroy prostatic tissue thoroughly or partially [165]. 
Cryotherapy can also be used to ablate the prostate. It uses needles to transmit low 
temperatures to prostatic tissue to freeze cells and cause protein denaturation [166]. So far, 
no comparative long-term studies on oncological outcomes of ablative treatments exist and 
they are currently not recommended for use by the EAU Guidelines [134,167]. 
 
2.5 Disease prediction 
 
2.5.1 Follow-up after radical prostatectomy 
After radical treatment, patients should be monitored for possible disease recurrence 
irrespective of RP, EBRT or HDR-BT. At three months after radical treatment, the aims are 
to ascertain that PSA levels have fallen below the limits of detection, and also to discuss with 
the patient any complications related to treatment. Radically treated PCa patients have been 
shown to suffer from treatment-related side effects such as urinary incontinence and erectile 
dysfunction, and also mental issues such as depression, lower general health perceptions 
and perceived limitations due to physical problems [168]. 
Six weeks after RP, the PSA value is expected to have fallen below the detection limit [169]. 
Different PSA assays use limits for detection between 0.1 to 0.4ng/ml [170]. If the PSA level 
remains elevated, it may be due to micrometastases, residual disease in the prostatic fossa 
or in the distant body. After EBRT, the decline in PSA to undetectable levels is slower with 
the interval being up to three years or even more [134]. ERBT monitoring with PSA-DT 
calculations may be beneficial. For example, a study showed an association of PSA-DT of 13 
months with local recurrence in comparison of PSA-DT of three months with distant 
metastases [171]. PSA testing at only three- to six-month intervals is sufficient for follow-up 
for the first two years, and thereafter biannually [172]. BCR can be seen with approximately 
30% of radically treated patients and most likely during the first seven years after RP 
[173,174]. However, BCR does not mean the clinical manifestation of recurrent PCa, as this 
can only be seen in about 15% of patients with BCR. Short PSA-DT and short interval to BCR 
after radical treatment are risk factors for poor outcome [175]. 
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2.5.2 Nomograms 
There are a number of different pre-treatment risk stratification nomograms that are used 
for predicting the extent of PCa and pathological stage at RP. The original idea of 
nomograms was to predict PCa death of untreated men, who had recently been diagnosed 
with PCa [176]. However, many nomograms have been developed that also use PCa cohorts 
of treated men and BCR as an end-point and thus have a preselected patient cohort, which 
may skew the results [177]. Some tools use a combination of clinical variables and imaging 
data to predict different stages of PCa, but validation of these nomograms is still needed 
before they can be accepted for wider clinical use [178-180]. mpMRI is expected to 
outperform clinical nomograms in PCa risk prediction [181] as is also discussed in Study IV 
in this PhD thesis. 
The hitherto validated, established risk stratification tools use clinical variables in the 
calculation. A large Swedish population-based registry study in which more than 154 000 
treated and untreated men with PCa were assessed for PCa death to compare different risk 
nomograms [182]. Among the best performing tools were the Memorial Sloan Kettering 
Cancer Center (MSKCC) nomogram and Cancer of the Prostate Risk Assessment (CAPRA) 
Score. However, Partin tables were not included in the study. 
 
2.5.2.1 Cancer of the Prostate Risk Assessment (CAPRA) 
The CAPRA score is a preoperative assessment score for BCR after RP. The original study 
that presented CAPRA, was published in 2005, and included a cohort of over 1400 men who 
were diagnosed with PCa between 1992 and 2001, and who had undergone a RP with no 
neoadjuvant or adjuvant radiation or hormonal therapy [183]. The variables that CAPRA 
evaluate are preoperative PSA, GS, cT stage, Bx results and age. Disease recurrence is 




Figure 8. The CAPRA scoring system. Scores 0-2 indicate low risk, 3-5 
intermediate risk and 6-10 high risk for disease recurrence after radical 
prostatectomy. Reprinted from Brajtbord et al. The CAPRA Score at 10 Years: 
Contemporary Perspectives and Analysis of Supporting Studies. Eur Urol. Copyright 2017, 
with permission from Elsevier, accessed Mar. 10, 2020. 
40 
CAPRA-S is a predictive nomogram for PCa recurrence after RP. In addition to preoperative 
CAPRA variables, it also accounts for extraprostatic extension (EPE), seminal vesicle 
invasion (SVI), lymph node metastases (LNM), pTNM scores and surgical margin status 
(Figure 9) [184].  
 
 
Figure 9. The CAPRA-S scoring system. Scores 0-2 indicate low risk, 3-5 
intermediate risk and 6-10 high risk for disease recurrence after radical 
prostatectomy. Reprinted from Brajtbord et al. The CAPRA Score at 10 Years: 
Contemporary Perspectives and Analysis of Supporting Studies. Eur Urol. Copyright 2017, 
with permission from Elsevier, accessed Mar. 24, 2020. 
 
Where CAPRA and CAPRA-S have been developed for localized PCa, Japan CAPRA (J-
CAPRA) is a risk nomogram for locally advanced or metastatic PCa treated with ADT (Figure 
10). All three CAPRA scores (CAPRA, CAPRA-S, J-CAPRA) have been evaluated recently and 




Figure 10. The J-CAPRA scoring system. Scores 0-2 indicate low risk, 3-5 
intermediate risk and 6-10 high risk for disease progression among patients 
with locally advanced prostate cancer using androgen deprivation therapy. 
Reprinted from Brajtbord et al. The CAPRA Score at 10 Years: Contemporary Perspectives 
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and Analysis of Supporting Studies. Eur Urol. Copyright 2017, with permission from 
Elsevier, accessed Mar. 24, 2020. 
 
2.5.2.2 The Memorial Sloan Kettering Cancer Center (MSKCC) nomogram 
It is likely that the most clinically relevant MSKCC nomogram predicts the probability of 
PCa progressing to LN prior to RP [186]. MSKCC provides different nomograms for pre-RP, 
post-RP and salvage radiation therapy patients and the risk calculation nomograms are 
available on their website (https://www.mskcc.org/nomograms/prostate). The variables 
MSKCC uses are preoperative PSA, age, GS, and cT stage. If available, positive Bx cores are 
also calculated. 
 
2.5.2.3 Partin tables 
Partin tables use preoperative data to predict pathological stage in men with localized 
(≤cT2b) PCa. Partin et al. published their study in 1993 [187]. The authors studied a cohort 
of 703 men with clinically localized PCa, and used GS and PSA combined with clinical stage 
for predicting their pathological stage. The study was conducted at a time when PSA had 
recently been accepted into clinical use and, as treatment protocols and Gleason scoring 
system have evolved, a few updates on the tables have therefore been published [188,189]. 
The Partin tables (Table 4) calculate the probability of different stages of PCa. They seem to 
perform equally good as the MSKCC nomogram in predicting the presence of LN invasion 
in a recent meta-analysis. However, Partin tables are developed for localized PCa whereas 




Table 4. Partin tables. Predicted probability (95% CI) of pathological stage 
according to clinical stage (cTNM), PSA level, and biopsy Gleason score. 
EPE=extraprostatic extension; LN+=lymph node involvement; OC=organ confined; 
RP=radical prostatectomy; SV+=seminal vesicle invasion. Modified from Eifler et al. An 
updated prostate cancer staging nomogram (Partin tables) based on cases from 2006 to 
2011. BJU Int, Copyright 2013, 111, 22-9. Reused with permission under a Creative 
Commons Attributions License, accessed Mar. 25, 2020. 
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2.5.3 Biomarkers in prostate cancer 
Biomarkers are biological molecules found in body fluids or tissues that can be measured 
and evaluated as a sign of abnormal or normal biological condition. They can be used for 
screening, diagnosis, prognosis and monitoring response to treatments. 
 
Figure 11. Clinically validated and novel prostate cancer biomarkers for 
prostate cancer diagnosis and disease prediction. Modified from Saini. PSA and 
beyond: alternative prostate cancer biomarkers. Copyright 2016. Cell Oncol (Dordr.). 
Reused with permission accessed Mar. 5, 2020. 
 
2.5.3.1 PTEN 
PTEN gene and its corresponding protein act as an antagonizing enzyme in the PI3K 
pathway, i.e. PTEN is a tumor-suppressor gene. PTEN is important in cell cycle progression, 
apoptosis, cellular proliferation, invasion and differentiation. It also seems to mediate some 
immune system activities. Inactivating mutations of tumor suppressor gene PTEN leads to 
PI3K activity and up-regulation of Akt/mTOR oncogenic signaling pathways, which cause 
activation of cellular mechanisms typical of cancer increase. PTEN loss is encountered in 
around 20% of primary PCa samples and in up to 50% of castration-resistant tumors, and 
due to this characteristic performance PTEN loss may help in distinguishing between 
aggressive and indolent PCas [190]. PTEN loss is therefore associated with adverse 
oncological outcome [191]. It has also been shown to associate with GU in AS [10], GU in 
RP, and BCR after RP [9,192,193]. Furthermore, PTEN loss has been shown to associate with 
a metastatic PCa becoming castration resistant during ADT [9]. PTEN loss can be detected 





Fusion of the AR regulated transmembrane protease serine 2 (TMPRSS2) with an oncogene 
v-ets avian erythroblastosis virus E26 oncogene homolog gene leads to AR-mediated cellular 
functions to accelerate and it is related to PCa progression and aggressiveness. 
TMPRSS2:ERG fusion and its corresponding protein expression (ERG) is found in body 
fluids and tissue and can be detected in 36-78% of primary PCa. The literature on the role of 
ERG in predicting PCa prognosis is inconsistent but ERG seems to act in concert with PTEN 
[9-11,191,195]. However, the prognostic significance of ERG in PCa as a single marker is 
unclear, and whether ERG positive or negative staining in tissue specimens associates with 
adverse findings is still debated [11,191,195]. However, in combination with other 




Prostate Health Index (PHI) is a blood test that combines the inactive proenzyme form of 
PSA (proPSA), free circulating PSA (fPSA) and actual PSA [197]. A large meta-analysis 
comprising over 2900 men showed that PHI detected PCa with more accuracy than fPSA at 
the first Bx among men with PSA between 2 and 10 ng/ml [198].  
PCA3 is a PCa specific antigen. It is not detected in benign prostate tissue, but is highly 
expressed in PCa. The PCA3 score is obtained in urine after manipulation of the prostate by 
DRE. The most studied benefit for PCA3 is its ability to predict malignancy in men with an 
elevated PSA and a prior negative Bx [196,197]. 
There are a number of other tests that are commercially available, but not yet officially 
approved for clinical use. These tests include the Mi-Prostate score test (incorporating blood 
PSA levels and urinary levels of ERG and PCA3 for prostate risk assessment); the Oncotype 
DX test (a validated multi-gene expression assay used as a predictor for aggressive PCa in 
Bx specimen); the ProMark test (a validated immunofluorescence analysis of eight proteins 
in Bx tissue that predict PCa aggressiveness); the Confirm MDx test (a DNA methylation 
level test used in identifying PCa among men with negative Bx); the Prolaris test (a gene test 
for PCa aggressiveness); the Prostate Core Mitomic test (a mitochondrial DNA alteration 
test for PCa detection); the 4K score test (measurements of total PSA, fPSA, intact PSA, 
human Kallikrein 2 [HK2] in blood plasma, which are later combined with clinical data for 
calculating the risk for csPCa); the Prostarix test (a urine metabolite test for risk 
stratification); and the Decipher test (a genomic test for risk progression after RP) [197]. 
Moreover, a model for detecting csPCa, the Stockholm-3 model (S3M), has been shown to 
perform better than PSA alone. The S3M consists of a combination of plasma biomarkers 
(PSA, fPSA, intact PSA, HK2, MSMB and MIC1), genetic markers, clinical biomarkers (age, 





3. Aims of the study 
 
The aims of the studies reported in this dissertation are as follows: 
 
1. To evaluate the performance of repeat mpMRI among PCa patients in AS, and to study 
the associations between mpMRI-related parameters in predicting GU in Bxs. 
 
2. To evaluate the differences in patient-reported discomfort, pain, and other non-
infectious complications between patients undergoing SBx or FBx. 
 
3. To evaluate the differences in biomarker PTEN and ERG status between preoperative 
mpMRI-visible and invisible PCa lesions, and assess the risk of BCR and non-OC PCa in 
an RP cohort. 
 
4. To evaluate the added value of mpMRI against common risk stratification tools (CAPRA, 


















4. Materials and methods 
 
4.1 Data sources 
All studies were conducted in the Department of Urology, HUS Helsinki University 
Hospitals, Finland. Patients’ prospective data were stored and retrospective data were 
obtained from data banks using the patient’s social security number, which is unique to each 
patient and is comprehensively used in Finland inter alia for identification issues relating to 
health and social services. The collected data include clinical variables such as age, and size 
of the prostate; laboratory data, such as PSA; pathology data in RP and Bx such as GG, cancer 
location, and extension; and imaging data, such as PI-RADS scores, ROI locations, and ROI 
dimensions. 
 
4.2 Study settings 
 
4.2.1 Study I 
In the first study, the study population consisted of men who were diagnosed with PCa and 
monitored according to the PRIAS protocol with at least one control Bx between January 
2002 and May 2015 (n=927). These data were linked to patients who had MRI of the prostate 
taken between January 2005 and May 2015 (n=3352). The final number of patients with 
<cT2, initially GS 3+3=6 PCa, ≥2 SBxs, PSA-density <0.2 ng/ml, and ≥2 MRIs of the 
prostate reported according to PI-RADS was 76. mpMRIs were reported according to PI-
RADS v 1.0 by four uroradiologists with at least five years of experience each in interpreting 
prostate MRI. One or more prostate MRIs had earlier been taken in the pre-PI-RADS era for 
58 patients, and these MRIs were re-reported by one uroradiologist who was blinded to the 
clinical data. Repeat mpMRIs were perfomed at the urologists’ decision when deemed 
clinically necessary. Lesions identified by mpMRI were graded as either positive (PI-RADS 
scores 3-5) or negative (PI-RADS scores 0-2), and each lesion was separately scored and 
measured. When multiple lesions were seen, the one with the highest PI-RADS score was 
included in the analysis. When multiple equally aggressive lesions as evaluated according to 
the PI-RADS were seen, the largest lesion was included in the analysis. 
Pathological progression was considered as GS ≥7 in any follow-up Bx during AS. Treatment 
change (TC) was considered as clinical stage ≥T3, ≥3 positive Bx cores, i.e. any event that 
discontinued AS based on the PRIAS protocol. mpMRI progression in subsequent mpMRIs 
was considered as an increase in PI-RADS score, appearance of new lesion(s), or an increase 
of ≥0.1 cm³ in lesion size. mpMRI regression in subsequent mpMRIs was considered as a 
decrease in PI-RADS score, disappearance of lesions(s), or a decrease of ≥0.1 cm³ in lesion 
size. 
The study end-points were the association of PI-RADS and mpMRI-related parameters in 
predicting GS upgrading >3+3=6 and protocol-based TC from AS to active treatment. We 
also sought to characterize and report the changes in repeat mpMRI during AS. 
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4.2.2 Study II 
In the second study we conducted a subanalysis of a prospective trial that was conducted 
between January 2015 and February 2016. The study evaluated the incidence of 
fluoroquinolone-resistant bacteria in prebiopsy rectal swabs and any Bx-associated 
complications (trial no. NCT02140502). The inclusion criteria for our study were age <80 
and referral for Bx due to suspicion of PCa because of abnormal DRE findings, elevated PSA 
or both. A total of 262 patients were eligible for our study, 203 of whom underwent SBx and 
and 59 FBx. One hour before Bx 750mg Ciprofloxacin was administered as antimicrobial 
prophylaxis. If patients had travelled to countries with a higher risk of extended-spectrum 
betalactamase-producing bacteria, or had a hypersensitivity reaction to fluoroquinolones, 
3g oral phosphomycin was used instead two hours before Bx. Moreover, all patients received 
a periprostatic 10-ml injection of 1% lidocaine under TRUS guidance prior to Bx.  
The end-points of the study were pain and discomfort at 0 days reported by patients using a 
numeric rating scale (NRS) of zero to ten. At 30 days, pain and discomfort were measured 
on a scale of one (no inconvenience) to four (maximal inconvenience). Symptoms, such as 
hematuria, hematospermia, rectal bleeding, and fever, were also reported dichotomously 
(yes/no) at 30 days. Patients’ willingness to undergo rebiopsy was also measured. The 
questionnaires used in this study were originally created for the use in the ProtecT trial [200] 
and later modified for the PRECISION trial [201]. We used the same questionnaires 
translated into Finnish. 
 
4.2.3 Studies III-IV 
In studies III and IV, we compared patients’ preoperative mpMRI images to their RP 
specimens. A 3T MRI scanner, with the modalities of T2WI, DWI, ADC mapping, and DCE, 
producing 3-mm thick image slices, was in use. In total, 598 patients underwent RALP 
between January 2014 and September 2015. An extended lymphadenectomy was performed 
when the MSKCC nomogram showed >5% scores and patient had a GG ≥3 disease. Prostate 
glands were processed in sagittal, vertical and horizontal planes. Lymphadenectomy 
specimens were dissected individually. The 598 patients were linked with imaging data and 
387 patients also had an mpMRI of the prostate prior to the operation. The 211 RALP 
patients who did not undergo a preoperative mpMRI were also monitored and any obvious 
selection bias was not encountered. 
In study III, PI-RADS scores of 3-5 with a corresponding histopathological cancer lesion(s) 
were considered as mpMRI visible lesion. Histopathological cancer lesions with absent or 
PI-RADS score 0-2 lesion were considered as mpMRI invisible lesion(s). The study cohort 
was divided into subgroups in accordance to mpMRI visibility: patients with mpMRI visible 
lesions only (Group A, n=90), patients with both mpMRI visible and invisible lesions (Group 
B, n=221), and patients with mpMRI invisible lesions only (Group C, n=35) as illustrated in 
Figure 12.  
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Figure 12. Flowchart of patients and division into groups A (mpMRI visible 
only, n = 35), B (mpMRI visible and invisible, n = 221) and C (mpMRI invisible, 
n = 35). Modified from Eineluoto et al., Eur Urol Focus 2020.  
 
Tissue micro arrays (TMA) were constructed from RP tissue and organized as follows: ROIs 
were punched with 1.0 mm puncher core per, which represented three cores per primary 
ROI, and two cores per secondary and tertiary ROI. One adjacent benign core was added as 
a staining control. Moreover, all missed csPCa foci were marked on the slides and the most 
significant missed foci were punched and these represented mpMRI invisible lesions. For 
the TMA blocks, 4 µm thick sections were cut, stained for H&E, PTEN and ERG and mounted 
on electrically charged glass slides. Annotations were made by three individual 
uropathologists (KeS, SN and TM), see Figures 12 and 13. Antibodies for PTEN and ERG in 
TMAs were scored by three individual observers (JE, KoS, TM). Benign prostatic epithelium 
for PTEN and endothelial cells for ERG were used as positive staining controls. Cytoplasmic 
PTEN expression in cancer cells were dichotomously interpreted as positive or negative in 
comparison to benign epithelium. Cancer epithelial cell nuclear ERG staining was reported 
as low, intermediate or strong, although later in the final analysis these were dichotomized 
as negative (negative or low) or positive (intermediate or strong). The biomarker data were 
compared with clinical and mpMRI data. A total of 346 patients were eligible for the 
analysis. The study end-points were used to assess whether pathology-verified PCa lesions 
in RP specimen differed in PTEN and ERG status between mpMRI invisible and mpMRI 
visible lesions. In addition, biomarker expression was compared with preoperative PI-RADS 




Figure 13. Immunohistochemical staining for PTEN. A) PTEN Negative 
(intact) in benign and tumor tissue; B) PTEN Loss in tumor but not in benign 
tissue. Reprinted from Lotan et al. PTEN loss as determined by clinical-grade 
immunohistochemistry assay is associated with worse recurrence-free survival in prostate 




Figure 14. Immunohistochemical stainings for PTEN and ERG. a) PTEN Loss; 
b) ERG Positive; c) PTEN Loss; d) ERG Negative. Reprinted by permission from 
Copyright Clearance Center: Nature Publishing Group. Lahdensuo et al. Loss of PTEN 
expression in ERG-negative prostate cancer predicts secondary therapies and leads to 
shorter disease-specific survival time after radical prostatectomy. Mod. Pathol. Copyright 
2016. 
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In study IV, data for CAPRA, Partin tables and MSKCC nomograms were collected for 
patients and these data were compared with prospectively collected RALP cohort data, 
which comprised age, clinical stage, PSA, primary GS, secondary GS, number of positive Bxs, 
and the total number of Bxs. mpMRI data were compared with these RALP data. Partin 
tables include only patients with TNM ≤cT2c. Therefore, Partin tables were excluded from 
the analyses of scores above that. GG (≥3), cTNM (≥3) and PI-RADS (≥3) scores were 
dichotomized for predicting adverse findings in RP. In total, 387 patients were eligible for 
the analysis. Study end-points were non-OC findings (SVI, LNM, EPE) of PCa and the 




4.3.1 Study I 
Pearson’s χ2 test of independence and Cramer’s V were used to analyze the association 
between the variables. All analyses were carried out using SPSS ® Statistics software 
(version 21; IBM, Armonk, NY, USA). A two-tailed p-value of less than 0.05 was considered 
significant. 
 
4.3.2 Study II 
Comparisons between the Bx groups were made using Pearson’s χ2 test and the Mann-
Whitney U test. The factors affecting willingness to undergo rebiopsy were assessed using 
logistic regression analysis. The factors studied were discomfort immediately after Bx, NRS 
immediately after Bx, age, Bx type (SBx or FBx), and the number of previous Bx procedures. 
Data were analyzed using SPSS ® Statistics software (version 23). A two-tailed p-value of 
less than 0.05 was considered significant. 
 
4.3.3 Studies III-IV 
In study III, Pearson’s χ2 test and Fisher’s exact test were used for analyzing comparisons 
between mpMRI visible and invisible groups. Logistic regression including the area under 
the receiver operating characteristics curve (ROC AUC) was used for investigating the (1) 
non-OC findings (EPE, SVI, LNM) in RP and (2) BCR after RP. Kaplan-Meier survival curve 
analysis for BCR (two consecutive PSA values >0.2 ng/ml after RALP) and Cox proportional 
hazard models were performed. 
In study IV, multivariable logistic regression models were run to address the relationship 
between adverse findings (EPE, SVI, LNM), Partin Table estimates, MSKCC preoperative 
nomogram, and clinical variables. Cox proportional hazards models and Kaplan-Meier 
survival curves for predicting BCR were constructed and analyzed. Models were evaluated 
with and without mpMRI using decision curve analysis, ROC AUC curve and the 
multiparametric Wald test. Imputation of missing values by chained equations was used for 
81 patients who had missing values for positive and total Bx cores [202]. 
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For both studies, a two-tailed p-value of less than 0.05 was considered significant. R 
Statistical Software v. 3.6.1 was used for statistical analyses using the packages survival and 
mice for study III, and, in addition to those, precrec and mfp for study IV [203]. 
 
4.4 Ethics statement 
The studies were approved by the Institutional Ethics Committee of Helsinki University 
Hospital. The Committee’s approval waived the need for patient consent in the retrospective 
setting of studies I and III-IV.  Study II was prospective and all participating patients gave 



























5.1 Study I 
The median (range) interval between the two MRIs was 24 months (4-73 months) for all 
patients, 41 months (5-73 months) for those patients who continued AS and 14 months (4-
72 months) for those who underwent TC from AS to active treatment. 
mpMRI progression in repeat mpMRIs was seen in 53/76 (69%) of the patients: a PI-RADS 
score increase was seen in 7 (9%), an increase in lesion size for only 8 (10%), an increase in 
the number of lesions in 6 (8%), and a combination of these for 32 (42%) patients (Figure 
15). mpMRI images were unchanged, i.e. radiologically stable, in 18 (24%) patients. mpMRI 
regression, i.e. a combination of decreases in the lesions’ number, size and PI-RADS score, 
was seen in five (7%) patients. 
 
 
Figure 15. Serial multiparametric MRI results. Modified from Eineluoto et al. PLOS 
ONE, 2017. 
 
mpMRI progression was not statistically significantly associated with GS upgrading (GU) 
>3+3=6 in repeated Bxs (χ2 = 0.12; φ = 0.039; p = 1) but it was moderately associated with 
TC (χ2 = 4.0; φ = 0.23; p = 0.045). PI-RADS scores of 4-5 in the primary mpMRI were 
strongly associated with GU (χ2 = 8.6; φ = 0.34; p = 0.008) and TC (χ2 = 6.8; φ = 0.30; p = 
0.009), see Table 5. PI-RADS scores of 4-5 predicted GU with a specificity of 0.62 (95% CI; 
0.52-0.77), and a sensitivity of 0.80 (95% CI; 0.51-0.95). Their negative and positive 
predictive values were 0.93 (95% CI; 0.80-0.98) and 0.34 (95% CI; 0.21-0.55). GU ≥7 in 




Table 5. Serial multiparametric MRI progression (an increase in tumor size, 
number or volume) and protocol based treatment change, cross-tabulation. 
Modified from Eineluoto et al. PLOS ONE, 2017. 
 
In total 14 patients had ≥3 mpMRIs and their performance in serial mpMRI is illustrated 




Figure 16. Characteristics of serial multiparametric MRI changes in 14 patients 
with ≥3 multiparametric MRIs.  Each ball refers to single mpMRI and the color 
indicates the PI-RADS score. Number refers to number of suspicious lesions. Horizontal axis 
= time in moths; Vertical axis = patient number. Modified from Eineluoto et al., PLOS ONE, 
2017. 
 
5.2 Study II 
Immediately after Bx, there were no differences between FBx and SBx groups in NRS pain 
scores (3.0 [interquartile range, IQR 1.0-5.0] vs 3.0 [IQR 2.0-5.0]; p=0.23) or median 
discomfort scores (4.0 [IQR 2.0-6.0] vs 5.0 [IQR 2.0-7.0]; p=0.35). At 30 days, pain scores 
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differed significantly between the FBx and SBx groups (12/59 [20%] vs 70/203 [34%]; 
p=0.043). Hematuria was also significantly less common in the FBx group (26/59 [44%] vs. 
140/203 [69%]; p<0.001). At 30 days, there were no statistically significant differences 
between the FBx and SBx groups for rectal bleeding, hematospermia, fever, or discomfort. 
Response rates for the questionnaires immediately after the FBx and at 30 days after the 
FBx were 51/59 (86%) and 50/59 (85%). The rates for both questionnaires in the SBx group 
were 180/203 (89%), see Table 6. 
 
 
Table 6. Symptoms immediately after biopsy and at 30 days after biopsy, and 
the number of responses to questions. Modified from Eineluoto et al. Eur Urol Oncol, 
2018. 
 
Patients who were willing to undergo a rebiopsy after initial Bx reported significantly lower 
median NRS pain (3.0 [IQR 2.0-5.0] vs 5.0 [IQR 4.3-6.0]; p<0.001) and discomfort scores 
(4.0 [IQR 2.0-6.0] vs 7.0 [5.0-8.0]; p<0.001) in comparison to the group unwilling to 
undergo rebiopsy (Table 7). The group willing to undergo rebiopsy reported significantly less 
fever (6/195 [3.1%] vs 6/28 [22%]; p=0.001) and discomfort (2.0 [IQR 1.0-2.0] vs 2.0 [IQR 
2.0-3.0]; p=0.008) at 30 days after Bx in comparison to the group unwilling to undergo a 
rebiopsy. There were no differences in hematuria, hematospermia, hematochezia, and pain 
at 30 days after the procedure between the willing and unwilling groups for rebiopsy. 
Multivariable ordinal logistic regression analysis showed that increasing discomfort scores 
immediately after Bx were significantly associated with a reluctance to undergo a rebiopsy 
at 30 days (OR 1.5; 95% CI 1.2-1.8). There were no statistically significant association in the 
ordinal logistic regression analysis between the willingness to undergo rebiopsy and age of 
the patient (OR 0.99; 95% CI 0.95-1.03), the NRS score immediately after Bx (OR 1.1; 95% 
CI 0.87-1.3), the number of previous Bxs (OR 0.95; 95% CI 0.73-1.2), and Bx type (OR 0.62; 




Table 7. Differences in symptoms between patients willing and unwilling to 
undergo repeat biopsy. Modified from Eineluoto et al. Eur Urol Oncol, 2018. 
 
5.3 Study III  
In the comparison of patients with mpMRI visible to those with mpMRI invisible lesions, 
the latter harbored significantly less EPE (44.6% vs. 11.4%; p<0.001), less SVI (21.1% vs 0%; 
p=0.003), fewer LNM (12.2% vs 0%; p=0.033), and more OC tumors (≤pT2; 55.4% vs 
88.6%; p<0.001) and their lesions had lower GG. PTEN loss was encountered significantly 
less often in mpMRI invisible than mpMRI visible lesions (17.2% vs 43.3%; p=0.006). 
Positive ERG expression was more often encountered in patients with mpMRI visible 
lesions, but the differences between the groups were not statistically significant (Table 8). 
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Table 8. Characteristics of radical prostatectomy patients in multiparametric 
MRI visible and invisible groups, and characteristics of tumor lesions between 
groups, cross-tabulation. Modified from Eineluoto et al. Eur Urol Focus, 2020. 
 
In ROC AUC analysis, mpMRI had a significant role in predicting non-OC findings after RP 
(p=0.006, Figure 17). Biomarkers did not add benefit significantly to this. In the multivariate 
logistic regression analysis, the clinical (age, cT≥3, preoperative PSA) and mpMRI (prostate 
volume, any non-OC finding) variables significantly predicted non-OC disease. PI-RADS 









Figure 17. Prediction of non-organ confined disease at radical prostatectomy 
histopathological analysis. ROC AUC analysis by DeLong’s test for significance 
between different groups of variables. Modified from Eineluoto et al. Eur Urol Focus, 
2020. 
 
BCR was encountered significantly less among patients with mpMRI invisible than those 
with mpMRI visible lesions (5.7% vs 21.1%; p=0.039; Table 8). Kaplan-Meier BCR-free 
survival curve analysis was carried out for groups A, B and C. Group C had the best BCR-free 
survival, but the result was not statistically significant (p=0.09; Figure 18a). The cohort was 
then dichotomized into groups A (mpMRI visible) vs B+C (mpMRI invisible and additional 
≥1 visible lesion) and same analysis was repeated. The groups were clearly separated in the 
analysis but the results were not statistically significant (p=0.055; Figure 18b). For clarity, 
the analysis was repeated with the dichotomization of groups A +B vs C and the results were 
non-significantly different (p=0.1; Figure 18c). 
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Figure 18. Biochemical recurrence-free survival curves between the groups 
with different multiparametric MRI visibility of prostate cancer lesions. a) 
Groups A vs B vs C; b) Groups A vs B + C; c) Groups A + B vs C. 
Group A = multiparametric MRI visible lesions only, n = 90;  
Group B = multiparametric MRI visible and invisible lesions, n = 221 
Group C = multiparametric MRI invisible lesions only, n = 35.  
Modified from Eineluoto et al. Eur Urol Focus 2020. 
 
The ROC AUC analysis for BCR-free survival found significant differences (p=0.001; Figure 





Figure 19. Prediction of biochemical recurrence after radical prostatectomy 
histopathological analysis. ROC AUC analysis with DeLong’s test for 
significance between different groups of variables. Modified from Eineluoto et al. 
Eur Urol Focus, 2020. 
 
PTEN loss/intact and ERG positive/negative staining did not statistically significantly 
differentiate the study cohort for BCR-free survival (p=0.5, and p=0.2; Figure 20). 
Moreover, biomarker statuses or mpMRI visibility groupings (A vs B vs C; A vs B + C) did 
not differ statistically significantly from a model without these variables in Cox proportional 




Figure 20. Biochemical recurrence-free survival between the groups with 
different biomarker status. a) PTEN intact/loss; b) ERG positive/negative. 
Modified from Eineluoto et al. Eur Urol Focus, 2020. 
 
5.4 Study IV 
In multivariable logistic regression models without mpMRI, all clinical variables except age 
were significantly associated with adverse findings in RP. All risk nomogram models in 
combination with mpMRI variables were significantly different from the models without 
mpMRI (Wald test, p <0.001), see Table 9. 
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Table 9. Regression model summaries: prediction of any adverse findings at 
prostatectomy. Modified from Sandeman et al. Prostate MRI added to CAPRA, MSKCC 
and Partin cancer nomograms significantly enhances the prediction of adverse findings and 
biochemical recurrence after radical prostatectomy. PLOS ONE, 2020. 
 
In ROC AUC analyses mpMRI was added to the models and the combination of mpMRI and 
risk nomograms outperformed every model without mpMRI. A net benefit was seen in the 
decision curve analysis in models that combined mpMRI (Figure 21). 
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Figure 21. Additive predictive value of any adverse findings by multiparametric 
MRI in ROC AUC and decision curve analysis for a) clinical characteristics; b) 
Partin table estimates; c) MSKCC nomogram parameters. Modified from 
Sandeman et al. Prostate MRI added to CAPRA, MSKCC and Partin cancer nomograms 
significantly enhances the prediction of adverse findings and biochemical recurrence after 
radical prostatectomy. PLOS ONE, 2020. 
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In Kaplan-Meier analysis for BCR-free survival, CAPRA risk groups (high, intermediate and 
low) and MSKCC 3-year survival probability at 80% separated the groups statistically 
significantly. Furthermore, mpMRI prediction for non-OC PCa shows a significantly worse 
BCR-free survival time than mpMRI with OC PCa (Figure 22). All preoperative clinical 
variables separated the nomogram vs nomogram + mpMRI groups statistically significantly 
in Kaplan-Meier survival curve analysis: clinical TNM stage ≥3 vs <3, p<0.001; percentage 
of positive Bxs ≥50% vs <50%, p<0.001; GG≥3 vs GG<3, p<0.001; preoperative PSA 
<10ug/l vs ≥10ug/l, p<0.001; mpMRI prediction of OC PCa vs any sign of non-OC PCa, 
p=0.001; age <65 years vs ≥65 years, p=0.034. 
 
 
Figure 22. Biochemical recurrence-free survival. a) CAPRA nomogram results 
for high, intermediate and low risk groups; b) CAPRA results with 
multiparametric MRI indicating non-organ confined findings; c) MSKCC 3-
year survival probability with a cut-off 80%; d) MSKCC with multiparametric 
MRI indicating non-organ confined findings. ANY=suggestion of extraprostatic 
extension, seminal vesicle invasion or lymph node involvement in prostate MRI; 
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MRI=magnetic resonance imaging; OC=organ confined. Modified from Sandeman et al. 
Prostate MRI added to CAPRA, MSKCC and Partin cancer nomograms significantly 
enhances the prediction of adverse findings and biochemical recurrence after radical 































6.1 Study I 
We found that 69% of patients had mpMRI progression in serial mpMRI during AS. Tumor 
progression in subsequent mpMRIs was significantly associated with TC. A negative mpMRI 
was also unlikely to show histological upgrading in follow-up Bxs.  
Our study cohort was highly preselected. Detecting GG ≥2 PCa after two “clean” mpMRIs 
and multiple Bxs is unlikely, as large, high-grade tumors are usually detected earlier during 
surveillance. Nevertheless, 20% of the study population still showed GU and 69% showed 
mpMRI progression. Similar proportions of follow-up drop-outs have been seen in a large 
GAP 3 cohort with over 15 000 patients [204]. This suggests that the current PRIAS 
monitoring protocol, which relies on PSA-DT and SBxs, is insufficient for identifying csPCa. 
It emphasizes the importance of regular follow-ups even when patients with low-risk PCa 
are selected to AS. It also reveals our limited ability to find csPCa at the time of diagnosis 
and consequently accurately predict the behavior of PCa over time using traditional tools. 
Follow-up with repeated Bxs may be harmful to patients and compliance rates fall due to 
Bx-related complications such as infections [205,206]. mpMRI might be an additional tool 
for monitoring patients on AS and in delaying or even avoiding Bxs, but the literature is 
scarce and contradictory. At the time of writing Study I, there were no standardized criteria 
for mpMRI progression and regression and also our cut-off criteria were completely 
arbitrary. Therefore, we focused on depicting the changes of serial mpMRIs over time as 
illustrated in Figure 15. To date, a task force comprising urologists, radiologists and 
radiation oncologists published PRECISE recommendations of how to perform mpMRI 
during AS [107]. However, the task force still could not reach a consensus about criteria for 
radiological progression or regression in mpMRI. 
Recently, a number of studies that evaluated serial mpMRI in AS have been published 
[95,98,207-211]. A study protocol close to ours was published by Hsiang et al. [207]. In their 
retrospective study, 129 AS patients underwent at least two consecutive mpMRIs and some 
radiologic reports of the study population had to be re-reviewed according to PI-RADS. 
Unlike in our study, every patient with PI-RADS ≥3 lesion underwent FBx in addition to 
SBx. Their criteria for mpMRI progression were an increase in lesion size, an increase in the 
number of ROIs or a doubling of index lesion volume. In our study, we did not use doubling 
of index lesion size as a criterion, but we used an arbitrary increase in size of ≥0.1cm³. The 
Hsiang study results show similarities with ours: histopathological upgrading in Bx occurred 
in 24% (ours 20%), median time interval between two mpMRIs was 14 months (ours 24 
months), and they could not demonstrate an association between mpMRI upgrading and 
GU, but PI-RADS 4-5 in the initial mpMRI associated with GU. Another multicenter study 
by Klotz et al. randomized 273 AS patients with GG 1 to receive either SBx or mpMRI and 
FBx at one year confirmatory biopsy [97]. Their end-point was the number of patients 
receiving GU (GG ≥2) at confirmatory Bx.  The results showed no difference in GU rates 
between the groups. Further, they conducted a follow-up of two years for patients with GG≤1 
at confirmatory Bx and mpMRI was performed at the end of follow-up [212]. Their end-
point was the difference in AS failure between the groups. There were 50% fewer AS failures 
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and significantly fewer csPCa in the mpMRI arm at two years. In the other studies 
mentioned above, study settings, follow-up protocols, and triggers for additional Bx or active 
treatment were found to differ and the number of patients in these cohorts were small. The 
results of the use of mpMRI in AS have been pooled together by a few systematic reviews 
and meta-analyses [213,214]. Results are somewhat concordant and show that mpMRI can 
be used as a monitoring tool for AS and even more data supports the view that it can 
substitute SBx during follow-up. A negative mpMRI also seems to carry a low probability of 
GU. 
mpMRI is recommended by the current PRIAS protocol instead of TC for patients with PSA 
DT <3 years, as PSA DT was found to be an insufficient variable for measuring PCa 
progression [64]. mpMRI shows high NPV in non-AS [89,215] and AS cohorts [216,217] and 
it is therefore a promising substitute for Bx in surveillance. Moreover, our results show an 
NPV of 0.93 and also that low PI-RADS scores were not useful in detecting high GS PCa. 
These findings are in concordance with other published results and they indicate the 
possible benefit of mpMRI in PCa diagnostics. However, longer follow-ups for studies are 
needed to confirm this, and also to elucidate the nature of serial mpMRI. 
The limitations of this study were its retrospective nature and the lack of a standardized Bx 
protocol based on mpMRI findings. FBx was not available at the time of study, and therefore 
cognitively assessed Bxs were occasionally taken in addition to SBxs. The retrospective 
nature of the study limits the use of these additional cores and also the accompanying data 
of that time cannot be identified and evaluated. The great technological advancements in 
mpMRI during the study period may have affected the diagnosis and interpretation of 
images. For instance, early mpMRI images may not be entirely corresponding by current 
standards, as tumor detection with lower b-values may be poorer. However, the T2 
sequences that measure tumor size remained unchanged and, therefore, we believe that 
these changes did not have a major impact on our study. Some of the mpMRIs in our study 
population had to be re-read by one radiologist. However, the radiologist was blinded to the 
clinical data. 
The strengths of our study include the use of the structured PI-RADS scoring system for PCa 
lesions, the comparatively long intervals between mpMRIs and the use of a well-established 
monitoring protocol for AS (PRIAS). Our previous study from the pre-PI-RADS era show 
poor results in the association of mpMRI and GU [218]. The results of our current study are 
in contrast to this. The cohort spans almost a decade, and during this time considerable 
technological developments in MRI imaging and the implementation of PI-RADS occurred, 
which probably explain the differences in results between our two studies. The European 
Society of Urogenital Radiology Guidelines for prostate imaging were published in 2012 and 
these further facilitate the repeatability of the procedure. Prostate mpMRI reported in a 
structured format is of greater value to the clinician than a subjective narrative, which 
highlights the importance of structured mpMRI evaluation [91,215]. 
The use of mpMRI and MRI-assisted applications in AS are becoming more commonplace. 
Grading factors other than GG and mpMRI, such as biomarkers, are expected to emerge in 
the years to come. Our results support the use of mpMRI in decision making whether 
patients on AS should continue surveillance or opt for active treatment. mpMRI should be 
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incorporated into randomized AS trials to elucidate further its potential benefits, and this is 
being done in the current SPCG-17 trial [114]. 
 
6.2 Study II 
We found FBx to be significantly associated with less pain and hematuria than SBx after 30-
day period following the procedure. Pain, fever and discomfort scores differed significantly 
between the two groups, either willing or unwilling, to undergo rebiopsy in favor of the 
willing group. 
Pain is a challenging concept to grasp. It is influenced by a variety of factors in the Bx 
procedure such as personal characteristics, transrectal probe insertion, and how local 
anesthetic is administered prior to the procedure [219-221]. Publications have shown that 
falling compliance rates during AS occur and this may be due to complications such as pain, 
discomfort and infections [205,222]. However, Bxs are needed in virtually all AS protocols, 
and as the median age for PCa diagnosis ranges between 64 and 70 years, patients probably 
will undergo many episodes of Bxs during years of follow-up [223]. The aim would therefore 
be to minimize harm in order to increase patient compliance to follow-up. Considering this 
mpMRI would offer benefits in two ways. First, if mpMRI can be coupled to a prognostic 
factor, such as a biomarker, it could help identifying patients with low-risk PCa for whom 
follow-up Bxs could be postponed or even avoided. Second, if mpMRI-based FBx technology 
reduces pain and complications, patient willingness to follow-up Bxs will be greater, as 
shown in our study. 
The literature concerning patient experience on MRI-assisted targeted Bx is sporadic [224-
227]. In contrast, SBx and pain prevention methods have been investigated more frequently 
[219,221,228]. With regard to pain, the optimum number of Bx cores is unknown. SBx 
consists of eight to 12 cores, whereas FBx uses fewer cores, usually one to four. We had a 
median of three cores per patient in the FBx group, and this is a mere 25% of the cores of 
the SBx group. This difference may partly explain the differences in pain and discomfort. 
Fusing MRI images to US requires more time, and this may contribute to the time the local 
anesthetic is allowed to function before the initiation of Bxs. Interestingly, a study showed 
no difference in patient-experienced pain with zero minutes vs five minutes of waiting time 
after administration of local anesthetic prior to Bxs [229]. We did not record the waiting 
times in this study, but it is unlikely that the mean exceeded five minutes as the whole FBx 
procedure generally lasts eight to ten minutes. Thus, the puzzle of lower pain scores of the 
FBx group remains unsolved. 
Most, if not all, AS protocols rely on repeat Bxs during follow-up. For this reason, in our 
study, one of the questions was: “How inconvenient would a rebiopsy be, if needed?” In the 
FBx and SBx groups, 73% and 75% of the cohort answered “no or minor inconvenience”, 
which is in line with a previous Finnish study where over 80% of the study cohort were 
willing to undergo rebiopsy and 2% refused [230]. In our study only 1% (2/362) answered 
that rebiopsy, if needed, would cause “maximal discomfort”. The method of questioning and 
study setting differ between these studies but the results are in still in agreement. 
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Limitations of the study include the nonrandomized design, as blinding for the Bx procedure 
cannot be feasibly achieved under normal clinical conditions. Therefore, any bias by the 
urologist or patient toward the outcome of one method or the other will remain even though 
randomization would allow for equal distribution of confounding factors and associated 
biases. Moreover, the small number of patients was a limitation and the response rates to 
questions were occasionally moderate, which may diminish the statistical power and 
introduce bias into the study. 
The strengths of this study, on the other hand, include its prospective setting, the use of a 
validated and commonly known NRS tool for measuring pain, and the 30-day questionnaire. 
Our results are directly reported by patients and analyzed by the authors and therefore omit 
any interpretation by a third party. The study cohort also included patients in a typical 
clinical setting and therefore our results can be generalized to everyday practice. 
Given these findings, we suggest that FBx may become the preferred method of choice not 
only for its diagnostic accuracy but also due to its fewer associated side effects. Infections 
and complications after Bx such as hematuria are a major cause of hospitalization. If SBx is 
increasingly replaced by FBx, this may reduce Bx-related complications and, thus, cut 
complication-related costs and allow for the higher expenditure for the use of mpMRI. These 
issues were more profoundly addressed by the PRECISION trial, which is a large prospective 
multicenter trial that compared FBx only, to SBx [201]. 
 
6.3 Study III 
We found that PTEN loss was seen significantly more often in mpMRI visible only (true 
positive) than mpMRI invisible only (false-negative) lesions. mpMRI visible lesions also had 
significantly higher GG, more EPE, SVI and LNM in RP and more frequent BCR after RP 
than mpMRI invisible lesions. mpMRI visibility clearly separated the Kaplan-Meier BCR-
free survival curves with a median follow-up of 3.3 years, but the results did not reach the 
conventional criteria for statistical significance. 
The characteristics of mpMRI invisible lesions is a fairly unknown chapter. mpMRI seems 
to miss the less aggressive (GG 1), multifocal and small (<5 mm in diameter) nonindex tumor 
lesions [231]. A recent study divided their patient cohort with ≥2 negative mpMRIs into Bx-
naïve and prior negative Bx groups and found no difference in the detection rates for csPCa 
[232]. Further, a study of over 320 men with only PI-RADS ≤2 lesions reported a csPCa 
disease-free survival of 99.6% with a median follow-up time of 57 months [233]. 
Biomarkers coupled to mpMRI may facilitate the detection of csPCa and this has been 
addressed in a few studies. Lee et al. compared mpMRI visible vs mpMRI invisible lesions 
in a retrospective cohort of 48 patients and found differences in their molecular 
characteristics: mpMRI invisible lesions only harbored CHD1-deletions whereas SPINK1-
biomarker was absent [234]. Gene expression and mpMRI visibility have been investigated 
and mpMRI invisible tumors were associated with favorable PCa prognosis [235]. The 
authors concluded that the result was not entirely explained by GG or tumor volume and 
that mpMRI visibility may have acted as an independent predictor. Further, the Decipher® 
gene panel is a commercially available test for PCa prognosis and a study that used 
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Decipher® reported lower panel scores and lower genetic risk for metastasis in mpMRI 
invisible lesions [236]. mpMRI visible tumors seem to be enriched with genes that are 
associated with a higher preponderance of cribriform structures and a higher mutational 
frequency [237]. All in all, these studies have small cohort sizes and their follow-up times 
were moderate. 
In our study, Kaplan-Meier BCR-free survival analysis did not show a statistically significant 
difference between the mpMRI visible and invisible groups. We did not find mpMRI 
visibility to be an independent prognostic factor for PCa prognosis in comparison with other 
clinical variables. However, ERG rearrangement and PTEN loss occurred in 14% (28/205) 
and 15% (28/192) in mpMRI invisible, and 27% (80/299) and 39% (113/292) in mpMRI 
visible lesions, respectively. This is in line with the literature, as published studies report 
data for ERG rearrangement between 36-78% and PTEN losses between 18-42% of PCa 
cases [10,11,195]. We found no added benefit for ERG and PTEN expressions using either 
logistic regression analysis or Kaplan-Meier survival analysis in our study. This may be a 
true finding or experimental artifact arising from either the limited number of patients or 
the short follow-up time. 
Limitations of the study comprise moderately short follow-up time, small numbers of 
patients in the groups only mpMRI visible (true positive) and only mpMRI invisible (false-
negative), and lack of a validation cohort. 
The strengths of the study include the use of RP whole-mount pathology specimen to control 
the accuracy of PI-RADS interpretation of the mpMRI images. Further, our cohort consisted 
of all RALP patients in our hospitals and there was no apparent bias for mpMRI selection. 
Whether mpMRI invisible lesions affect the course of PCa will hopefully be clarified by long-
term clinical studies that incorporate longitudinal imaging and follow-up data. The use of 
mpMRI is on the rise and knowledge on mpMRI features and characteristics accumulates 
rapidly. Biomarkers are a promising tool for PCa prognostication as their profiles could be 
defined as early as at Bxs and their features could help in the decision making prior to 
definitive treatment. However, their incorporation into clinical use still needs validation. 
The future will show whether mpMRI coupled to biomarkers may truly act as an aid for 
clinicians. 
 
6.4 Study IV 
We combined mpMRI with clinical parameters, Partin tables and MSKCC nomogram to 
predict EPE, SVI, LNM, i.e. adverse findings, in RP. We found that mpMRI significantly 
enhances the prediction of adverse pathology at RP when it is combined with the traditional 
tools for prediction. Moreover, mpMRI showed added benefit in predicting BCR when 
combined with CAPRA and MSKCC nomograms. 
Our results are mostly in line with other published studies. A recent meta-analysis that 
involved more than 9700 patients pooled mpMRI results for non-OC findings together using 
RP as a reference standard [238]. That study reported a sensitivity of 0.57, 0.58, and 0.61, 
and a specificity of 0.91, 0.96, and 0.88, for EPE, SVI and overall stage T3 detection, 
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respectively. The use of 3T field improved the sensitivity for EPE and SVI. Heterogeneity of 
the studies, however, hampers the generalization of the results.  
A few recent studies have addressed the added benefit of mpMRI in addition to using risk 
nomograms. Morlacco et al. evaluated 914 patients of which 501 patients had endorectal coil 
[239]. Their and our study cohorts are relatively similar regarding the risk factors (≥pT3 
49% vs 44%) but differ considerably in mpMRI characteristics (1.5T mpMRI, endorectal coil 
and non-structured reporting vs 3T pelvic coil and structured reporting). They reported that 
mpMRI is beneficial for staging purposes, but their cohort was of high-risk and from the 
pre-PIRADS era, thus, their results may underestimate the effect of mpMRI. Further, 
Morlacco et al. did not report the characteristics of their non-MRI cohort, and it is therefore 
uncertain whether clinical decision making in the selection of patients for MRI was skewed 
towards those who would have benefited from imaging. Another study by Grivas et al. 
evaluated the added value of preoperative 3T mpMRI with endorectal coil and non-
structured reporting for staging SVI using RP as a reference [240]. They compared inter alia 
SVI with and without mpMRI and reported substantially higher AUC values for Partin 
nomogram to predict SVI with (0.93) and without (0.84). Our results for the same 
comparison were: with 0.73 and without 0.69, and this disparity suggests a different 
background risk in these cohorts between the two studies. In another study, a cohort of 60 
men was evaluated for mpMRI and Partin tables to predict EPE, but they did not analyze the 
added value of mpMRI [241]. In com parison to our results, EPE prediction by Partin tables 
was equally good (AUC of 0.62 vs 0.56), whereas mpMRI had significantly better 
performance in their study (AUC 0.82 vs 0.62). A subsequent study by the same group 
reported a higher detection rate of OC PCa by mpMRI than by Partin tables (AUC 0.88 vs 
0.70) using RP as a reference standard [242]. Prediction of EPE for Partin tables and MSKCC 
were also evaluated by Feng et al., and they reported AUCs of 0.85 and 0.86, respectively 
[243]. When mpMRI was added to the model, AUC increased to 0.92 and 0.94, respectively. 
However, the studies by Gupta et al. and Feng et al. relied only on the reporting of mpMRI 
data of one radiologist in their study protocols and this may have contributed to some bias 
and diminished the effect of interreader variability in the results of their studies [241-243].  
Our data suggest that mpMRI is a valuable tool in predicting BCR after RP when used along 
with well-known prediction tools, as was seen for the more specific high-risk CAPRA and 
MSKCC groups. When considering mpMRI as a standalone investigative modality, we found 
that mpMRI was also able to differentiate BCR survival between two groups. Our results are 
in line with a previous study from the pre-PI-RADS era, which reported that mpMRI helped 
in predicting BCR after RP in clinically localized PCa [244]. Structured imaging reporting is 
expected to improve its predictive value further, as adverse findings in RP are known to 
predict BCR. We used PI-RADS 1.0, as it was the recommended reporting system at the time 
of our study. By using PI-RADS 1.0 we gained a longer follow-up time and the possibility to 
study BCR as an end-point. The more recent PI-RADS 2.0/2.1 versions may improve 
diagnostic reliability and diminish inter-observer variance further [245]. 
When taken together, the literature and our present results support the use of preoperative 
mpMRI as a staging tool particularly in the prediction of EPE and SVI. However, it is not 
clear, whether mpMRI is an adequate staging tool for LNM. The size, location and many 
other features of the tumor can be assessed using mpMRI, which may affect preoperative 
clinical decision making and help facilitate the planning the surgical procedure, even though 
71 
there is inevitable uncertainty in predicting the presence of EPE and SVI. This was shown in 
a recent study in which patients, who underwent a preoperative mpMRI, were less likely to 
have a nerve-sparing RP and a lower likelihood for positive surgical margins [246]. A 
considerable proportion of node metastasis are microscopic, whereas, enlarged LNs may be 
reactive. To address the issues of nodal involvement, a novel nomogram that incorporates 
several mpMRI related variables has been developed for nodal status evaluation before RP 
[247]. This further encourages the use of preoperative mpMRI despite that the exact nodal 
evaluation seems to be suboptimal using current mpMRI techniques. 
Limitations of the study include single center data and its retrospective nature. Not all RALP 
patients underwent mpMRI during the study period. However, in comparison to patients 
who did not undergo preoperative mpMRI, we found no obvious differences in their 
demographics. Further, pathologists are encouraged to initiate a regional reporting system 
similar to PI-RADS to improve translational PCa research, enhance diagnostic accuracy and 
better integrate mpMRI with pathology for more precise decision making.  
The strengths of the study include a cohort of all RALP patients in our hospitals and no bias 
for mpMRI selection. We also had four radiologists who assessed and reported our mpMRIs 
using a structured PI-RADS system for accurate description of tumors, and also RP 
specimen was used as a reference for imaging. 
The preoperative prostate mpMRI enhances the prediction of adverse findings at RP and 




Taken together, these studies address the issue of how to detect as few clinically insignificant 
and as many clinically significant PCa as possible with the least harm for the patient. We 
approached this dilemma in multiple ways including clinical, imaging, laboratory and 
histopathological means. 
Study I evaluated how mpMRI contributes to AS at diagnosis and during follow-up. From a 
certain perspective AS can be seen as a compromise between not treating and monitoring 
indolent tumors at all, and treating all initially but sparing the patient treatment related side 
effects. Unfortunately, a great number of patients still discontinue AS and instead opt for 
active treatment even though many show low-risk characteristics at subsequent RP. 
Undoubtedly, we need better and more refined tools to detect csPCa earlier. Prostate mpMRI 
may achieve this by detecting more men with csPCa at diagnosis. This will translate to fewer 
men initially being misclassified and probably a lowered need for initial repeat Bxs in AS 
protocols. Futhermore, mpMRI at diagnosis will probably result in fewer men needing AS 
since fewer men are diagnosed with clinically insignificant PCa. On the other hand, men with 
favorable mpMRI (no lesions initially and no progression during follow-up) might be 
candidates for reduced rebiopsy protocol. However, men should be followed-up in cases of 
true biological progression of PCa. The estimated rate of true biological progression is 
around 1-2% per year [248] thus it may be that the taking of routine Bxs can be postponed 
until years after diagnosis. The technical progress of mpMRI and mpMRI devices has been 
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rapid. During the early stage of mpMRI in early 2010s, we could not show much of a benefit 
of MRI in PCa AS [218]. However, less than a decade later we could report an association 
between mpMRI PI-RADS score 4-5 and GS upgrading in subsequent Bx in addition to 
transition from AS to active treatment. This suggests that serial mpMRI along with 
structured reporting may be useful monitoring tools in PCa AS. Nonetheless, serial mpMRI 
cannot as yet substitute histopathological analysis, i.e. repeated Bxs, in assessing disease 
characteristics due to the fact that mpMRI currently misses up to 30% of csPCa. 
Repeat Bxs are the current norm in AS to detect initial misclassification and true biological 
progression, but they are also an inevitable burden for the patients. In study II, we evaluated 
this by studying patient experience after FBx and SBx. We found significant comparative 
differences in pain, discomfort and treatment related side effects in favor of FBx. By 
choosing optimal diagnostic pathways for patients we may be able to minimize treatment 
related side effects and enhance compliance for surveillance. We expected this to improve 
results in PCa treatment as fewer Bxs will be taken overall, fewer unnecessary Bxs will be 
taken, and plausibly more men in need of Bx will eventually comply. The aim with mpMRI 
is that we will be able to detect aggressive forms of PCa early on and direct them to receive 
adequate immediate treatments. Subsequent biomarker analysis utilizing Bxs may aid in 
this. 
Study III focused on the characteristics of biomarkers in mpMRI visible and invisible tumors 
in RALP patients and reported significant differences between the groups. This is interesting 
as mpMRI is known for its high NPV, yet this rate varies significantly. Currently, there is 
ongoing debate about whether men with negative mpMRI should undergo SBx or not. 
Whether these false-negative mpMRI lesions possess a similar threat to a man’s well-being 
as true positive mpMRI lesions, is currently unknown. Our results contribute to this by 
evaluating the surrogate markers of biological aggressiveness, and they show that mpMRI 
false-negative lesions seem less aggressive than mpMRI true positive lesions. PTEN and 
ERG in PCa prognostication are still under debate and not yet in clinical use. However, 
evidence concerning especially PTEN loss and its association on aggressive types of PCa 
seems to be consistent and PTEN may become the next biomarker adapted for clinical use. 
Detecting biomarkers that would help in risk stratification would be immensely important. 
Study IV described the added value of mpMRI as an adjunct to traditional risk prediction 
nomograms in detecting adverse findings in PCa. We found that mpMRI is beneficial in 
detecting non-OC disease at RP and also in predicting BCR after RP. As the use of mpMRI 
increases continuously and guidelines recommend prostate mpMRI before first Bxs, mpMRI 
data would be readily available and could be added at no extra cost to the existing prediction. 
This would offer the possibility for PCa prediction as early as during the diagnostic phase. 
Nevertheless, this may be problematic due to the fact that those investigated lesions that are 
not detected by mpMRI cannot by definition be targeted by this modality. Hence, SBx may 
still play a role in the future until we discover the true nature of mpMRI invisible PCa lesions. 
Such data should also be validated in large, longitudinal mpMRI cohorts with long follow-
up times using RP as a reference. 
In the future, we will probably see a spectrum of different modalities to assess better the true 
nature of PCa, including prognostic biomarkers and genome sequencing. Importantly, the 
aim is to make PCa diagnostics and treatments more personalized. The path towards 
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precision medicine will be multidisciplinary in the way that PCa diagnosis and treatment 
decisions will be made increasingly on the basis of imaging and biomarker data in addition 
to clinical data. Importantly, these approaches will have to be tested prospectively in multi-































1. mpMRI is a useful tool for men with PCa to guide patient selection for AS and 
monitoring. 
 
2. The FBx diagnostic pathway causes less harm for the patient when compared with the 
traditional SBx pathway. 
 
3. mpMRI invisible tumors appear less aggressive than mpMRI visible tumors in terms of 
the following: PTEN loss, EPE, SVI, LNM, GG score and BCR after RP. 
 
4. The addition of preoperative mpMRI data to existing prediction tools increases their 
predictive performance in terms of stage at RP and the prediction of time to BCR. mpMRI 
is currently readily available prior to RP and should be considered as an additional tool 






















The studies were conducted in the Departments of Urology and Pathology, University of 
Helsinki and Helsinki University Hospital, under Research Program in Systems Oncology 
during 2015-2020. The research was supported by the Cancer Foundation Finland, the 
Finnish-Norwegian Medical Foundation, the Ida Montin Foundation, the Orion Research 
Foundation, the Paulo Foundation, the Finnish Urological Association, the Urological 
Research Foundation, and the Biomedicum Helsinki Foundation. I am grateful for your 
financial aid which enabled my research. I am also grateful to numerous people who have 
supported this process. At least the following deserve a mention. 
I received enormous help from my supervisors during this period. My closest supervisor 
Petrus Järvinen guided me to the world of medical science and was tremendously 
supportive during my first flimsy baby steps with my own research from 2015 onwards. 
Petrus has a talent to make complicated issues comprehensible and he is very effective in 
solving problems. Petrus helped me steer through my first congress and oral presentation in 
2016 in Estonia, what a trip! Professor Antti Rannikko was my grand supervisor during 
these years. He is a man pulling the strings behind the scenes. The first meeting with Antti 
in 2015 was pleasant as he treated me, a young and insecure MD recently graduated from 
medical school, warm-heartedly and helped in setting clear goals for the future. He is 
inspiring with his all embracing ideas, encouraging with his can-do attitude and a convincing 
urological scientist with years of expertise in the field. Together with Tuomas Mirtti, my 
second grand supervisor, he arranged the superb facilities and financed our study group so 
that we could concentrate on our research. These two grand men form quite an effective 
team. I remember meeting Tuomas the first time during medical school in the early 2010s 
and little did I know that he would be supervising my PhD thesis a decade later. Tuomas has 
a very supportive, effective attitude in producing science and transforming them into 
scientific papers. He is always positive. Tuomas also has the strength and patience to go 
through revisions for papers many times over. I thank you all three gentlemen from the 
bottom of my heart for helping me widen my perspective in science and also for the off-
science talks about life during these years. 
My family has always been there for me. My mother Marjatta was extremely supportive 
during school years and helped me find my strengths. She is the role model who made me 
choose medicine and become a doctor many years ago, and she has greatly helped me later 
professionally. Unfortunately, she passed away abruptly and unexpectedly during the 
finalization phase of this thesis. Life is unfair. Mum, I love you and you will always have a 
place in my heart. My father Timo is a fantastic teacher and he guided me through school 
time teaching mathematics, physics and chemistry. Together with my sister Heini they 
helped me follow the steps of science early in life. You are the best. Thank you Satu and 
Finlay for your kind support and help in English. Juha Reivonen, you teased me just the 
right way and helped me find motivation to finish this project. 
I would like to thank Professor Peter Black for serving as my dissertation opponent. Also, 
Matti Laato and Mika Mustonen agreed to review my dissertation and I thank you for 
that. 
76 
Many other people helped in specific studies. I’d like to thank all the co-authors. Kevin 
Sandeman, it has been a pleasure working and learning with you. Kanerva Lahdensuo, 
Inari Kalalahti and Hanna Vasarainen, your valuable comments and help made this 
happen and our cooperation was great. Teijo Pellinen, you provided me data at a very 
crucial step in Study III and I truly appreciate your help. Radiologist Anu Kilpeläinen, 
your efforts on going through data for our studies was priceless. Tuomas Kilpeläinen and 
Joona Pohjonen, without your expertise in statistics I would have been lost. Andrew 
Erickson, the man bristling with energy, thank you for your positive attitude and fresh 
ideas on numerous aspects in life. Every time we meet I feel inspired. My fellow students 
Carolin Stürenberg and Adrian Malén, you are on the same path as I am, just a few 
steps behind me, and I am sure you will get here one day. You have a fantastic group and 
innovative supervisors around you. The rest of the urology community at HUS urology, 
thank you all for your valuable input for these studies and happy memories from congress 
meetings. I look forward to working with you later in academic and work life. To Central 
Finland Central Hospital I am indebted for the fantastic surgical training they gave me 
and their flexibility for letting me off the clinical duties to focus on research. 
Friends make life worth living. Going to medical school was a happy period in my life and 
I’d like to thank all the people involved. Veli-Matti Isoviita, Olli Suomalainen, Antti 
Voutilainen, it is always a pleasure to spend time with you. Tuomas and Saara 
Mertsalmi, big cheers for the encouragement for finalizing my thesis during the spring of 
2020. Thank you Kalle and Vuokko as well as Markus and Riikka for the years in 
Jyväskylä and thank you Jyväskylä for your fantastic ski tracks and many good runs around 
some of your numerous lakes. Emil Katajainen, your wizard skills and international Excel 
online support service were priceless. The Lauttasaari crew, I would like to thank for the 
refreshing runs and pumped-up work-outs at the gym, they helped me ventilate my thoughts 
after a long day at the lab. Apa and Maija, you guys are fantastic and it is so nice to live life 
with you. Chrissie in Germany, thank you for all the eye-opening medical books and talks 
I could share with you during the years. 
My whole existence has no meaning if it was not for my family. You are my everything. I am 
blessed to have two magnificent boys, Erik and Elias. Your energy and joy are 
overwhelming and it has been fantastic to see you grow. What a life you have ahead of you. 
Finally, my dear wife Maija deserves my deepest gratitude. She is a tremendously capable 
woman who sees only possibilities ahead of her. Thank you for taking care of our sons and 
letting me concentrate on this thesis especially during the hectic finalization process in the 
“Corona-spring of 2020”. There are no words that can describe my feelings for you, but as 








[1] . Finnish Cancer Registry; https://syoparekisteri.fi. ; 2018. 
[2] Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and 
mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin; 68:394-424; 2018. 
[3] Loeb S, Vellekoop A, Ahmed HU, Catto J, Emberton M, Nam R, Rosario DJ, Scattoni V, Lotan Y. Systematic review of complications 
of prostate biopsy. Eur Urol; 64:876-92; 2013. 
[4] Weinreb JC, Barentsz JO, Choyke PL, Cornud F, Haider MA, Macura KJ, Margolis D, Schnall MD, Shtern F, Tempany CM, Thoeny 
HC, Verma S. PI-RADS Prostate Imaging - Reporting and Data System: 2015, Version 2. Eur Urol; 69:16-40; 2016. 
[5] Ahmed HU, El-Shater Bosaily A, Brown LC, Gabe R, Kaplan R, Parmar MK, Collaco-Moraes Y, Ward K, Hindley RG, Freeman A, 
Kirkham AP, Oldroyd R, Parker C, Emberton M. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer 
(PROMIS): a paired validating confirmatory study. Lancet; 389:815-22; 2017. 
[6] Le JD, Tan N, Shkolyar E, Lu DY, Kwan L, Marks LS, Huang J, Margolis DJ, Raman SS, Reiter RE. Multifocality and prostate cancer 
detection by multiparametric magnetic resonance imaging: correlation with whole-mount histopathology. Eur Urol; 67:569-76; 
2015. 
[7] Bratan F, Niaf E, Melodelima C, Chesnais AL, Soucho R, Mege-Lechevallier F, Colombel M, Rouviere O. Influence of imaging and 
histological factors on prostate cancer detection and localisation on multiparametric MRI: a prospective study. Eur Radiol; 23:2019-
29; 2013. 
[8] Drost FH, Osses D, Nieboer D, Bangma CH, Steyerberg EW, Roobol MJ, Schoots IG. Prostate magnetic resonance imaging, with or 
without magnetic resonance imaging-targeted biopsy, and systematic biopsy for detecting prostate cancer: A Cochrane systematic 
review and meta-analysis. Eur Urol; 77:78-94; 2020. 
[9] Ullman D, Dorn D, Rais-Bahrami S, Gordetsky J. Clinical utility and biologic implications of phosphatase and tensin homolog (PTEN) 
and ETS-related gene (ERG) in prostate cancer. Urology; 113:59-70; 2018. 
[10] Lokman U, Erickson AM, Vasarainen H, Rannikko AS, Mirtti T. PTEN loss but not ERG expression in diagnostic biopsies is associated 
with increased risk of progression and adverse surgical findings in men with prostate cancer on active surveillance. Eur Urol Focus; 
4:867-73; 2017. 
[11] Lahdensuo K, Erickson A, Saarinen I, Seikkula H, Lundin J, Lundin M, Nordling S, Butzow A, Vasarainen H, Bostrom PJ, Taimen P, 
Rannikko A, Mirtti T. Loss of PTEN expression in ERG-negative prostate cancer closepredicts secondary therapies and leads to 
shorter disease-specific survival time after radical prostatectomy. Mod Pathol; 29:1565-74; 2016. 
[12] Turnbull J, Deuter M, Bradbery J. Oxford Advanced Learner's Dictionary. Oxford University Press; 2020. 
[13] Cheng L, MacLennan G, Bostwick D. Urologic Surgical Pathology, 4th edition. Saunders; 2019. 
[14] Ahlgren G, Rannevik G, Lilja H. Impaired secretory function of the prostate in men with oligo-asthenozoospermia. J Androl; 16:491-
8; 1995. 
[15] McNeal JE. The zonal anatomy of the prostate. Prostate; 2:35-49; 1981. 
[16] Cohen RJ, Shannon BA, Phillips M, Moorin RE, Wheeler TM, Garrett KL. Central zone carcinoma of the prostate gland: a distinct 
tumor type with poor prognostic features. J Urol; 179:1762-7; 2008. 
[17] Bratt O, Drevin L, Akre O, Garmo H, Stattin P. Family history and probability of prostate cancer, differentiated by risk category: A 
nationwide population-based study. J Natl Cancer Inst; 108; 2016. 
[18] Page EC, Bancroft EK, Brook MN, Assel M, M HAB, Thomas S, Taylor N, Chamberlain A, Pope J, Raghallaigh HN, Evans DG, Rothwell 
J, Maehle L, Grindedal EM, James P, Mascarenhas L, McKinley J, Side L, Thomas T, van Asperen C, Vasen H, Kiemeney LA, 
Ringelberg J, Jensen TD, Osther PJS, Helfand BT, Genova E, Oldenburg RA, Cybulski C, Wokolorczyk D, Ong KR, Huber C, Lam J, 
Taylor L, Salinas M, Feliubadaló L, Oosterwijk JC, van Zelst-Stams W, Cook J, Rosario DJ, Domchek S, Powers J, Buys S, O'Toole 
K, MGEM A, Schmutzler RK, Rhiem K, Izatt L, Tripathi V, Teixeira MR, Cardoso M, Foulkes WD, Aprikian A, van Randeraad H, 
Davidson R, Longmuir M, Ruijs MWG, Helderman van den EA, Adank M, Williams R, Andrews L, Murphy DG, Halliday D, Walker 
L, Liljegren A, Carlsson S, Azzabi A, Jobson I, Morton C, Shackleton K, Snape K, Hanson H, Harris M, Tischkowitz M, Taylor A, 
Kirk J, Susman R, Chen-Shtoyerman R, Spigelman A, Pachter N, Ahmed M, Ramon Y Cajal T, Zgajnar J, Brewer C, Gadea N, Brady 
AF, van Os T, Gallagher D, Johannsson O, Donaldson A, Barwell J, Nicolai N, Friedman E, Obeid E, Greenhalgh L, Murthy V, 
78 
Copakova L, Saya S, McGrath J, Cooke P, Rønlund K, Richardson K, Henderson A, Teo SH, Arun B, Kast K, Dias A, Aaronson NK, 
Ardern-Jones A, Bangma CH, Castro E, Dearnaley D, Eccles DM, Tricker K, Eyfjord J, Falconer A, Foster C, Gronberg H, Hamdy 
FC, Stefansdottir V, Khoo V, Lindeman GJ, Lubinski J, Axcrona K, Mikropoulos C, Mitra A, Moynihan C, Rennert G, Suri M, Wilson 
P, Dudderidge T, Offman J, Kote-Jarai Z, Vickers A, Lilja H, Eeles RA. Interim results from the IMPACT study: evidence for prostate-
specific antigen screening in BRCA2 mutation carriers. Eur Urol; 76:831-42; 2019. 
[19] Thompson IM,Jr., Goodman PJ, Tangen CM, Parnes HL, Minasian LM, Godley PA, Lucia MS, Ford LG. Long-term survival of 
participants in the prostate cancer prevention trial. N Eng J Med; 369:603-10; 2013. 
[20] Esposito K, Chiodini P, Capuano A, Bellastella G, Maiorino MI, Parretta E, Lenzi A, Giugliano D. Effect of metabolic syndrome and 
its components on prostate cancer risk: meta-analysis. J Endocrinol Invest; 36:132-9; 2013. 
[21] YuPeng L, YuXue Z, PengFei L, Cheng C, YaShuang Z, DaPeng L, Chen D. Cholesterol levels in blood and the risk of prostate cancer: 
A meta-analysis of 14 prospective studies. Cancer Epidemiol Biomarkers Prev; 24:1086-93; 2015. 
[22] Chang SL, Harshman LC, Presti JCJ. Impact of common medications on serum total prostate-specific antigen levels: analysis of the 
National Health and Nutrition Examination Survey. J Clin Oncol; 28:3951-7; 2010. 
[23] Preston MA, Riis AH, Ehrenstein V, Breau RH, Batista JL, Olumi AF, Mucci LA, Adami HO, Sorensen HT. Metformin use and prostate 
cancer risk. Eur Urol; 66:1012-20; 2014. 
[24] Hamilton RJ, Goldberg KC, Platz EA, Freedland SJ. The influence of statin medications on prostate-specific antigen levels. J Natl 
Cancer Inst; 100:1511-8; 2008. 
[25] Miyazawa Y, Sekine Y, Kato H, Furuya Y, Koike H, Suzuki K. Simvastatin up-regulates Annexin A10 that can inhibit the proliferation, 
migration, and invasion in androgen-independent human prostate cancer cells. Prostate; 77:337-49; 2017. 
[26] Tan N, Klein EA, Li J, Moussa AS, Jones JS. Statin use and risk of prostate cancer in a population of men who underwent biopsy. J 
Urol; 186:86-90; 2011. 
[27] Murtola TJ, Tammela TL, Maattanen L, Huhtala H, Platz EA, Ala-Opas M, Stenman UH, Auvinen A. Prostate cancer and PSA among 
statin users in the Finnish prostate cancer screening trial. Int J Cancer; 127:1650-9; 2010. 
[28] Freedland SJ, Hamilton RJ, Gerber L, Banez LL, Moreira DM, Andriole GL, Rittmaster RS. Statin use and risk of prostate cancer and 
high-grade prostate cancer: results from the REDUCE study. Prostate Cancer Prostatic Dis; 16:254-9; 2013. 
[29] Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montors F, Pettaway CA, Tammela TL, Teloken C, Tindall DJ, 
Somerville MC, Wilson TH, Fowler IL, Rittmaster RS. Effect of dutasteride on the risk of prostate cancer. N Eng J Med; 362:1192-
202; 2010. 
[30] Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, Carlin 
SM, Ryan A, Szczepanek CM, Crowley JJ, Coltman CAJ. The influence of finasteride on the development of prostate cancer. N Eng 
J Med; 349:215-24; 2003. 
[31] Thompson IMJ, Goodma PJ, Tangen CM, Parnes HL, Minasian LM, Godley PA, Lucia MS, Ford LG. Long-term survival of participants 
in the prostate cancer prevention trial. N Eng J Med; 369:603-10; 2013. 
[32] Kramer BS, Hagerty KL, Justman S, Somerfield MR, Albertsen PC, Blot WJ, Ballentine CH, Costantino JP, Epstein JI, Godley PA, 
Harris RP, Wilt TJ, Wittes J, Zon R, Schellhammer P. Use of 5-alpha-reductase inhibitors for prostate cancer chemoprevention: 
American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline. J Clin Oncol; 27:1502-
16; 2009. 
[33] Haider A, Zitzmann M, Doros G, Isbarn H, Hammerer P, Yassin A. Incidence of prostate cancer in hypogonadal men receiving 
testosterone therapy: observations from 5-year median followup of 3 registries. J Urol; 193:80-6; 2015. 
[34] Cook LS, Goldoft M, Schwartz SM, Weiss NS. Incidence of adenocarcinoma of the prostate in Asian immigrants to the United States 
and their descendants. J Urol; 161:152-5; 1999. 
[35] Vidal AC, Howard LE, Moreira DM, Castro-Santamaria R, Andriole G,Jr, Freedland SJ. Obesity increases the risk for high-grade 
prostate cancer: results from the REDUCE study. Cancer Epidemiol Biomarkers Prev; 23:2936-42; 2014. 
[36] Bylsma LC, Alexander DD. A review and meta-analysis of prospective studies of red and processed meat, meat cooking methods, 
heme iron, heterocyclic amines and prostate cancer. Nutr J; 14; 2015. 
[37] Alexander DD, Bassett JK, Weed DL, Barrett EC, Watson H, Harris W. Meta-analysis of long-chain Omega-3 polyunsaturated fatty 
acids (LComega-3PUFA) and prostate cancer. Nutr Cancer; 67:543-54; 2015. 
79 
[38] Lippi G, Mattiuzzi C. Fried food and prostate cancer risk: systematic review and meta-analysis. Int J Food Sci Nutr; 66:587-9; 2015. 
[39] Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, Parnes HL, Minasian LM, Gaziano JM, Hartline JA, Parsons 
JK, Bearden JD3, Crawford ED, Goodman GE, Claudio J, Winquist E, Cook ED, Karp DD, Walthe P, Lieber MM, Kristal AR, Darke 
AK, Arnold KB, Ganz PA, Santella RM, Albanes D, Taylor PR, Probstfield JL, Jagpal TJ, Crowley JJ, Meyskens FLJ, Baker LH, 
Coltman CAJ. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer 
Prevention Trial (SELECT). JAMA; 301:39-51; 2009. 
[40] Zhang M, Wang K, Chen L, Yin B, Song Y. Is phytoestrogen intake associated with decreased risk of prostate cancer? A systematic 
review of epidemiological studies based on 17,546 cases. Andrology; 4:745-56; 2016. 
[41] Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, Fossati N, Gross T, Henry AM, Joniau S, Lam TB, Mason 
MD, Matveev VB, Moldovan PC, van den Bergh RCN, Van den Broeck T, van der Poel HG, van der Kwast TH, Rouviere O, Schoots 
IG, Wiegel T, Cornford P. EAU-ESTRO-SIOG Guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with 
curative intent. Eur Urol; 71:618-29; 2017. 
[42] Sakr WA, Grignon DJ, Crissman JD, Heilbrun LK, Cassin BJ, Pontes JJ, Haas GP. High grade prostatic intraepithelial neoplasia 
(HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. In Vivo; 8:439-43; 1994. 
[43] Bell KJ, Del Mar C, Wright G, Dickinson J, Glasziou P. Prevalence of incidental prostate cancer: A systematic review of autopsy 
studies. Int J Cancer; 137:1749-57; 2015. 
[44] James ND, Spears MR, Clarke NW, Dearnaley DP, De Bono JS, Gale J, Hetherington J, Hoskin PJ, Jones RJ, Laing R, Lester JF, 
McLaren D, Parker CC, Parmar MKB, Ritchie AWS, Russell JM, Strebel RT, Thalmann GN, Mason MD, Sydes MR. Survival with 
newly diagnosed metastatic prostate cancer in the "Docetaxel era": Data from 917 patients in the control arm of the STAMPEDE 
trial (MRC PR08, CRUK/06/019). Eur Urol; 67:1028-38; 2015. 
[45] Engholm G, Ferla J, Christensen N, Bray F, Gjerstorff ML, Klint A, Kotlum JE, Olafsdottir E, Pukkala E, Storm HH. NORDCAN--a 
Nordic tool for cancer information, planning, quality control and research. Acta Oncol; 49:725-36; 2010. 
[46] Sawczuk I, Tannenbaum M, Olsson CA, deVere White R. Primary transitional cell carcinoma of prostatic periurethral ducts. Urology; 
25:339-43; 1985. 
[47] Venyo AK. A review of the literature on primary leiomyosarcoma of the prostate gland. Adv Urol; 485786; 2015. 
[48] Bostwick DG, Mann RB. Malignant lymphomas involving the prostate. A study of 13 cases. Cancer; 56:2932-8; 1985. 
[49] di Sant'Agnese PA. Neuroendocrine differentiation in human prostatic carcinoma. Hum Pathol; 23:287-96; 1992. 
[50] Sargos P, Ferretti L, Gross-Goupil M, Orre M, Cornelis F, Henriques de Figueiredo B, Houede N, Merino C, Roubaud G, Dallaudiere 
B, Richaud P, Flechon A. Characterization of prostate neuroendocrine cancers and therapeutic management: a literature review. 
Prostate Cancer Prostatic Dis; 17:220-6; 2014. 
[51] Davies AH, Beltran H, Zoubeidi A. Cellular plasticity and the neuroendocrine phenotype in prostate cancer. Nat Rev Urol; 15:271-86; 
2018. 
[52] Akamatsu S, Inoue T, Ogawa O, Gleave ME. Clinical and molecular features of treatment-related neuroendocrine prostate cancer. Int 
J Urol; 25:345-51; 2018. 
[53] Westphalen AC, Coakley FV, Kurhanewicz J, Reed G, Wang ZJ, Simko JP. Mucinous adenocarcinoma of the prostate: MRI and MR 
spectroscopy features. AJR Am J Roentgenol; 193:W238-43; 2009. 
[54] Wang W, Epstein JI. Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases. Am J Surg 
Pathol; 32:65-71; 2008. 
[55] Priemer DS, Montironi R, Wang L, Williamson SR, Lopez-Beltran A, Cheng L. Neuroendocrine tumors of the prostate: emerging 
insights from molecular data and updates to the 2016 World Health Organization classification. Endocrin Pathol; 27:123-35; 2016. 
[56] Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality 
worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer; 136:359-86; 2015. 
[57] Richie JP, Catalona WJ, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, deKernion JB, Ratliff TL, Kavoussi LR, Dalkin BL, 
Waters WB, MacFarlane MT, Southwick PC. Effect of patient age on early detection of prostate cancer with serum prostate-specific 
antigen and digital rectal examination. Urology; 42:365-74; 1993. 
80 
[58] Smeenge M, Barentsz J, Cosgrove D, de la Rosette J, de Reijke T, Eggener S, Frauscher F, Kovacs G, Matin SF, Mischi M, Pinto P, 
Rastinehad A, Rouviere O, Salomon G, Polascik T, Walz J, Wijkstra H, Marberger M. Role of transrectal ultrasonography (TRUS) 
in focal therapy of prostate cancer: report from a consensus panel. BJU Int; 110:942-8; 2012. 
[59] Xue J, Qin Z, Cai H, Zhang C, Li X, Xu W, Wang J, Xu Z, Yu B, Xu T, Zou Q. Comparison between transrectal and transperineal 
prostate biopsy for detection of prostate cancer: a meta-analysis and trial sequential analysis. Oncotarget; 8:23322-36; 2017. 
[60] Lilja H. A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. J Clin Invest; 76:1899-
903; 1985. 
[61] Kvale R, Auvinen A, Adami HO, Klint A, Hernes E, Moller B, Pukkala E, Storm HH, Tryggvadottir L, Tretli S, Wahlqvist R, Weiderpass 
E, Bray F. Interpreting trends in prostate cancer incidence and mortality in the five Nordic countries. J Natl Cancer Inst; 99:1881-
7; 2007. 
[62] Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ, Panser LA, Lieber MM. Serum prostate-specific antigen in a 
community-based population of healthy men. Establishment of age-specific reference ranges. JAMA; 270:860-4; 1993. 
[63] Carter HB, Pearson JD, Metter EJ, Brant LJ, Chan DW, Andres R, Fozard JL, Walsh PC. Longitudinal evaluation of prostate-specific 
antigen levels in men with and without prostate disease. JAMA; 267:2215-20; 1992. 
[64] Vickers AJ, Thompson IM, Klein E, Carroll PR, Scardino PT. A commentary on PSA velocity and doubling time for clinical decisions 
in prostate cancer. Urology; 83:592-6; 2014. 
[65] Bonkat G, Pilatz A, Wagenlehner F. Time to adapt our practice? The European Commission has restricted the use of fluoroquinolones 
since March 2019. Eur Urol; 76:273-5; 2019. 
[66] Eichler K, Hempel S, Wilby J, Myers L, Bachmann LM, Kleijnen J. Diagnostic value of systematic biopsy methods in the investigation 
of prostate cancer: a systematic review. J Urol; 175:1605-12; 2006. 
[67] Lahdensuo K, Mirtti T, Petas A, Rannikko A. Performance of transrectal prostate biopsies in detecting tumours and implications for 
focal therapy. Scand J Urol; 49:90-6; 2015. 
[68] Tosoian JJ, JohnBull E, Trock BJ, Landis P, Epstein JI, Partin AW, Walsh PC, Carter HB. Pathological outcomes in men with low risk 
and very low risk prostate cancer: implications on the practice of active surveillance. J Urol; 190:1218-22; 2013. 
[69] Dall´Era MA, Albertsen PC, Bangma C, Carroll PR, Carter HB, Cooperberg MR, Freedland SJ, Klotz LH, Parker C, Soloway MS. Active 
surveillance for prostate cancer: a systematic review of the literature. Eur Urol; 62:976–83; 2012. 
[70] Overduin CG, Fütterer JJ, Barentsz JO. MRI-guided biopsy for prostate cancer detection: a systematic review of current clinical 
results. Curr Urol Rep; 14:209-13; 2013. 
[71] Wegelin O, van Melick HHE, Hooft L, JLHR B, Reitsma HB, Barentsz JO, Somford DM. Comparing three different techniques for 
magnetic resonance imaging-targeted prostate biopsies: A systematic review of in-bore versus magnetic resonance imaging-
transrectal ultrasound fusion versus cognitive registration. Is there a preferred technique? Eur Urol; 71:517-31; 2017. 
[72] Brierley JD, Gospodarowicz MK. TNM classification of malignant tumors (8th ed). Wiley & Sons; 2017. 
[73] Gleason DF. Classification of prostatic carcinomas. Cancer Chemother Rep; 50:125-8; 1966. 
[74] Epstein JI, Allsbrook WJ, Amin MB, Egevad LL. The 2005 International Society of Urological Pathology (ISUP) consensus conference 
on Gleason grading of prostatic carcinoma. Am J Surg Pathol; 29:1228-42; 2005. 
[75] Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA. The 2014 International Society of Urological Pathology (ISUP) 
consensus conference on Gleason grading of prostatic carcinoma: Definition of grading patterns and proposal for a new grading 
system. Am J Surg Pathol; 40:244-52; 2016. 
[76] Epstein JI, Zelefsky MJ, Sjoberg DD, Nelson JB, Egevad L, Magi-Galluzzi C, Vickers AJ, Parwani AV, Reuter VE, Fine SW, Eastham 
JA, Wiklund P, Han M, Reddy CA, Ciezki JP, Nyberg T, Klein EA. A contemporary prostate cancer grading system: a validated 
alternative to the Gleason score. Eur Urol; 69:428-35; 2016. 
[77] Sarkar S, Das S. A Review of Imaging Methods for Prostate Cancer Detection. Biomed Eng Comput Biol; 7 (Suppl 1):1-15; 2016. 
[78] Porter KK, King A, Galgano SJ, Sherrer RL, Gordetsky JB, Rais-Bahrami S. Financial implications of biparametric prostate MRI. 
Prostate Cancer Prostatic Dis; 23:88-93; 2019. 
81 
[79] Alabousi M, Salameh JP, Gusenbauer K, Samoilov L, Jafri A, Yu H, Alabousi A. Biparametric vs multiparametric prostate magnetic 
resonance imaging for the detection of prostate cancer in treatment-naive patients: a diagnostic test accuracy systematic review and 
meta-analysis. BJU Int; 124:209-20; 2019. 
[80] Di Campli E, Delli Pizzi A, Seccia B, Cianci R, d'Annibale M, Colasante A, Cinalli S, Castellan P, Navarra R, Iantorno R, Gabrielli D, 
Buffone A, Caulo M, Basilico R. Diagnostic accuracy of biparametric vs multiparametric MRI in clinically significant prostate cancer: 
Comparison between readers with different experience. Eur J Radiol; 101:17-23; 2018. 
[81] Boesen L, Nørgaard N, Løgager V, Balslev I, Bisbjerg R, Thestrup KC, Winther MD, Jakobsen H, Thomsen HS. Assessment of the 
Diagnostic Accuracy of Biparametric Magnetic Resonance Imaging for Prostate Cancer in Biopsy-Naive Men: The Biparametric MRI 
for Detection of Prostate Cancer (BIDOC) Study. JAMA Netw Open; 1:e180219; 2018. 
[82] Turkbey B, Rosenkrantz AB, Haider MA, Padhani AR, Villeirs G, Macura KJ, Tempany CM, Choyke PL, Cornud F, Margolis DJ, 
Thoeny HC, Verma S, Barentsz J, Weinreb JC. Prostate Imaging Reporting and Data System version 2.1: 2019 update of Prostate 
Imaging Reporting and Data System version 2. Eur Urol; 76:340-51; 2019. 
[83] Barentsz JO, Richenberg J, Clements R, Choyke P, Verma S, Villeirs G, Rouviere O, Logager V, Futterer JJ. ESUR prostate MR 
guidelines 2012. Eur Radiol; 22:746–57; 2012. 
[84] 1Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaarala MH, Briganti A, Budaus L, Hellawell G, Hindley 
RG, Roobol MJ, Eggener S, Ghei M, Villers A, Bladou F, Villeirs GM, Virdi J, Boxler S, Robert G, Singh PB, Venderink W, Hadaschik 
BA, Ruffion A, Hu JC, Margolis D, Crouzet S, Klotz L, Taneja SS, Pinto P, Gill I, Allen C, Giganti F, Freeman A, Morris S, Punwani 
S, Williams NR, Brew-Graves C, Deeks J, Takwoingi Y, Emberton M, Moore CM. MRI-targeted or standard biopsy for prostate-
cancer diagnosis. N Eng J Med; 378:1767-77; 2018. 
[85] van der Leest M, Cornel E, Israël B, Hendriks R, Padhani AR, Hoogenboom M, Zamecnik P, Bakker D, Setiasti AY, Veltman J, van 
den Hout H, van der Lelij H, van Oort I, Klaver S, Debruyne F, Sedelaar M, Hannink G, Rovers M, Hulsbergen-van de Kaa C, 
Barentsz JO. Head-to-head comparison of transrectal ultrasound-guided prostate biopsy versus multiparametric prostate 
resonance imaging with subsequent magnetic resonance-guided biopsy in biopsy-naïve men with elevated prostate-specific antigen: 
A large prospective multicenter clinical study. Eur Urol; 75:570-8; 2019. 
[86] Rouviere O, Puech P, Renard-Penna R, Claudon M, Roy C, Mege-Lechevallier F, Decaussin-Petrucci M, Dubreuil-Chambardel M, 
Magaud L, Remontet L, Ruffion A, Colombel M, Crouzet S, Schott AM, Lemaitre L, Rabilloud M, Grenier N. Use of prostate 
systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): a prospective, 
multicentre, paired diagnostic study. Lancet Oncol; 20:100-9; 2019. 
[87] Kasivisvanathan V, Stabile A, Neves JB, Giganti F, Valerio M, Shanmugabavan Y, Clement KD, Sarkar D, Philippou Y, Thurtle D, 
Deeks J, Emberton M, Takwoingi Y, Moore CM. Magnetic resonance imaging-targeted biopsy versus systematic biopsy in the 
detection of prostate cancer: A systematic review and meta-analysis. Eur Urol; 76:284-303; 2019. 
[88] Goldberg H, Ahmad AE, Chandrasekar T, Klotz L, Emberton M, Haider MA, Taneja SS, Arora K, Fleshner N, Finelli A, Perlis N, Tyson 
MD, Klaassen Z, Wallis CJD. Comparison of magnetic resonance imaging and transrectal ultrasound informed prostate biopsy for 
prostate cancer diagnosis in biopsy naïve men: A systematic review and meta-analysis. J Urol; 203:1085-93; 2020. 
[89] Siddiqui MM, Rais-Bahrami S, Turkbey B, George AK, Rothwax J, Shakir N, Okoro C, Raskolnikov D, Parnes HL, Linehan WM, 
Merino MJ, Simon RM, Choyke PL, Wood BJ, Pinto PA. Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-
guided biopsy for the diagnosis of prostate cancer. JAMA; 313:390–7; 2015. 
[90] Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaarala MH, Briganti A, Budaus L, Hellawell G, Hindley 
RG, Roobol MJ, Eggener S, Ghei M, Villers A, Bladou F, Villeirs GM, Virdi J, Boxler S, Robert G, Singh PB, Venderink W, Hadaschik 
BA, Ruffion A, Hu JC, Margolis D, Crouzet S, Klotz L, Taneja SS, Pinto P, Gill I, Allen C, Giganti F, Freeman A, Morris S, Punwani 
S, Williams NR, Brew-Graves C, Deeks J, Takwoingi Y, Emberton M, Moore CM. MRI-Targeted or Standard Biopsy for Prostate-
Cancer Diagnosis. N Eng J Med; 378(19):1767-77; 2018. 
[91] Pokorny MR, de Rooij M, Duncan E, Schroder FH, Parkinson R, Barentsz JO, Thompson LC. Prospective study of diagnostic accuracy 
comparing prostate cancer detection by transrectal ultrasound-guided biopsy versus magnetic resonance (MR) imaging with 
subsequent MR-guided biopsy in men without previous prostate biopsies. Eur Urol; 66:22-9; 2014. 
[92] Moldovan PC, Van den Broeck T, Sylvester R, Marconi L, Bellmunt J, van den Bergh RCN, Bolla M, Briers E, Cumberbatch MG, 
Fossati N, Gross T, Henry AM, Joniau S, van der Kwast TH, Matveev VB, van der Poel HG, De Santis M, Schoots IG, Wiegel T, Yuan 
CY, Cornford P, Mottet N, Lam TB, Rouvière O. What Is the Negative Predictive Value of Multiparametric Magnetic Resonance 
Imaging in Excluding Prostate Cancer at Biopsy? A Systematic Review and Meta-analysis from the European Association of Urology 
Prostate Cancer Guidelines Panel. Eur Urol; 72:250-66; 2017. 
[93] Dell'Oglio P, Stabile A, Soligo M, Brembilla G, Esposito A, Gandaglia G, Fossati N, Bravi CA, Dehò F, De Cobelli F, Montorsi F, Karnes 
RJ, Briganti A. There is no way to avoid systematic prostate biopsies in addition to multiparametric magnetic resonance imaging 
targeted biopsies. Eur Urol Oncol; 3:112-8; 2020. 
82 
[94] Briganti A, Fossati N, Catto JWF, Cornford P, Montorsi F, Mottet N, Wirth M, Van Poppel H. Active surveillance for low-risk prostate 
cancer: The European Association of Urology position in 2018. Eur Urol; 74:357-68; 2018. 
[95] Diaz AW, Shakir NA, George AK, Rais-Bahrami S, Turkbey B, Rothwax JT, Stamatakis L, Hong CW, Siddiqui MM, Okoro C, 
Raskolnikov D, Su D, Shih J, Han H, Parnes HL, Merino MJ, Simon RM, Wood BJ, Choyke PL, Pinto PA. Use of serial 
multiparametric magnetic resonance imaging in the management of patients with prostate cancer on active surveillance. Urol 
Oncol; 33:202.e1–7; 2015. 
[96] Nassiri N, Margolis DJ, Natarajan S, Sharma DS, Huang J, Dorey FJ, Marks LS. Targeted biopsy to detect Gleason score upgrading 
during active surveillance for men with low versus intermediate risk prostate cancer. J Urol; 197:632-9; 2017. 
[97] Klotz L, Loblaw A, Sugar L, Moussa M, Berman DM, Van der Kwast T, Vesprini D, Milot L, Kebabdjian M, Fleshner N, Ghai S, Chin 
J, Pond GR, Haider M. Active surveillance magnetic resonance imaging study (ASIST): Results of a randomized multicenter 
prospective trial. Eur Urol; 75:300-9; 2019. 
[98] Thurtle D, Barrett T, Thankappan-Nair V, Koo B, Warren A, Kastner C, Saeb-Parsy K, Kimberley-Duffell J, Gnanapragasam VJ. 
Progression and treatment rates using an active surveillance protocol incorporating image-guided baseline biopsies and 
multiparametric magnetic resonance imaging monitoring for men with favourable-risk prostate cancer. BJU Int; 122:59-65; 2018. 
[99] Greer MD, Brown AM, Shih JH, Summers RM, Marko J, Law YM, Sankineni S, George AK, Merino MJ, Pinto PA, Choyke PL, Turkbey 
B. Accuracy and agreement of PIRADSv2 for prostate cancer mpMRI: A multireader study. J Magn Reson Imaging; 45:579-85; 
2017. 
[100] Hofbauer SL, Maxeiner A, Kittner B, Heckmann R, Reimann M, Wiemer L, Asbach P, Haas M, Penzkofer T, Stephan C, Friedersdorff 
F, Fuller F, Miller K, Cash H. Validation of Prostate Imaging Reporting and Data System version 2 for the detection of prostate 
cancer. J Urol; 200:767-73; 2018. 
[101] Auer T, Edlinger M, Bektic J, Nagele U, Herrmann T, Schafer G, Aigner F, Junker D. Performance of PI-RADS version 1 versus 
version 2 regarding the relation with histopathological results. World J Urol; 35:687-93; 2017. 
[102] Tewes S, Mokov N, Hartung D, Schick V, Peters I, Schedl P, Pertschy S, Wacker F, Voshage G, Hueper K. Standardized reporting of 
prostate MRI: Comparison of the Prostate Imaging Reporting and Data System (PI-RADS) version 1 and version 2. PLoS One; 11; 
2016. 
[103] Schaudinn A, Gawlitza J, Mucha S, Linder N, Franz T, Horn LC, Kahn T, Busse H. Comparison of PI-RADS v1 and v2 for 
multiparametric MRI detection of prostate cancer with whole-mount histological workup as reference standard. Eur J Radiol; 
116:180-5; 2019. 
[104] Woo S, Suh CH, Kim SY, Cho JY, Kim SH. Diagnostic performance of Prostate Imaging Reporting and Data System version 2 for 
detection of prostate cancer: A systematic review and diagnostic meta-analysis. Eur Urol; 72:177-88; 2017. 
[105] Zhang L, Tang M, Chen S, Lei X, Zhang X, Huan Y. A meta-analysis of use of Prostate Imaging Reporting and Data System version 
2 (PI-RADS V2) with multiparametric MR imaging for the detection of prostate cancer. Eur Radiol; 27:5204-14; 2017. 
[106] Harada T, Abe T, Kato F, Matsumoto R, Fujita H, Murai S, Miyajima N, Tsuchiya K, Maruyama S, Kudo K, Shinohara N. Five-point 
Likert scaling on MRI predicts clinically significant prostate carcinoma. BMC Urol; 15; 2015. 
[107] Moore CM, Giganti F, Albertsen P, Allen C, Bangma C, Briganti A, Carroll P, Haider M, Kasivisvanathan V, Kirkham A, Klotz L, 
Ouzzane A, Padhani AR, Panebianco V, Pinto P, Puech P, Rannikko A, Renard-Penna R, Touijer K, Turkbey B, van Poppel H, 
Valdagni R, Walz J, Schoots I. Reporting magnetic resonance imaging in men on active surveillance for prostate cancer: The 
PRECISE recommendations-A report of a European School of Oncology Task Force. Eur Urol; 71:648-55; 2017. 
[108] Khoo CC, Eldred-Evans D, Peters M, Bertoncelli Tanaka M, Noureldin M, Miah S, Shah T, Connor MJ, Reddy D, Clark M, Lakhani 
A, Rockall A, Hosking-Jervis F, Cullen E, Arya M, Hrouda D, Qazi H, Winkler M, Tam H, Ahmed HU. Likert vs PI-RADS v2: a 
comparison of two radiological scoring systems for detection of clinically significant prostate cancer. BJU Int; 125:49-55; 2019. 
[109] Bul M, Zhu X, Valdagni R, Pickles T, Kakehi Y, Rannikko A, Bjartell A, van der Schoot DK, Cornel EB, Conti GN, Boevé ER, Staerman 
F, Vis-Maters JJ, Vergunst H, Jaspars JJ, Strölin P, van Muilekom E, Schroder FH, Bangma CH, Roobol MJ. Active surveillance for 
low-risk prostate cancer worldwide: the PRIAS study. Eur Urol; 63:597-603; 2013 Apr. 
[110] Thomsen FB, Brasso K, Klotz LH, Roder MA, Berg KD, Iversen P. Active surveillance for clinically localized prostate cancer--a 
systematic review. J Surg Oncol; 109:830-5; 2014. 
[111] Schoots IG, Nieboer D, Giganti F, Moore CM, Bangma CH, Roobol MJ. Is magnetic resonance imaging-targeted biopsy a useful 
addition to systematic confirmatory biopsy in men on active surveillance for low-risk prostate cancer? A systematic review and 
meta-analysis. BJU Int; 122:946-58; 2018. 
83 
[112] Tosoian JJ, Mamawala M, Epstein JI, Landis P, Wolf S, Trock BJ, Carter HB. Intermediate and longer-term outcomes from a 
prospective active-surveillance program for favorable-risk prostate cancer. J Clin Oncol; 33:3379-85; 2015. 
[113] Borghesi M, Ahmed H, Nam R, Schaeffer E, Schiavina R, Taneja S, Weidner W, Loeb S. Complications after systematic, random, and 
image-guided prostate biopsy. Eur Urol; 71:353–65; 2017. 
[114] Ahlberg MS, Adami HO, Beckmann K, Bertilsson H, Bratt O, Cahill D, Egevad L, Garmo H, Holmberg L, Johansson E, Rannikko A, 
Van Hemelrijck M, Jaderling F, Wassberg C, Aberg UWN, Bill-Axelson A. PCASTt/SPCG-17-a randomised trial of active surveillance 
in prostate cancer: rationale and design. BMJ Open; 9; 2019. 
[115] Ross AE, Loeb S, Landis P, I P,A.W., Epstein JI, Kettermann A, Feng Z, Carter HB, Walsh PC. Prostate-specific antigen kinetics 
during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. J Clin Oncol; 28:2810-6; 2010. 
[116] Bokhorst LP, Valdagni R, Rannikko A, Kakehi Y, Pickles T, Bangma CH, Roobol MJ. A decade of active surveillance in the PRIAS 
study: An update and evaluation of the criteria used to recommend a switch to active treatment. Eur Urol; 70:954-60; 2016. 
[117] Berg KD, Vainer B, Thomsen FB, Roder MA, Gerds TA, Toft BG, Brasso K, Iversen P. ERG protein expression in diagnostic specimens 
is associated with increased risk of progression during active surveillance for prostate cancer. Eur Urol; 66:851-60; 2014. 
[118] Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holding P, Davis M, Peters TJ, Turner EL, Martin RM, Oxley J, Robinson 
M, Staffurth J, Walsh E, Bollina P, Catto J, Doble A, Doherty A, Gillatt D, Kockelbergh R, Kynaston H, Paul A, Powell P, Prescott S, 
Rosario DJ, Rowe E, Neal DE. 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Eng J 
Med; 375:1415-24; 2016. 
[119] Lam TBL, MacLennan S, Plass K, Willemse PM, Mason MD, Cornford P, Donaldson J, Davis NF, Dell'Oglio P, Fankhauser C, Grivas 
N, Ingels A, Lardas M, Liew M, Pang KH, Paterson C, Omar MI, Zattoni F, Buddingh KT, Van den Broeck T, Cumberbatch MG, 
Fossati N, Gross T, Moris L, Schoots IG, van den Bergh RCN, Briers E, Fanti S, De Santis M, Gillessen S, Grummet JP, Henry AM, 
van der Poel HG, van der Kwast TH, Rouviere O, Tilki D, Wiegel T, N'Dow J, Van Poppel H, Mottet N. Study protocol for the 
DETECTIVE study: An international collaborative study To develop consensus statements for deferred treatment with curative 
intent for localised prostate cancer. Eur Urol; 75:699-702; 2019. 
[120] Amin MB, L L,D.W., Gore JL, Srigley JR, Samaratunga H, Egevad L, Rubin M, Nacey J, Carter HB, Klotz L, Sandler H, Zietman AL, 
Holden S, Montironi R, Humphrey PA, Evans AJ, Epstein JI, Delahunt B, McKenney JK, Berney D, Wheeler TM, Chinnaiyan AM, 
True L, Knudsen B, Hammond ME. The critical role of the pathologist in determining eligibility for active surveillance as a 
management option in patients with prostate cancer: consensus statement with recommendations supported by the College of 
American Pathologists, International Society of Urological Pathology, Association of Directors of Anatomic and Surgical Pathology, 
the New Zealand Society of Pathologists, and the Prostate Cancer Foundation. Arch Pathol Lab Med; 138:1387-405; 2014. 
[121] Leong JY, Capella C, Teplitsky S, Gomella LG, Trabulsi EJ, Lallas CD, Chandrasekar T. Impact of tumor regional involvement on 
active surveillance outcomes: Validation of the Cumulative Cancer Location metric in a US population. Eur Urol Focus; 6:235-41; 
2020. 
[122] Erickson AM, Luzzago S, Semjonow A, Vasarainen H, Laajala TD, Musi G, de Cobelli O, Mirtti T, Rannikko A. Cumulative Cancer 
Locations is a novel metric for predicting active surveillance outcomes: A multicenter study. Eur Urol Oncol; 1:268-75; 2018. 
[123] Albertsen PC, Moore DF, Shih W, Lin Y, Li H, Lu-Yao GL. Impact of comorbidity on survival among men with localized prostate 
cancer. J Clin Oncol; 29:1335-41; 2011. 
[124] Chodak GW, S T,R.A., Gerber GS, Johansson JE, Adolfsson J, Jones GW, Chisholm GD, Moskovitz B, Livne PM, Warner J. Results 
of conservative management of clinically localized prostate cancer. N Eng J Med; 330:242-8; 1994. 
[125] Michalski JM, Moughan J, Purdy J, Bosch W, Bruner DW, Bahary JP, Lau H, Duclos M, Parliament M, Morton G, Hamstra D, Seider 
M, Lock MI, Patel M, Gay H, Vigneault E, Winter K, Sandler H. Effect of standard vs dose-escalated radiation therapy for patients 
with intermediate-risk prostate cancer: The NRG Oncology RTOG 0126 randomized clinical trial. JAMA; 4; 2018. 
[126] Bolla M, Van Tienhoven G, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Billiet I, Torecilla JL, 
Pfeffer R, Cutajar CL, Van der Kwast T, Collette L. External irradiation with or without long-term androgen suppression for prostate 
cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol; 11:1066-73; 2010. 
[127] Bolla M, van Poppel H, Tombal B, Vekemans K, Da Pozzo L, de Reijke TM, Verbaeys A, Bosset JF, van Velthoven R, Colombel M, 
van de Beek C, Verhagen P, van den Bergh A, Sternberg C, Gasser T, van Tienhoven G, Scalliet P, Haustermans K, Collette L. 
Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled 
trial (EORTC trial 22911). Lancet; 380:2018-27; 2012. 
[128] Pfister D, Bolla M, Briganti A, Carroll P, Cozzarini C, Joniau S, van Poppel H, Roach M, Stephenson A, Wiegel T, Zelefsky MJ. Early 
salvage radiotherapy following radical prostatectomy. Eur Urol; 65:1034-43; 2014. 
84 
[129] Kollmeier MA, McBride S, Taggar A, Anderson E, Lin M, Pei X, Weiji S, Voros L, Cohen G, Yamada Y, Zelefsky MJ. Salvage 
brachytherapy for recurrent prostate cancer after definitive radiation therapy: A comparison of low-dose-rate and high-dose-rate 
brachytherapy and the importance of prostate-specific antigen doubling time. Brachytherapy; 16:1091-8; 2017. 
[130] Bill-Axelson A, Holmberg L, Garmo H, Rider JR, Taari K, Busch C, Nordling S, Haggman M, Andersson SO, Spangberg A, Andren 
O, Palmgren J, Steineck G, Adami HO, Johansson JE. Radical prostatectomy or watchful waiting in early prostate cancer. N Eng J 
Med; 370:932-42; 2014. 
[131] Wilt TJ, Brawer MK, Jones KM, Barry MJ, Aronson WJ, Fox S, Gingrich JR, Wei JT, Gilhooly P, Grob BM, Nsouli I, Iyer P, Cartagena 
R, Snider G, Roehrborn C, Sharifi R, Blank W, Pandya P, Andriole GL, Culkin D, Wheeler T. Radical prostatectomy versus 
observation for localized prostate cancer. N Engl J Med; 367:203-13; 2012. 
[132] Wilt TJ, Vo TN, Langsetmo L, Dahm P, Wheeler T, Aronson WJ, Cooperberg MR, Taylor BC, Brawer MK. Radical prostatectomy or 
observation for clinically localized prostate cancer: extended follow-up of the Prostate Cancer Intervention Versus Observation Trial 
(PIVOT). Eur Urol; 77:713-24; 2020. 
[133] Ilic D, Evans SM, Allan CA, Jung JH, Murphy D, Frydenberg M. Laparoscopic and robotic-assisted versus open radical prostatectomy 
for the treatment of localised prostate cancer. Cochrane Database Syst Rev; 9; 2017. 
[134] Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, van der Poel HG, van 
der Kwast TH, Rouviere O, Wiegel T, Mottet N. EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: Treatment of relapsing, 
metastatic, and castration-resistant prostate cancer. Eur Urol; 71:630-42; 2017. 
[135] Cimino S, Reale G, Castelli T, Favilla V, Giardina R, Russo GI, Privitera S, Morgia G. Comparison between Briganti, Partin and 
MSKCC tools in predicting positive lymph nodes in prostate cancer: a systematic review and meta-analysis. Scand J Urol; 51:345-
50; 2017. 
[136] Fossati N, Willemse PM, Van den Broeck T, van den Bergh RCN, Yuan CY, Briers E, Bellmunt J, Bolla M, Cornford P, De Santis M, 
MacPepple E, Henry AM, Mason MD, Matveev VB, van der Poel HG, van der Kwast TH, Rouviere O, Schoots IG, Wiegel T, Lam TB, 
Mottet N, Joniau S. The benefits and harms of different extents of lymph node dissection during radical prostatectomy for prostate 
cancer: A systematic review. Eur Urol; 72:84-109; 2017. 
[137] Kumar S, Shelley M, Harrison C, Coles B, Wilt TJ, Mason MD. Neo-adjuvant and adjuvant hormone therapy for localised and locally 
advanced prostate cancer. Cochrane Database Syst Rev; 4; 2006. 
[138] Bianco F,Jr, A S,P.T., Eastham JA. Radical prostatectomy: long-term cancer control and recovery of sexual and urinary function 
("trifecta"). Urology; 66:83-94; 2005. 
[139] Walz J, Joniau S, Chun FK, Isbarn H, Jeldres C, Yossepowitch O, Chao-Yu H, Klein EA, Scardino PT, Reuther A, Poppel HV, Graefen 
M, Huland H, Karakiewicz PI. Pathological results and rates of treatment failure in high-risk prostate cancer patients after radical 
prostatectomy. BJU Int; 107:765-70; 2011. 
[140] Van Poppel H, Joniau S. An analysis of radical prostatectomy in advanced stage and high-grade prostate cancer. Eur Urol; 53:253-
9; 2008. 
[141] Stranne J, Brasso K, Brennhovd B, Johansson E, Jaderling F, Kouri M, Lilleby W, Meidahl P, Mirtti T, Pettersson A, Rannikko A, 
Thellenberg C, Akre O. SPCG-15: a prospective randomized study comparing primary radical prostatectomy and primary 
radiotherapy plus androgen deprivation therapy for locally advanced prostate cancer. Scand J Urol; 52:313-20; 2018. 
[142] Oefelein MG, Feng A, Scolieri MJ, Ricchiutti D, Resnick MI. Reassessment of the definition of castrate levels of testosterone: 
implications for clinical decision making. Urology; 56:1021-4; 2000. 
[143] Nguyen PL, Alibhai SM, Basaria S, D'Amico AV, Kantoff PW, Keating NL, Penson DF, Rosario DJ, Tombal B, Smith MR. Adverse 
effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol; 67:825-36; 2015. 
[144] Thomsen FB, Sandin F, Garmo H, Lissbrant IF, Ahlgren G, Van Hemelrijck M, Adolfsson J, Robinson D, Stattin P. Gonadotropin-
releasing hormone agonists, orchiectomy, and risk of cardiovascular disease: semi-ecologic, nationwide, population-based study. 
Eur Urol; 72:920-8; 2017. 
[145] Desmond AD, Arnold AJ, Hastie KJ. Subcapsular orchiectomy under local anaesthesia. Technique, results and implications. Br J 
Urol; 61:143-5; 1988. 
[146] Bubley GJ. Is the flare phenomenon clinically significant? Urology; 58:5-9; 2001. 
[147] Seidenfeld J, V S,D.J., Hasselblad V, Aronson N, Albertsen PC, Bennett CL, Wilt TJ. Single-therapy androgen suppression in men 
with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med; 132:566-77; 2000. 
85 
[148] Sciarra A, Fasulo A, Ciardi A, Petrangeli E, Gentilucci A, Maggi M, Innocenzi M, Pierella F, Gentile V, Salciccia S, Cattarino S. A 
meta-analysis and systematic review of randomized controlled trials with degarelix versus gonadotropin-releasing hormone 
agonists for advanced prostate cancer. Medicine (Baltimore); 95; 2016. 
[149] Margel D, Peer A, Ber Y, Shavit-Grievink L, Tabachnik T, Sela S, Witberg G, Baniel J, Kedar D, Duivenvoorden WCM, Rosenbaum 
E, Pinthus JH. Cardiovascular morbidity in a randomized trial comparing GnRH agonist and GnRH antagonist among patients with 
advanced prostate cancer and preexisting cardiovascular disease. J Urol; 202:1199-208; 2019. 
[150] Melloni C, Slovin SF, Blemings A, Goodman SG, Evans CP, Nilsson J, Bhatt DL, Zubovskiy K, Olesen TK, Dugi K, Claske NW, Higano 
CS, Roe MT. Cardiovascular safety of Degarelix versus Leuprolide for advanced prostate cancer. JACC:CardioOncology; 2; 2020. 
[151] Wadhwa VK, Weston R, Mistry R, Parr NJ. Long-term changes in bone mineral density and predicted fracture risk in patients 
receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values. BJU Int; 
104:800-5; 2009. 
[152] Kunath F, Gerta G,H.R., Rucker G, Motschall E, Antes G, Dahm P, Wullich B, Meerpohl JJ. Non-steroidal antiandrogen monotherapy 
compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer. 
Cochrane Database Syst Rev; 6; 2014. 
[153] Hedlund PO, Inger D,J.E., Hagerman I, Haukaas S, Henriksson P, Iversen P, Johansson R, Klarskov P, Lundbeck F, Rasmussen F, 
Varenhorst E, Viitanen J. Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic 
cancer: part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5. Scand J Urol Nephrol; 42:220-9; 
2008. 
[154] James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, Ritchie AWS, Amos CL, Gilson C, Jones RJ, Matheson 
D, Millman R, Attard G, Chowdhury S, Cross WR, Gillessen S, Parker CC, Russell JM, Berthold DR, Brawley C, Adab F, Aung S, 
Birtle AJ, Bowen J, Brock S, Chakraborti P, Ferguson C, Gale J, Gray E, Hingorani M, Hoskin PJ, Lester JF, Malik ZI, McKinna F, 
McPhail N, Money-Kyrle J, O'Sullivan J, Parikh O, Protheroe A, Robinson A, Srihari NN, Thomas C, Wagstaff J, Wylie J, Zarkar A, 
Parmar MKB, Sydes MR. Abiraterone for prostate cancer not previously treated with hormone therapy. N Eng J Med; 377:335-51; 
2017. 
[155] Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, Ozguroglu M, Ye D, Feyerabend S, Protheroe A, De Porre 
P, Kheoh T, Park YC, Todd MB, Chi KN. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Eng J 
Med; 377:352-60; 2017. 
[156] Hussain M, Fizazi K, Saad F, Rathenborg P, Shore N, Ferreira U, Ivashchenko P, Demirhan E, Modelska K, Phung, Krivoshik A, 
Sternberg CN. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Eng J Med; 378:2465-74; 2018. 
[157] Beer TM, E A,A.J., Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, Iversen P, Bhattacharya S, Carles J, Chowdhury S, Davis ID, de 
Bono JS, Evans CP, Fizazi K, Joshua AM, Kim CS, Kimura G, Mainwaring P, Mansbach H, Miller K, Noonberg SB, Perabo F, Phung 
D, Saad F, Scher HI, Taplin ME, Venner PM, Tombal B. Enzalutamide in metastatic prostate cancer before chemotherapy. N Eng J 
Med; 371:424-33; 2014. 
[158] Smith MR, Antonarakis ES, Ryan CJ, Berry WR, Shore ND, Liu G, Alumkal JJ, Higano CS, Chow Maneval E, Bandekar R, de Boer 
CJ, Yu MK, Rathkopf DE. Phase 2 study of the safety and antitumor activity of apalutamide (ARN-509), a potent androgen receptor 
antagonist, in the high-risk nonmetastatic castration-resistant prostate cancer cohort. Eur Urol; 70:963-70; 2016. 
[159] Rathkopf DE, J M,M.J., Fox JJ, Danila DC, Slovin SF, Hager JH, Rix PJ, Chow Maneval E, Chen I, Gönen M, Fleisher M, Larson SM, 
Sawyers CL, Scher HI. Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer. J 
Clin Oncol; 28:3525-30; 2013. 
[160] Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, Olmos D, Mainwaring PN, Lee JY, Uemura H, Lopez-Gitlitz 
A, Trudel GC, Espina BM, Shu Y, Park YC, Rackoff WR, Yu MK, Small EJ. Apalutamide treatment and metastasis-free survival in 
prostate cancer. N Eng J Med; 378:1408-18; 2018. 
[161] Moilanen AM, Riikonen R, Oksala R, Ravanti L, Aho E, Wohlfahrt G, Nykanen PS, Tormakangas OP, Palvimo JJ, Kallio PJ. Discovery 
of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed 
prostate cancer therapies. Sci Rep; 5; 2015. 
[162] Fizazi K, Massard C, Bono P, Jones R, Kataja V, James N, Garcia JA, Protheroe A, Tammela TL, Elliott T, Mattila L, Aspegren J, 
Vuorela A, Langmuir P, Mustonen M. Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant 
prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial. Lancet Oncol; 
15:975-85; 2014. 
[163] Fizazi K, Massard C, Bono P, Kataja V, James N, Tammela TL, Joensuu H, Aspegren J, Mustonen M. Safety and antitumour activity 
of ODM-201 (BAY-1841788) in castration-resistant, CYP17 inhibitor-naïve prostate cancer: results from extended follow-up of the 
ARADES trial. Eur Urol Focus; 6:606-14; 2017. 
86 
[164] Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Kuss I, Kappeler C, Snapir A, Sarapohja 
T, Smith MR. Darolutamide in nonmetastatic, castration-resistant prostate cancer. N Eng J Med; 380:1235-46; 2019. 
[165] Madersbacher S, Marberger M. High-energy shockwaves and extracorporeal high-intensity focused ultrasound. J Endourol; 17:667-
72; 2003. 
[166] Fahmy WE, Bissada NK. Cryosurgery for prostate cancer. Arch Androl; 49:397-407; 2003. 
[167] Ramsay CR, Adewuyi TE, Gray J, Hislop J, Shirley MD, Jayakody S, MacLennan G, Fraser C, MacLennan S, Brazzelli M, N'Dow J, 
Pickard R, Robertson C, Rothnie K, Rushton SP, Vale L, Lam TB. Ablative therapy for people with localised prostate cancer: a 
systematic review and economic evaluation. Health Technol Assess; 19:1-490; 2015. 
[168] van Stam MA, van der Poel HG, JLHR B, Tillier CN, Horenblas S, Mols F, Aaronson NK. Prevalence and correlates of mental health 
problems in prostate cancer survivors: A case-control study comparing survivors with general population peers. Urol Oncol; 
35:531.e1-7; 2017. 
[169] Stamey TA, E K,J.N., McNeal JE, Johnstone IM, Freiha F, Redwine EA, Yang N. Prostate specific antigen in the diagnosis and 
treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients. J Urol; 141:1076-83; 1989. 
[170] Shen S, Lepor H, Yaffee R, Taneja SS. Ultrasensitive serum prostate specific antigen nadir accurately predicts the risk of early relapse 
after radical prostatectomy. J Urol; 173:777-80; 2005. 
[171] Hancock SL, Cox RS, Bagshaw MA. Prostate specific antigen after radiotherapy for prostate cancer: a reevaluation of long-term 
biochemical control and the kinetics of recurrence in patients treated at Stanford University. J Urol; 154:1412-7; 1995. 
[172] Chaplin BJ, H W,M.F., Schroder FH, Kirkels WJ, Bangma CH. Digital rectal examination is no longer necessary in the routine follow-
up of men with undetectable prostate specific antigen after radical prostatectomy: the implications for follow-up. Eur Urol; 48:906-
10; 2005. 
[173] Wilt TJ, Jones KM, Barry MJ, Andriole GL, Culkin D, Wheeler T, Aronson WJ, Brawer MK. Follow-up of Prostatectomy versus 
Observation for Early Prostate Cancer. N Eng J Med; 377:132-42; 2017. 
[174] Boorjian SA, K T,R.H., Tollefson MK, Rangel LJ, Bergstralh EJ, Blute ML, Karnes RJ. Long-term risk of clinical progression after 
biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence. Eur Urol; 59:893-9; 2011. 
[175] Van den Broeck T, van den Bergh RCN, Arfi N, Gross T, Moris L, Briers E, Cumberbatch M, De Santis M, Tilki D, Fanti S, Fossati N, 
Gillessen S, Grummet JP, Henry AM, Lardas M, Liew M, Rouviere O, Pecanka J, Mason MD, Schoots IG, van Der Kwast TH, van 
Der Poel HG, Wiegel T, Willemse PM, Yuan Y, Lam TB, Cornford P, Mottet N. Prognostic value of biochemical recurrence following 
treatment with curative intent for prostate cancer: A systematic review. Eur Urol; 75:967-87; 2019. 
[176] Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA; 
293:2095-101; 2005. 
[177] Ross PL, W S,P.T., Kattan MW. A catalog of prostate cancer nomograms. J Urol; 5:1562-8; 2001. 
[178] Alberts AR, Roobol MJ, Verbeek JFM, Schoots IG, Chiu PK, Osses DF, Tijsterman JD, Beerlage HP, Mannaerts CK, Schimmoller L, 
Albers P, Arsov C. Prediction of high-grade prostate cancer following multiparametric magnetic resonance imaging: improving the 
Rotterdam European Randomized Study of Screening for Prostate Cancer risk calculators. Eur Urol; 75:310-8; 2019. 
[179] Lee SM, Liyanage SH, Wulaningsih W, Wolfe K, Carr T, Younis C, Van Hemelrijck M, Popert R, Acher P. Toward an MRI-based 
nomogram for the prediction of transperineal prostate biopsy outcome: A physician and patient decision tool. Urol Oncol; 
35:664.e11-8; 2017. 
[180] Wang R, Wang J, Gao G, Hu J, Jiang Y, Zhao Z, Zhang X, Zhang YD, Wang X. Prebiopsy mp-MRI can help to improve the predictive 
performance in prostate cancer: A prospective study in 1,478 consecutive patients. Clin Cancer Res; 23:3692-99; 2017. 
[181] Zanelli E, Giannarini G, Cereser L, Zuiani C, Como G, Pizzolitto S, Crestani A, Valotto C, Ficarra V, Girometti R. Head-to-head 
comparison between multiparametric MRI, the partin tables, memorial sloan kettering cancer center nomogram, and CAPRA score 
in predicting extraprostatic cancer in patients undergoing radical prostatectomy. J Magn Reson Imaging; 50:1604-13; 2019. 
[182] Zelic R, Garmo H, Zugna D, Stattin P, Richiardi L, Akre O, Pettersson A. Predicting prostate cancer death with different pretreatment 
risk stratification tools: A head-to-head comparison in a nationwide cohort study. Eur Urol; 77:180-8; 2020. 
[183] Cooperberg MR, Pasta DJ, Elkin EP, M L,M.S., Latini DM, Du Chane J, Carroll PR. The University of California, San Francisco 
Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after 
radical prostatectomy. J Urol; 173(6):1938-42; 2005. 
87 
[184] Cooperberg MR, Hilton JF, Carroll PR. The CAPRA-S score: A straightforward tool for improved prediction of outcomes after radical 
prostatectomy. Cancer; 117:5039-46; 2011. 
[185] Brajtbord JS, Leapman MS, Cooperberg MR. The CAPRA score at 10 years: Contemporary perspectives and analysis of supporting 
studies. Eur Urol; 71:705-9; 2017. 
[186] Cagiannos I, Karakiewicz P, Eastham JA, Ohori M, Rabbani F, Gerigk C, Reuter V, Graefen M, Hammerer PG, Erbersdobler A, 
Huland H, Kupelian P, Klein E, Quinn DI, Henshall SM, Grygiel JJ, Sutherland RL, Stricker PD, Morash CG, Scardino PT, Kattan 
MW. A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer. J Urol; 
170:1798-803; 2003. 
[187] Partin AW, Yoo J, Carter HB, Pearson JD, Chan DW, Epstein JI, Walsh PC. The use of prostate specific antigen, clinical stage and 
Gleason score to predict pathological stage in men with localized prostate cancer. J Urol; 150:110-4; 1993. 
[188] Eifler JB, Feng Z, Lin BM, Partin MB, Humphreys EB, Han M, Epstein JI, Walsh PC, Trock BJ, Partin AW. An updated prostate 
cancer staging nomogram (Partin tables) based on cases from 2006 to 2011. BJU Int; 111:22-9; 2013. 
[189] Partin AW, Mangold LA, Lamm DM, Walsh PC, Epstein JI, Pearson JD. Contemporary update of prostate cancer staging nomograms 
(Partin Tables) for the new millennium. Urology; 58:843-8; 2001. 
[190] Jamaspishvili T, Berman DM, Ross AE, Scher HI, De Marzo AM, Squire JA, Lotan TL. Clinical implications of PTEN loss in prostate 
cancer. Nat Rev Urol; 15:222-34; 2018. 
[191] Haney NM, Faisal FA, Lu J, Guedes LB, Reuter VE, Scher HI, Eastham JA, Marchionni L, Joshu C, Gopalan A, Lotan TL. PTEN loss 
with ERG negative status is associated with lethal disease after radical prostatectomy. J Urol; 203:344-50; 2020. 
[192] Krohn A, Diedler T, Burkhardt L, Mayer PS, De Silva C, Meyer-Kornblum M, Kotschau D, Tennstedt P, Huang J, Gerhauser C, Mader 
M, Kurtz S, Sirma H, Saad F, Steuber T, Graefen M, Plass C, Sauter G, Simon R, Minner S, Schlomm T. Genomic deletion of PTEN 
is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer. Am J 
Pathol; 181:401-12; 2012. 
[193] Mithal P, Allott E, Gerber L, Reid J, Welbourn W, Tikishvili E, Park J, Younus A, Sangale Z, Lanchbury JS, Stone S, Freedland SJ. 
PTEN loss in biopsy tissue predicts poor clinical outcomes in prostate cancer. Int J Urol; 21:1209-14; 2014. 
[194] Lotan TL, Gurel B, Sutcliffe S, Esopi D, Liu W, Xu J, Hicks JL, Park BH, Humphreys E, Partin AW, Han M, Netto GJ, Isaacs WB, De 
Marzo AM. PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of 
prostate cancer patients. Clin Cancer Res; 17:6563-73; 2011. 
[195] Boström PJ, Bjartell AS, Catto JW, Eggener SE, Lilja H, Loeb S, Schalken J, Schlomm T, Cooperberg MR. Genomic predictors of 
outcome in prostate cancer. Eur Urol; 68:1033-44; 2015. 
[196] Tomlins SA, Day JR, Lonigro RJ, Hovelson DH, Siddiqui J, Kunju LP, Dunn RL, Meyer S, Hodge P, Groskopf J, Wei JT, Chinnaiyan 
AM. Urine TMPRSS2:ERG plus PCA3 for individualized prostate cancer risk assessment. Eur Urol; 70:45-53; 2016. 
[197] Saini S. PSA and beyond: alternative prostate cancer biomarkers. Cell Oncol; 39:97-106; 2016. 
[198] Bruzzese D, Mazzarella C, Ferro M, Perdona S, Chiodini P, Perruolo G, Terracciano D. Prostate health index vs percent free prostate-
specific antigen for prostate cancer detection in men with "gray" prostate-specific antigen levels at first biopsy: systematic review 
and meta-analysis. Transl Res; 164:444-51; 2014. 
[199] Strom P, Nordstrom T, Aly M, Egevad L, Gronberg H, Eklund M. The Stockholm-3 model for prostate cancer detection: algorithm 
update, biomarker contribution, and reflex test potential. Eur Urol; 74:204-10; 2018. 
[200] Rosario DJ, Lane JA, Metcalfe C, Donovan JL, Doble A, Goodwin L, Davis M, Catto JW, Avery K, Neal DE, Hamdy FC. Short term 
outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study. 
BMJ; 344:d7894; 2012. 
[201] Kasivisvanathan V, Jichi F, Klotz L, Villers A, Taneja SS, Punwani S, Freeman A, Emberton M, Moore CM. A multicentre randomised 
controlled trial assessing whether MRI-targeted biopsy is non-inferior to standard transrectal ultrasound guided biopsy for the 
diagnosis of clinically significant prostate cancer in men without prior biopsy: a study protocol. BMJ Open; 7; 2017. 
[202] van Buuren S, Groothuis-Ouodshoorn K. MICE: Multivariate imputation by chained equations in R. J Stat Softw; 45:1-60; 2011. 
[203] Team RC. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 
https://www.R-project.org/; 2018. 
88 
[204] Bruinsma SM, Zhang L, Roobol MJ, Bangma CH, Steyerberg EW, Nieboer D, Van Hemelrijck M. The Movember Foundation's GAP3 
cohort: a profile of the largest global prostate cancer active surveillance database to date. BJU Int; 121:737-44; 2018. 
[205] Bokhorst LP, Alberts AR, Rannikko A, Valdagni R, Pickles T, Kakehi Y, Bangma CH, Roobol MJ. Compliance rates with the Prostate 
Cancer Research International Active Surveillance (PRIAS) protocol and disease reclassification in noncompliers. Eur Urol; 
68:814–21; 2015. 
[206] Bokhorst LP, Lepisto I, Kakehi Y, Bangma CH, Pickles T, Valdagni R, Alberts AR, Semjonow A, Strolin P, Montesino MF, Berge V, 
Roobol MJ, Rannikko A. Complications after prostate biopsies in men on active surveillance and its effect on receiving further 
biopsies in the Prostate Cancer Research International: Active Surveillance (PRIAS) study. BJU Int; 118:366–71; 2016. 
[207] Hsiang W, Ghabili K, Syed JS, Holder J, Nguyen KA, Suarez-Sarmiento A, Huber S, Leapman MS, Sprenkle PC. Outcomes of serial 
multiparametric magnetic resonance imaging and subsequent biopsy in men with low-risk prostate cancer managed with active 
surveillance. Eur Urol Focus; Online ahead of print:S2405-4569; 2019. 
[208] Gallagher KM, Christopher E, Cameron AJ, Little S, Innes A, Davis G, Keanie J, Bollina P, McNeill A. Four-year outcomes from a 
multiparametric magnetic resonance imaging (MRI)-based active surveillance programme: PSA dynamics and serial MRI scans 
allow omission of protocol biopsies. BJU Int; 123:429-38; 2019. 
[209] Elkjaer MC, Andersen MH, Hoyer S, Pedersen BG, Borre M. Multi-parametric magnetic resonance imaging monitoring patients in 
active surveillance for prostate cancer: a prospective cohort study. Scand J Urol; 52:8-13; 2018. 
[210] Osses DF, Drost FH, Verbeek JFM, Luiting HB, van LG, Bangma CH, Krestin GP, Roobol MJ, Schoots IG. Prostate cancer upgrading 
with serial prostate MRI scans and repeat biopsy in men on active surveillance: are confirmatory biopsies still necessary? BJU 
Int:Online ahead of print; 2020. 
[211] Hamoen EHJ, Hoeks CMA, Somford DM, van Oort IM, Vergunst H, Oddens JR, Smits GA, Bokhorst LP, Witjes JA, Rovers MM, 
Hulsbergen-van de Kaa CA, Barentsz JO. Value of serial multiparametric magnetic resonance imaging and magnetic resonance 
imaging-guided biopsies in men with low-risk prostate cancer on active surveillance after 1 yr follow-up. Eur Urol Focus; 5:407-15; 
2019. 
[212] Klotz L, Pond G, Loblaw A, Sugar L, Moussa M, Berman D, Van der Kwast T, Vesprini D, Milot L, Kebabdjian M, Fleshner N, Ghai 
S, Chin J, Haider M. Randomized study of systematic biopsy versus magnetic resonance imaging and targeted and systematic biopsy 
in men on active surveillance (ASIST): 2-year postbiopsy follow-up. Eur Urol; 77:311-17; 2020. 
[213] Cantiello F, Russo GI, Kaufmann S, Cacciamani G, Crocerossa F, Ferro M, De Cobelli O, Artibani W, Cimino S, Morgia G, Damiano 
R, Nikolaou K, Kroger N, Stenzl A, Bedke J, Kruck S. Role of multiparametric magnetic resonance imaging for patients under active 
surveillance for prostate cancer: a systematic review with diagnostic meta-analysis. Prostate Cancer Prostatic Dis; 22:206-20; 2019. 
[214] Schoots IG, Petrides N, Giganti F, Bokhorst LP, Rannikko A, Klotz L, Villers A, Hugosson J, Moore CM. Magnetic resonance imaging 
in active surveillance of prostate cancer: a systematic review. Eur Urol; 67:627-36; 2015. 
[215] Turkbey B, Brown AM, Sankineni S, Wood BJ, Pinto PA, Choyke PL. Multiparametric prostate magnetic resonance imaging in the 
evaluation of prostate cancer. CA Cancer J Clin; 66:326-36; 2016. 
[216] Felker ER, Wu J, Natarajan S, Margolis DJ, Raman SS, Huang J, Dorey F, Marks LS. Serial MRI in active surveillance of prostate 
cancer: incremental value. J Urol; 195:1421-7; 2015. 
[217] Moore CM, Petrides N, Emberton M. Can MRI replace serial biopsies in men on active surveillance for prostate cancer? Curr Opin 
Urol; 24:280-7; 2014. 
[218] Vasarainen H, Lahdensuo K, Savolainen R, Ruutu M, Taari K, Rannikko A. Diffusion-weighted magnetic resonance imaging in 
prostate cancer patients on active surveillance one year after diagnosis and before repeat biopsy. Scand J Urol; 47:456-61; 2013. 
[219] De Sio M, D´Armiento M, Di Lorenzo G, Damiano R, Perdona S, De Placido S, Autorino R. The need to reduce patient discomfort 
during transrectal ultrasonography-guided prostate biopsy: what do we know? BJU Int; 96:977–83; 2005. 
[220] Seckiner I, Sen H, Erturhan S, Yagci F. A prospective, randomized controlled study comparing lidocaine and tramadol in 
periprostatic nerve blockage for transrectal ultrasound-guided prostate biopsy. Urology; 78:257–60; 2011. 
[221] Lee C, Woo HH. Current methods of analgesia for transrectal ultrasonography (TRUS)-guided prostate biopsy—a systematic review. 
BJU Int; 113(Suppl 2):48–56; 2014. 
[222] Loeb S, Carter HB, Berndt SI, Ricker W, Schaeffer EM. Complications after prostate biopsy: data from SEER-Medicare. J Urol; 
186:1830-4; 2011. 
89 
[223] Cooperberg MR, Carroll PR, Klotz L. Active surveillance for prostate cancer: progress and promise. J Clin Oncol; 29:3669–76; 2011. 
[224] Wegelin O, Exterkate L, van der Leest M, Kelder JC, Bosch J, Barentsz JO, Somford DM, van Melick HHE. Complications and 
adverse events of three magnetic resonance imaging-based target biopsy techniques in the giagnosis of prostate cancer among men 
with prior negative biopsies: results from the FUTURE trial, a multicentre randomised controlled trial. Eur Urol Oncol; 2:617-24; 
2019. 
[225] Overduin CG, Futterer JJ. MRI-guided biopsy for prostate cancer detection: a systematic review of current clinical results. Curr Urol 
Rep; 14:209–13; 2013. 
[226] Egbers N, Schwenke C, Maxeiner A, Teichgraber U, Franiel T. MRI-guided core needle biopsy of the prostate: acceptance and side 
effects. Diagn Interv Radiol; 21:215–21; 2015. 
[227] Arsov C, Rabenalt R, Quentin M, Hiester A, Blondin D, Albers P, Antoch G, Schimmoller L. Comparison of patient comfort between 
MR-guided in-bore and MRI/ultrasound fusion-guided prostate biopsies within a prospective randomized trial. World J Urol; 
34:215–20; 2016. 
[228] Tiong HY, Liew LC, Samuel M, Consigliere D, Esuvaranathan K. A meta-analysis of local anesthesia for transrectal ultrasound-
guided biopsy of the prostate. Prostate Cancer Prostatic Dis; 10:127–36; 2007. 
[229] Du J, Johnston J, Studd R. Does waiting after peri-prostatic nerve block reduce pain during transrectal ultrasound-guided prostate 
biopsy? A randomized controlled trial. ANZ J Surg; 87:262–5; 2017. 
[230] Mäkinen T, Auvinen A, Hakama M, Stenman UH, Tammela TL. Acceptability and complications of prostate biopsy in population-
based PSA screening versus routine clinical practice: a prospective, controlled study. Urology; 60:846–50; 2002. 
[231] Johnson DC, Raman SS, Mirak SA, Kwan L, Bajgiran AM, Hsu W, Maehara CK, Ahuja P, Faiena I, Pooli A, Salmasi A, Sisk A, Felker 
ER, Lu DSK, Reiter RE. Detection of individual prostate cancer foci via multiparametric magnetic resonance imaging. Eur Urol; 
75:712-20; 2019. 
[232] Panebianco V, Barchetti G, Simone G, Del Monte M, Ciardi A, Grompone MD, Campa R, Indino EL, Barchetti F, Sciarra A, Leonardo 
C, Gallucci M, Catalano C. Negative multiparametric magnetic resonance imaging for prostate cancer: What's next? Eur Urol; 74:48-
54; 2018. 
[233] Venderink W, van Luijtelaar A, van der Leest M, Barentsz JO, Jenniskens SFM, Sedelaar MJP, Hulsbergen-van de Kaa C, Overduin 
CG, Futterer JJ. Multiparametric magnetic resonance imaging and follow-up to avoid prostate biopsy in 4259 men. BJU Int; 
124:775-84; 2019. 
[234] 1Lee D, Fontugne J, Gumpeni N, Park K, MacDonald TY, Robinson BD, Sboner A, Rubin MA, Mosquera JM, Barbieri CE. Molecular 
alterations in prostate cancer and association with MRI features. Prostate Cancer Prostatic Dis; 20:430-5; 2017. 
[235] Li P, You S, Nguyen C, Wang Y, Kim J, Sirohi D, Ziembiec A, Luthringer D, Lin SC, Daskivich T, Wu J, Freeman MR, Saouaf R, Li 
D, Kim HL. Genes involved in prostate cancer progression determine MRI visibility. Theranostics; 8:1752-65; 2018. 
[236] Purysko AS, Magi-Galluzzi C, Mian OY, Sittenfeld S, Davicioni E, du Plessis M, Buerki C, Bullen J, Li L, Madabhushi A, Stephenson 
A, Klein EA. Correlation between MRI phenotypes and a genomic classifier of prostate cancer: preliminary findings. Eur Radiol; 
29:4861-70; 2019. 
[237] Houlahan KE, Salmasi A, Sadun TY, Pooli A, Felker ER, Livingstone J, Huang V, Raman SS, Ahuja P, Sisk A,Jr, Boutros PC, Reiter 
RE. Molecular hallmarks of multiparametric magnetic resonance imaging visibility in prostate cancer. Eur Urol; 76:18-23; 2019. 
[238] de Rooij M, Hamoen EH, Witjes JA, Barentsz JO, Rovers MM. Accuracy of magnetic resonance imaging for local staging of prostate 
cancer: a diagnostic meta-analysis. Eur Urol; 70:233-45; 2016. 
[239] Morlacco A, Sharma V, Viers BR, Rangel LJ, Carlson RE, Froemming AT, Karnes RJ. The incremental role of magnetic resonance 
imaging for prostate cancer staging before radical prostatectomy. Eur urol; 71:701-4; 2017. 
[240] Grivas N, Hinnen K, de Jong J, Heemsbergen W, Moonen L, Witteveen T, van der Poel H, Heijmink S. Seminal vesicle invasion on 
multi-parametric magnetic resonance imaging: Correlation with histopathology. Eur J Radiol; 98:107-12; 2018. 
[241] Gupta RT, Faridi KF, Singh AA, Passoni NM, Garcia-Reyes K, Madden JF, Polascik TJ. Comparing 3-T multiparametric MRI and 
the Partin tables to predict organ-confined prostate cancer after radical prostatectomy. Urol Oncol; 32:1292-9; 2014. 
[242] Gupta RT, Brown AF, Silverman RK, Tay KJ, Madden JF, George DJ, Polascik TJ. Can Radiologic Staging With Multiparametric 
MRI Enhance the Accuracy of the Partin Tables in Predicting Organ-Confined Prostate Cancer? AJR Am J Roentgenol; 207:87-95; 
2016. 
90 
[243] Feng TS, Sharif-Afshar AR, Wu J, Li Q, Luthringer D, Saouaf R, Kim HL. Multiparametric MRI improves accuracy of clinical 
nomograms for predicting extracapsular extension of prostate cancer. Urology; 86:332-7; 2015. 
[244] Nishida K, Yuen S, Kamoi K, Yamada K, Akazawa K, Ito H, Okihara K, Kawauchi A, Miki T, Nishimura T. Incremental value of T2-
weighted and diffusion-weighted MRI for prediction of biochemical recurrence after radical prostatectomy in clinically localized 
prostate cancer. Acta Radiol; 52:120-6; 2011. 
[245] Kasel-Seibert M, Lehmann T, Aschenbach R, Guettler FV, Abubrig M, Grimm MO, Teichgraeber U, Franiel T. Assessment of PI-
RADS v2 for the detection of prostate cancer. Eur J Radiol; 85:726-31; 2016. 
[246] Jaderling F, Akre O, Aly M, Bjorklund J, Olsson M, Adding C, Oberg M, Blomqvist L, Nyberg T, Wiklund P, Carlsson S. Preoperative 
staging using magnetic resonance imaging and risk of positive surgical margins after prostate-cancer surgery. Prostate Cancer 
Prostatic Dis; 22:391-8; 2019. 
[247] Gandaglia G, Ploussard G, Valerio M, Mattei A, Fiori C, Fossati N, Stabile A, Beauval JB, Malavaud B, Roumiguie M, Robesti D, 
Dell'Oglio P, Moschini M, Zamboni S, Rakauskas A, De Cobelli F, Porpiglia F, Montorsi F, Briganti A. A novel nomogram to identify 
candidates for extended pelvic lymph node dissection among patients with clinically localized prostate cancer diagnosed with 
magnetic resonance imaging-targeted and systematic biopsies. Eur Urol; 75:506-14; 2019. 



















CHARACTERISTICS OF MULTIPARAMETRIC 
MAGNETIC RESONANCE IMAGING IN 





























































































ISBN 978-951-51-6747-7 (paperback) 
978-951-51-6748-4 (PDF)
PAINOSALAMA
TURKU 2020
